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Abstract
Extracorporeal life support (ECLS) is a class of technologies used to support or replace the
function of failing organs. During ECLS, blood is withdrawn from systemic circulation and
circulated through an artificial organ or “treatment membrane” that performs the function of the
failing organ, prior to return to systemic circulation. While ECLS provides life-saving therapy to
wide patient populations from pre-term infants to combat-wounded soldiers, this therapy is limited
due to secondary thrombotic and bleeding complications that result from: 1) exposure of blood to
the foreign surfaces in the device circuit and 2) administration of anticoagulant drugs to prevent
clot formation in the circuit.
In this study, we assessed a biomaterial solution to the challenge of hemostasis during
ECLS by modifying surfaces in the circuit to improve compatibility with blood. This approach
would provide local coagulation management at the blood-biomaterial interface, obviating the use
of systemic anticoagulant drugs that cause secondary bleeding. We investigated a non-adhesive,
liquid-infused coating called tethered liquid perfluorocarbon (TLP) that prevents plasma protein
adsorption. We also investigated a metal-organic framework that catalyzes nitric oxide release
from endogenous donors, localizing the platelet inhibitory effects of nitric oxide to the biomaterial
surface as occurs in the endothelium. Our objective was to determine if these coatings were a
robust biomaterials solution for ECLS without administration of anticoagulant drugs. We
developed a three-step approach to assess the efficacy and safety of biomaterials for ECLS. First,
materials were first evaluated in vitro in healthy donor blood using thromboelastography and

ix

platelet aggregometry. Second, we proceeded with evaluation of TLP applied to complete ECLS
circuits in vivo using a swine model for 6 hours of circulation. We assessed thrombus formation
by scanning electron microscopy, coagulation function using clinical tests, gas exchange
performance of the membrane using pre- and post-membrane blood gases and assessed safety
using vital signs and histology. Finally we evaluated TLP in a 72-hour intensive care unit study
without supplemental anticoagulation utilizing similar methods as described in our 6 hour model,
with additional analysis of mechanical ventilation settings, systemic cytokine expression,
hematology and protein adhesion. We hypothesized that TLP would enable 72 hours of heparinfree ECLS by inhibiting protein adsorption, preventing thrombotic circuit occlusion and preserving
native blood parameters; all without impeding membrane performance or causing systemic
complications.
Both TLP and the nitric oxide catalyst reduced the time and rate of thrombus initiation as
well as clot strength ex vivo. The nitric oxide catalyst also reduced platelet aggregation. In our 6
hour evaluation, TLP applied to ECLS circuits reduced thrombus formation compared to control,
heparin-coated circuits and did not affect gas transfer across the membrane lung or cause untoward
effects. In our 72 hour evaluation, TLP failed to prevent thrombotic circuit occlusion, and
additionally altered the performance of the membrane lung requiring greater support from the
mechanical ventilator compared to control animals that received heparin-coated ECLS circuits
with systemic anticoagulation therapy. We concluded that TLP is currently not an efficacious
solution to permit ECLS for 72 hours without anticoagulant drugs. Future studies are needed that
utilize the three-step assessment method we have developed here to evaluate multi-functional
biomaterials with combined ability to prevent protein adsorption and inhibit platelet activation,
such as occurs in the endothelium.

x

Chapter One
Extracorporeal life support: history, development and future applications
1.1 Abstract.
Extracorporeal life support (ECLS) was developed for temporary, partial replacement of
cardiopulmonary function but has evolved to include technologies for extended support for
multiple forms of organ failure. This therapy was originally highly invasive, required continuous
support by expert clinicians, necessitated extensive rudimentary equipment and resources, and
posed significant risk to the patient. Today this therapy has become a life-saving intervention for
broad patient populations from neonates to adults, utilizing advanced modern, portable technology.
Future plans for minimally invasive ECLS that can be used out of hospital for support in the
patient’s home; and incorporation of ECLS technology into autonomous critical care platforms to
be piloted to the site of battlefield injury are under development. Despite technological advances,
one paramount challenge limits widespread use of ECLS – management of coagulation. Exposure
of blood to foreign surfaces and sheer stress in the extracorporeal circuit invokes damage to blood
cells and causes circuit thrombosis. Administration of anticoagulant drugs to prevent thrombosis
causes secondary bleeding complications. This dissertation proposes a novel solution to this
challenge of hemostasis by improving the biocompatibility of the materials used to construct the
ECLS circuit; and outlines a methodological roadmap for evaluation of these biomaterials. This
chapter introduces ECLS technology and describes the current state and future directions for this
therapy.
1

1.2 Introduction.
ECLS is a class of technologies used to support or replace the function of failing organs –
to include the lungs, liver, heart, and kidneys. The prefix “extra-”, meaning “outside”, and
“-corporeal”, or “pertaining to the body”, describes the general function of these devices which
remove blood from the systemic circulation and direct it outside the body to an external treatment
membrane or artificial organ. The treatment membrane performs the function of the failing organ
(e.g. add oxygen (O2) to the blood and remove carbon dioxide (CO2) for pulmonary support). The
treated blood is then returned to the systemic circulation. This therapy was initially utilized in the
operating room for cardiopulmonary support during invasive surgical procedures and was
eventually modified for use in the intensive care unit (ICU) for extended duration of support (1).
Today this technology is utilized outside the ICU in deployed military surgical hospitals (2-4) and
in ground and aeromedical transport of unstable patients (5-7). Future applications such as
extended support for patients awaiting an organ transplant (“bridge to transplant”) or destination
therapies for those with chronic diseases, such as Chronic Obstructive Pulmonary Disease
(COPD), are under development (8). These applications will depend on improving the safety
profile of the devices and developing miniaturized, wearable technologies that can be operated out
of the hospital in the patient’s home. The major hurdle limiting development of such devices is
selection of biocompatible materials that reduce thrombotic, hemorrhagic and inflammatory
complications associated with blood-foreign surface interactions in the ECLS circuit.
1.3 The ECLS circuit: an overview.
The ECLS circuit consists of the following five key components: 1) treatment
membrane/artificial organ, 2) blood pump, 3) vascular access catheter(s), 4) connective tubing, 5)
heat exchanger (Figure 1.1). Each of these components can be modified depending on the
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Figure 1.1 A) Image of extracorporeal life support device for partial lung support (Maquet Getinge Group,
Rastatt, Germany). Picture includes the key components of an extracorporeal circuit: 1) treatment
membrane, 2) blood pump, 3) vascular access catheter(s), 4) connective tubing, 5) heat exchanger. B) The
treatment membrane shown is composed of hollow gas-exchange fibers (see schematic of oxygen (O2)
diffusion out of the fiber lumen into the blood, and carbon dioxide (CO2) diffusion from the blood into the
fiber lumen. C) The treatment membrane also includes an integrated heat exchanger depicted with heated
water (H2O) flowing through the lumen of the heat exchange fibers, transferring heat to blood passing
around the fibers.
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indication for use and the physiological requirements of the patient. For the purpose of this review,
we will focus on ECLS technologies for pulmonary support, as these devices will be the focus of
the research described in this dissertation.
1.3.1 Treatment membrane. The treatment membrane is the most variable component of
the ECLS circuit, as it determines the type of support delivered (renal, hepatic, pulmonary, cardiac,
etc.) and can be modified based on the size (e.g. neonates versus adults) and physiological demands
(partial or total organ support) of the patient. A treatment membrane designed for pulmonary
support, also referred to as a “membrane lung”, is designed to add O2 to venous blood and remove
CO2. These membranes consist of a series of hollow fibers encased in a plastic housing. Gas (called
the “sweep gas” -- usually 100% O2) is ventilated through the lumen of the hollow gas-exchange
fibers. Venous blood enters the membrane and contacts the outside of the gas exchange fibers
where gas transfer – addition of O2 from the sweep gas into the blood and removal of CO2 from
the blood into the sweep gas – occurs by diffusion (Figure 1.1, Panel B). The blood exiting the
membrane is oxygenated, with CO2 reduced, prior to being returned to the patient’s systemic
circulation. The size of the membrane is modified based on the metabolic demands of the patient.
For example, a membrane with a greater surface area for gas diffusion and larger blood path to
maximize gas mixing and the rate of blood flow through the membrane will provide the highest
level of support (1). The maximum rate of gas exchange (both O2 and CO2) by the average
membrane lung (200-400 mL/min) is comparable to and can exceed the gas exchange rate of the
native lung at rest (200-250 mL/min) (9). This exemplifies the potent gas exchange capabilities of
modern ECLS systems.
Gas exchange in the membrane lung is comparable to the human lung; and is subject to
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similar limitations, albeit by different mechanisms. In the native lung, gas exchange depends on
both proper ventilation, which is delivery of air into the alveolar space; and proper perfusion,
which is delivery of blood to the pulmonary capillaries that encapsulate the alveoli (10). Gas
exchange occurs across the alveolar-pulmonary capillary membrane where CO2 diffuses from the
mixed venous blood into the alveolar space, and O2 diffuses from the alveolar space into the blood.
In the membrane lung, the sweep gas is ventilated through the air space/inner lumen of the gas
exchange fibers; and perfusion occurs as blood is pumped into the membrane and surrounds the
gas exchange fibers. If an area of the lung is perfused but the air space is obstructed, gas exchange
cannot occur causing pulmonary shunt (11). For example, if the alveoli are filled with edematous
fluid or become consolidated during pneumonia, O2 will not be available to the blood passing
through the associated capillaries, and the gradient for CO2 removal will be absent. In the
membrane lung, if the lumen of the gas exchange fibers in the membrane becomes filled with fluid,
for example due to sweep gas condensate or plasma leakage through the fibers into the lumen, this
is reminiscent to pulmonary shunt, limiting gas exchange. If a pulmonary embolism or occlusive
thrombus prevents blood flow to pulmonary capillaries, the O2 in the associated alveoli would not
be accessible and no CO2 could be offloaded, causing pulmonary dead space (11). Similarly, if an
occlusive thrombus prevents blood flow through a region of the membrane lung, the sweep gas in
those fibers cannot be accessed for gas exchange, causing a form of dead space (9).
In the blood, O2 and CO2 are transported to and from the tissue by different mechanisms.
Because of this, the rate of transfer of O2 and CO2 by the native lung and membrane lung are
controlled by different methods. The total O2 content of the blood is the sum of the dissolved O2
and hemoglobin-bound O2. The solubility of O2 in blood is low (0.0031 mL / mmHg O2 / dL blood)
such that the dissolved O2 in blood generally represents < 1% of the total O2 content in clinical
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practice (12, 13). This means that the majority of O2 in the blood is bound to hemoglobin, and only
small increases in O2 content can be achieved once hemoglobin is saturated (13). The O2 content
of the blood and rate of delivery of blood to the tissue – the cardiac output (heart rate x stroke
volume) – determine oxygen delivery to the tissue (10). Likewise, the major factors that determine
oxygenation by the membrane lung are the O2 carrying capacity of the blood (dependent on
hemoglobin concentration, CO2 content and oxyhemoglobin saturation of the blood), and the rate
of blood flow through the circuit (12, 14). When the metabolic needs of the patient cannot be
supported by the membrane lung, the blood flow rate through the membrane must be increased
(similar to an increase in cardiac output in the body) or hemoglobin concentration must be
increased by transfusion (12). In this way, O2 transfer by the ECLS circuit is generally perfusion
limited.
CO2 is ~20 times more soluble in blood and is also more diffusible than O2, such that the
CO2 elimination capacity of the membrane is almost always greater than the oxygenation capacity
(12, 15). This means that for patients requiring CO2 removal without oxygenation support, lower
blood flow rates and smaller membrane lungs can be utilized (12). CO2 is carried in the blood in
three main forms: 1) dissolved (~5-10%), 2) reversibly bound to the amino terminal of blood borne
proteins forming carbamino compounds (~5-30%) or 3) hydrolyzed to form the bicarbonate ion
(~60-90%) (15). In this way, the major factors that determine CO2 removal by the membrane lung
are the partial pressure gradient of CO2 across the membrane and the sweep gas delivery rate. The
sweep gas flow is generally adjusted to achieve a target systemic PCO2 (12). Unlike oxygenation,
CO2 removal is more dependent on sweep gas flow rate (ventilation) than the blood flow rate (1,
9, 12). Albeit, CO2 removal is still positively correlated with blood flow as demonstrated by Park
and colleagues (14).

6

1.3.2 Blood pump. The blood pump drives the flow of blood from the patient, through the
ECLS tubing and membrane, and back to the patient’s systemic circulation. The two primary types
of pumps utilized for ECLS are peristaltic pumps and centrifugal pumps. Extracorporeal Life
Support Organization (ELSO) registry report indicates a trend in increased centrifugal pump usage
versus peristaltic pumps over the past 15 years, with the exception of pediatric populations (1).
The pumps are designed to support high (2-10 L / min) or low (<2 L / min) blood flow rates
depending on the indication of use (1). The most common pump-related complication is hemolysis,
largely due to shear stress, but also can include tubing cavitation and excessive negative pressure,
high outlet pressure, power failure and thrombosis (1). While most pumps provide continuous
flow, certain applications for pulsatile blood flow have been developed.
1.3.3 Vascular access catheter(s). The ECLS catheter is the point of access by which
blood is withdrawn and/or returned to the systemic circulation. The size of the catheter varies based
on blood flow rate requirements, where larger catheters are needed to support higher flow rates.
There are two main methods of cannulation for ECLS: 1) veno-arterial (VA) ECLS – where blood
is withdrawn from a major vein and returned to an artery; and 2) veno-venous (VV) ECLS – where
blood is withdrawn and reinfused into venous circulation (1). For pulmonary ECLS, VA
cannulation provides pulmonary and circulatory support, while VV ECLS provides primarily
pulmonary support; although, some data suggests that VV ECLS may unload the function of the
right heart providing cardiac benefits (16). VV ECLS also indirectly provides circulatory support
by allowing for reduction in mechanical ventilator settings, decreasing the negative effects of
mechanical ventilation on systemic blood pressure (17). For VV ECLS, catheters can be placed
into two separate veins (dual-site cannulation) or in one vein using a dual-lumen catheter. During
VV ECLS with single-site cannulation a dual-lumen catheter is placed into the right jugular vein
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(Figure 1.2). Venous blood is withdrawn from the superior and inferior vena cava into the outer
lumen of the catheter, where it is then circulated through the ECLS circuit. Blood from the ECLS
circuit is then reinfused into the right atrium, where it is pumped through the pulmonary circulation
and out to the systemic circulation (1). Single-site cannulation is becoming the standard method
for pulmonary applications and is the method of cannulation utilized in this dissertation.
1.3.4 Connective tubing. The connective tubing links all components of the ECLS circuit.
The tubing is generally composed of polyvinylchloride (PVC) combined with a plasticizer to
increase the flexibility of the tubing. A minimal tubing length is desired to decrease resistance to
blood flow in the circuit; however, the length of the tubing is also an important consideration for
mobilization of the patient and prevention of circuit disconnects (1). The inner diameter of the
tubing is selected based on the desired blood flow rate, where a larger internal diameter supports
a higher rate of flow at a constant pressure (18).
1.3.5 Heat exchanger. During extracorporeal circulation, blood is removed from the body
and exposed to ambient temperature, cooling the patient. To maintain normothermia, a heat
exchanger is often incorporated into the treatment membrane or direct blood warming can be
applied. When the heater is incorporated into the treatment membrane, heated water is circulated
within an additional set of fibers (separate from the hollow gas exchange fibers) and heat is
transferred (rather than gas) as blood passes over the surface (Figure 1.1, Panel C) (1).
1.4 A brief history of ECLS.
The first successful clinical usage of ECLS was performed in 1953 by Dr. John H. Gibbon
Jr. (1). This initial device, which weighed over 1,000 kg and required two technicians to operate,
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Figure 1.2. Depiction of veno-venous cannulation for extracorporeal pulmonary support using an Avalon
dual-lumen catheter (Maquet Getinge Group; Rastatt, Germany). Panel A shows catheter placement and
connection to an extracorporeal circuit. Panel B is a diagram of catheter placement within the right jugular
vein. Blue arrows show drainage of deoxygenated venous blood and red arrows show reinfusion of
oxygenated blood from the extracorporeal circuit. SVC = superior vena cava, IVC = inferior vena cava, RA
= right atrium, TV = tricuspid valve. Reused with permission from AME Publishing Company. “Venovenous extracorporeal membrane oxygenation: cannulation techniques,” by Carl Banfi, Matteo Pozzi, Nils
Siegenthaler, Marie-Eve Brunner, Didier Tassaux, Jean-Francois Obadia, Karim Bendjelid and Raphael
Giraud, 2006, Journal of Thoracic Disease, 8(12), page 3768. © 2016 AME Publishing Company.
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provided 26 minutes of cardiopulmonary support to a young woman with right ventricular failure
during repair of an atrial septal defect (19). The invention of silicone rubber for durable, gaspermeable silicone membrane lungs; as well as advances in controlled management of
anticoagulation administration allowed for extended use of ECLS, for several hours, in the
operating room and the post-operative recovery period (1). In 1973, the first reported use of ECLS
outside the operating room in the intensive care unit was performed by Dr. J.D. Hill for 75 hours
of cardiopulmonary support in a trauma patient with a ruptured aorta and traumatic acute
respiratory distress syndrome (ARDS) (20). The patient survived to discharge. In 1985, Dr. Robert
Bartlett, the “father of extracorporeal membrane oxygenation (ECMO)” in the USA, pioneered the
use of ECLS in neonatal populations for respiratory diseases (21). His success brought attention
to ECLS technology and led to an increase in ECLS centers from 18 to 100 word-wide in the 1990s
(20).
Adoption of ECLS in adult populations was much slower than in pediatric and neonatal
populations, and a series of randomized controlled trials in the 1990s and early 2000s failed to
demonstrate a clear survival benefit. These trials were complicated by a lack of ECLS expertise in
many centers, use of dated equipment that was highly invasive and caused significant blood
trauma, and selection of declining patients in whom ECLS would be a last resort therapy (1, 22,
23). At that time, use of ECLS was still highly invasive, requiring complete sedation and intubation
of the patient, continuous support and supervision from a specialist, and was accompanied with
major bleeding complications (8). In 2009, advancements in ECLS technology and an increases in
ECLS center expertise were realized and demonstrated to the medical community in the
“Conventional Ventilatory Support Versus Extracorporeal Membrane Oxygenation for Severe
Adult Respiratory Failure” (CESAR) randomized control trial, where patients assigned to ECLS

10

therapy had a 63% survival rate as opposed to 47% in the conventional management group,
showing the significant survival benefit from ECLS in adults with reversible respiratory failure
(24). The results of this trial were released prior to the 2009 H1N1 influenza pandemic when a
rapid rise in cases of severe adult respiratory failure presented a clear need for ECLS when
mechanical ventilation was insufficient to support the respiratory demands of the patient or
exacerbated lung injury (25, 26). This led to an increase in the number of worldwide ECLS centers
to 467 by 2016 (1).
1.5 ECLS today.
At the same time as the CESAR trial and H1N1 pandemic, ECLS technology began to evolve
such that the therapy could be carried out in a significantly less invasive manner. Treatment
membranes were miniaturized due to optimization of blood flow dynamics and utilization of highly
gas permeable materials that were durable and resistant to plasma leakage, allowing for sufficient
gas exchange using a smaller surface area for gas transfer than previously required (27). Blood
pumps were miniaturized and configured to reduce hemolysis. Miniaturization of ECLS circuits
allowed for use of smaller vascular access catheters; and surgical practice advanced to allow for
percutaneous catheter placement, rather than invasive surgical operation (1). Biocompatible
coatings were developed to prevent blood disturbance by the foreign materials in the circuit, which
will be discussed in detail in the next chapters (28). It is important to note that to date, the coated
materials still require administration of systemic anticoagulant drugs to prevent thrombosis. These
advances in ECLS technology now allowed for patients receiving therapy to be awake,
spontaneously breathing, extubated and ambulatory with assistance (8).
These technological advances reduced invasiveness of ECLS therapy and led to a marked
increase in utilization. As of July 2018, there have been over 100,000 ECLS cases across
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disciplines reported in the Extracorporeal Life Support Organization Registry (29). Specifically
for adult respiratory support, there has been an increase from 200 cases in 2008 (prior to release
of the CESAR trial and H1N1 pandemic) to 2,732 cases in 2017. The average duration of support
increased from 195 hours in 2008 to 271 hours in 2017 (29).
In addition to increased utilization in the general population an important modern
application for ECLS, which is the primary motivation behind the research described in this
dissertation, is to support combat casualties and battlefield wounded.The United States military
currently utilizes ECLS outside the ICU in deployed military hospitals and on rotary and fixed
wing aircrafts to support combat casualties with trauma-induced organ failure (30, 31). ECLS for
both cardiopulmonary (2) and renal support (3, 4) has been successfully utilized in military
hospitals, and has proven to be safe and effective during local and transcontinental aeromedical
patient transport (32, 33). This capability was only possible following miniaturization of ECLS
technology and improvements in ease of operation as described above. To date, ECLS for combat
casualties cannot be performed at the point of injury, and requires initial stabilization and transport
of the patient to a combat hospital with specialized surgical capabilities (34).
Despite the technological advances mentioned above that have expanded utilzation of
ECLS, complications still remain. Many centers report hemorrhagic complications from blood
trauma and anticoagulant administration as the most common complication for ECLS patients
(estimated 30-60%, but as high as 100% in some cohorts); however the reported rate is highly
variable due to inconsistent methods for determination of “bleeding episodes” (35-38). Bleeding
and blood stress require most patients to receive blood transfusions, which is associated with
increased morbidity and mortality (39). While anticoagulant administration to prevent thrombosis
results in frequent bleeding, ELSO reports that from 2013 to the present the most frequently

12

reported mechanical complication during ECLS for adult respiratory care is circuit clotting, seen
in 16.4% of cases (29). The second most common mechanical complication was membrane lung
failure (6.1%). Additionally, infectious complications were reported in 14.5% of cases and reduced
the rate of survival to 52% (29). Solutions to these complications will be the subject of this
dissertation.
1.6 ECLS future applications.
Utilization of ECLS is expected to continue to grow, with hopes for extracorporeal respiratory
support to become as common as mechanical ventilation in the ICU (8). Increased usage and
provider familiarity would allow for conventional patient management, without continuous
oversight of specialists. Improvements in biocompatability of ECLS materials and optimization of
flow patterns to eliminate hemolysis could reduce the need for systemic anticoagulant drugs (40).
This would address the high instance of bleeding complications currently observed and allow for
patients to be supported for months at a time, rather than the average 1-2 weeks of support that is
current practice (1, 8). Development of miniaturized wearable ECLS devices would allow for
long-term bridge-to-transplant patients and chronic support patients to receive therapy out of
hospital in their own homes. New applications, such as support of pre-term neonates using an
“artifical placenta” that consists of ECLS circulation via the jugular and umbilical vein in lieu of
mechanical ventilation while lungs are filled with fluid, have shown promise in laboratory settings
(41). Multi-functional membranes that combine different organ support functions within one
treatment membrane could provide support for multi-organ failure without increasing bloodcontact area, flow-related stress or logistical impact.
U.S. military physicians are interested in adapting ECLS technology to allow for use of the
devices on the battlefield at the point of injury (34). This would be a life-saving intervention by
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providing cardiopulmonary stabilization prior to patient transport and during damage-control
surgical interventions. Additionally, because ECLS allows for control of cardiac output,
oxygenation, metabolite removal, temperature and more this technology could be incorporated into
self-regulated, autonomous critical care platforms. These platforms containing ECLS technologies
could be remotely piloted to the site of injury where a medic could initiate extracorporeal
circulation. The casualty could then be evacuated from the battlefield while being remotely
monitored by a clinician during transport to a higher echelon of care. Still, in discussion of the
feasibility of ECLS on the battlefield, the need to administer anticoagulants is identified as a major
challenge, especially in treatment of patients with coagulopathies induced by trauma and the
austere field care environment (34).
1.7 Conclusions.
ECLS technology has evolved significantly since its introduction in the 1970s. Advances
in safety and feasibility of use have sparked rapid increase in utilization and inspired physician
scientists to develop novel applications for ECLS. Still, development and adoption of these novel
therapies require the challenge of hemostasis during ECLS to be resolved. Despite advances in
cannulation procedures, reduction in membrane size and blood contact area, increased bloodmaterial compatability and reductions in pump-related hemolysis, bleeding and thrombotic
complications are still exceedingly high and caution practitioners to utilize this life-saving therapy.
Future applications for home-wear devices, extended patient support and early intervention for
traumatic injury are dependent on a solution to ECLS-induced coagulopathy. Understanding the
origins of ECLS, developments in the past decades and scope of proposed future applications
demonstrates a clear need for secondary bleeding and thrombotic complications to be resolved.
Novel solutions to this challenge will be the subject of this dissertation.
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Chapter Two:
Extracorporeal life support and the incessant challenge of coagulation
2.1 Introduction.
Management of coagulation during extracorporeal life support (ECLS) is a significant
challenge where both thrombotic and bleeding complications occur, often simultaneously. The
vascular endothelium actively maintains blood fluidity and hemostasis via a delicate balance of
pro- and anti-thrombotic factors. When blood is pumped outside the endothelium into the ECLS
circuit foreign surface contact, shear stress and variable flow activate coagulation and cause
inflammation. This results in thrombus formation, which can occur in the ECLS membrane, pump,
tubing and catheters. Return of activated blood to the patient’s circulation can cause systemic
thrombosis, and circuit clots can become dislodged and cause life-threatening thromboembolism.
Systemic anticoagulant drugs are administered to prevent thrombosis; however, these
anticoagulants can be difficult to titrate, especially in patients with underlying coagulopathy. This
can lead to life-threatening bleeding complications. To understand the complex challenge of
coagulation management during ECLS, we first describe coagulation and maintenance of blood
fluidity as it occurs in the endothelium – highlighting key pro- and anti-inflammatory regulators.
We then describe key alterations to hemostasis during ECLS, discussing how blood chemistry,
biomaterial surface characteristics and blood flow determine the coagulation response. Finally, we
describe how coagulation is managed clinically during ECLS, prior to discussion of alternative
management strategies.
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2.2 Hemostasis in the vascular endothelium.
The endothelium serves as a blood-compatible vascular lining in vertebrates and is estimated
to cover a surface area of 3,000 to 6,000 m2 in an adult human (1). Once thought to be a passive
barrier separating blood from foreign sources of activation, the vascular endothelium is now
understood to be a highly active surface that not only regulates expression of pro- and antithrombotic factors to preserve blood fluidity and prevent thrombus formation and bleeding; but
also provides targeted delivery of immune cells, regulation of vascular tone and perfusion, and
support of healing through angiogenesis following inflammatory injury or tissue trauma – in
addition to countless location and tissue-specific functions (1, 2). The endothelium regulates
coagulation through expression of surface receptors, alteration of flow distribution, control of fluid
transfer and permeability, as well as secretion of regulatory molecules and factors that mediate
blood cell activity (3). Here we describe a general overview of the coagulation and fibrinolytic
systems, and then discuss key endothelial surface receptors and secreted factors that regulate
hemostasis -- understanding that many of these mediators play a joint role in the tightly integrated
systems of coagulation and inflammation.
2.2.1 Overview of coagulation. The balance of thrombosis and bleeding is controlled by
interactions between the coagulation, fibrinolytic and inflammatory systems, as well as the
endothelium, blood cells and platelets. Coagulation was initially described as a “cascade” model
where a series of enzymatic reactions were initiated along one of two distinct pathways (the
extrinsic and intrinsic pathways) that converged at a common pathway (Factor Xa) which led to
thrombin generation and fibrin activation (4). This model describes coagulation as it occurs in
plasma, but does not account for the interaction of endothelial, blood and inflammatory cell
surfaces (4). The more recent “cell-based” model of coagulation emphasizes the active role of
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cellular surfaces in regulating coagulation activity (Figure 2.1) (5). The cell-based model is
divided into 3 phases: 1) initiation, 2) amplification and 3) propagation (6). The initiation phase
occurs on tissue factor (TF) bearing surfaces – such as fibroblasts, damaged/stimulated
endothelium, activated monocytes, and cellular fragments/microparticles (7). Circulating plasma
Factor VII binds surface-bound TF and becomes activated, leading to subsequent activation of
Factor X and a small amount of thrombin formation (6). The amplification phase occurs as platelets
adhere to subendothelial matrix proteins at the site of vascular injury, which causes the platelets
to become partially activated and localizes them to the site of TF release. Then, thrombin released
in the initiation phase fully activates the platelets, as well as other co-factors (Factors V, VIII and
XI), to prepare the platelet for pro-thrombinase complex formation and thrombin burst (4, 6).
Activated platelets tightly bind circulating Factors IXa, Xa, and XI, and thrombin mediates
adhesion and activation of von Willebrand Factor (vWF) bound-Factor VIII (6). In the propagation
phase, the tenase complex (Factor VIIIa/IXa) assembles on the platelet surface, causing Factor X
activation and prothrombinase complex (Factor Va/Xa) formation. The assembly of the
prothrombinase complex leads to rapid thrombin (Factor IIa) formation, or “thrombin burst.”
Thrombin cleaves fibrinogen to fibrin, which polymerizes to form a stable fibrin clot from the
initial platelet plug (6). This model demonstrates how platelets serve as the surface on which the
majority of thrombin required for clot formation occurs (6).
2.2.2 Overview of fibrinolysis.

The fibrinolytic system counteracts thrombosis by

dissolving the fibrin clot into soluble degradation products. This process occurs through
conversion of plasminogen, a circulating zymogen, to the active form plasmin. Plasminogen
associates with fibrinogen in the circulation so that when fibrin forms and cross-links, plasminogen
is incorporated within the clot and is in close proximity to fibrin prior to activation to plasmin (8).
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Figure 2.1 The proposed cell-based model of coagulation consisting of the following three key
phases: initiation, amplification and propagation. Reproduced with permission of Bentham
Plasminogen Science Publishers Ltd. from Frederick R, Pochet L, Charlier B, Masereel B.
Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor,
factor VIIa and their complex. Current Medicinal Chemistry. 2005;12(4): 397-417.
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There are multiple plasminogen activators, such as tissue-type plasminogen activator (t-PA),
which is constitutively expressed by the endothelium, as well as urinary-type plasminogen
activator (u-PA), high molecular weight kininogen, prekallikrein and Factor XII (8). t-PA and uPA are inhibited primarily by plasminogen activator inhibitor-1 (PAI-1), which is synthesized by
endothelial cells, platelets and other cell types to reduce fibrinolysis (8, 9).
2.2.3 Pro-coagulant factors in the endothelium. Pro-coagulant, anti-fibrinolytic factors
are generally not constitutively expressed on the endothelium but are primarily expressed or
released in response to vascular injury, inflammation and other pathological responses.
2.2.3.1 Tissue factor (TF). TF is a transmembrane protein that is not normally present on
circulating blood or endothelial cells but is constitutively expressed on cells surrounding
the endothelium such as smooth muscle cells and fibroblasts (10). When the endothelial
barrier is compromised, TF from the surrounding cells comes into contact with blood and
initiates thrombosis through formation of the TF/Factor VIIa complex (11). Cytokines and
inflammatory complexes can also stimulate TF expression in monocytes and endothelial
cells, promoting pathological, immune-mediated thrombogenesis (10).
2.2.3.2 von Willebrand factor (vWF). vWF is synthesized in endothelial cells and
megakaryocytes and stored for secretion in Weibel-Palade bodies and platelet α-granules
(3). When the endothelial surface is compromised, vasoactive substances such as thrombin,
histamine or bradykinin trigger vWF release to the endothelial surface where it contributes
to platelet adhesion to the sub-endothelial matrix via Gp1bα; or in instances of high flow
promotes platelet aggregation by binding glycoprotein IIb/IIIa and stabilizing interactions
between platelets and collagen (3, 12). vWF also carries and stabilizes Factor VIII, which
is a part of the tenase complex that activates Factor Xa leading to conversion of
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prothrombin to thrombin (13). vWF has been well-utilized as a plasma marker of
endothelial damage (14).
2.2.3.3 Platelet activating factor (PAF). PAF is synthesized in endothelial cells in
response to agonists such as thrombin and bradykinin. PAF promotes recruitment and
activation of leukocytes at the endothelial surface where leukocytes release pro-coagulant
factors, provide binding sites for fibrinogen and associate with platelets to cause further
platelet and leukocyte activation (15, 16).
2.2.3.4 Plasminogen activator inhibitor 1 (PAI-1). PAI-1 is the most ubiquitously found
plasminogen activator inhibitor and is the primary inhibitor of t-PA and u-PA, decreasing
fibrinolysis (17). It is released from endothelial cells when stimulated by certain proinflammatory cytokines, growth factors and lipoproteins. PAI-1 is also released by
platelets, monocytes, macrophages and other cells (17).
2.2.4 Anti-coagulant factors in the endothelium. Anti-coagulant, pro-fibrinolytic factors
are generally constitutively expressed on the endothelium to maintain blood fluidity and prevent
thrombosis in the absence of injury or disease.
2.2.4.1 Tissue factor pathway inhibitor (TFPI). TFPI is a serine protease inhibitor that
prevents thrombin generation by inhibiting factor Xa and the TF/Factor VIIa complex (17).
TFPI is primarily synthesized in endothelial cells and remains on the endothelial surface
bound to heparin sulfates or circulates in plasma bound to lipoproteins (18).
2.2.4.2 Tissue plasminogen activator (t-PA). t-PA activates the fibrinolytic system by
converting plasminogen to plasmin. Its activity is increased as much as 500-fold in the
presence of fibrin (19). t-PA is synthesized by endothelial cells from multiple sources in
culture; however, known synthesis in vivo is primarily restricted to small vessels and
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vascular branches (17). Synthesis and secretion of t-PA is stimulated by thrombin,
bradykinin, oxygen free-radicals, laminar shear stress and other agents (20, 21).
2.2.4.3 Heparin-containing proteoglycans. Endothelial cells synthesize and secrete
heparin and heparin sulfate, which is anchored to the endothelial surface by a proteoglycan
core (22). Heparin sulfate binds to and accelerates the activity of Antithrombin III (ATIII),
an enzyme that inhibits thrombin and Factor Xa; heparin binding also localizes ATIII on
the endothelial surface (23). These proteoglycans are also key constituents of the
endothelial glycocalyx, a membrane-bound surface layer of proteoglycans, glycoproteins
and other soluble proteins that regulates endothelial permeability, responds to mechanical
signals and contributes to the pathological response of the endothelium in a number of
disease states (24).
2.2.4.4 Thrombomodulin (TM). Thrombomodulin is a protein receptor found on the
endothelial surface that binds and inhibits thrombin. TM is primarily synthesized by
endothelial cells and is upregulated in areas of high flow (arteries) and down-regulated in
a pro-inflammatory environment (3). In addition to inhibiting thrombin-mediated
fibrinogen activation, thrombin bound to TM activates the anti-coagulant protein C
pathway (25).
2.2.4.5 Protein C and protein S. Protein C circulates in plasma in inactive form until it is
cleaved by thrombin bound to TM, forming activated Protein C (aPC). aPC proteolytically
degrades Factors Va and VIIIa and can increase fibrinolysis by neutralizing PAI-1 (26).
Endothelial cells express the endothelial cell protein C receptor (EPCR) which binds
protein C and accelerates its activation to aPC by thrombin-TM by ~20-fold (26). Protein
S, which is also synthesized by the endothelium, is an important Protein C co-factor that
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accelerates aPC activity and is thought to be instrumental in the close association of aPC
with the phospholipid surface, which is necessary for its function (17, 27, 28).
2.2.4.6 Prostacyclin (PGI2). PGI2 is an eicosanoid constitutively secreted by the
endothelium that inhibits platelet activity, promotes vasodilation and stimulates cytokine
production (17). Release of PGI2 is rapidly and temporarily elevated in response to
thrombin, bradykinin, histamine and several cytokines (29).
2.2.4.7 Nitric oxide (NO). In the endothelium, NO is catalyzed by endothelial nitric oxide
synthase (eNOS) which converts L-arginine to L-citrulline. The activity of eNOS is
modified by several factors including shear stress, proinflammatory cytokine expression
and ADP release (29). NO promotes vasodilation, reduces leukocyte adhesion to and
migration through the endothelium, prevents vWF release from thrombin-stimulated
Weibel-Palade bodies and inhibits platelet adhesion and activation (29). The potent
anticoagulant effect of NO on platelet function, which will be later emphasized in this
dissertation, has been well characterized (30, 31). NO reduces platelet activation and
aggregation through cyclic guanosine monophosphate (cGMP) mediated mechanisms.
Platelet agonists, such as collagen and ADP, activate signaling pathways that increase
platelet intracellular Ca2+ concentrations ([Ca2+]i ). Elevation of [Ca2+]i stimulates
reorganization of the platelet cytoskeleton to form an activated conformation, induces
expression of platelet surface activation makers and binding sites for aggregation, and
triggers release of platelet granules that stimulate adjacent platelet activation (32).
Endothelium-derived NO stimulates soluble guanylate cyclase, which increases platelet
cGMP. cGMP mediates sequestration of Ca2+, reducing the [Ca2+]i and suppressing Ca2+
mediated platelet activation (33). In addition to endothelium-derived NO, platelets express
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nitric oxide synthase and produce NO as a method of auto-inhibition, further demonstrating
the importance of NO as a mediator of platelet function (34)
2.3 Altered hemostasis during ECLS.
The biomaterials that construct the ECLS circuit do not actively regulate homeostasis as
occurs in the endothelium. Without a protective surface layer, such as the endothelial glycocalyx,
or constitutive secretion of antithrombotic factors like NO and heparin, blood becomes activated
upon exposure to the foreign surface. There are multiple factors that determine the compatibility
of blood with the surfaces in the extracorporeal circuit. Virchow’s triad describes the three major
factors that affect blood coagulation which are: 1) chemistry of the blood, 2) characteristics of the
blood-contacting surface and 3) the blood flow path and rate (35). The impact of these key factors
on coagulation during ECLS will be discussed in the next paragraphs.
2.3.1. Blood chemistry. The quantity, composition and activity of cellular elements (red
and white blood cells, platelets), clotting factors and hemostatic regulators in the blood affect
coagulation on the biomaterial surface (36). This can vary depending on species (37), gender (38),
age (39, 40), genetics (41), injury status (42), temperature (43), pH and more (44). This is an
important consideration for a diverse therapy like ECLS that is utilized for numerous pathological
conditions. For example, blood from an elderly female with pneumonia receiving ECLS therapy
for partial lung support in the intensive care unit will behave very differently than blood from a
young combat casualty at an austere military hospital with pre-existing hemorrhagic shock
receiving resuscitation and ECLS for cardiopulmonary support. This is also an important
consideration for selection of blood for laboratory testing of biomaterials (36). In addition to the
patient’s underlying blood chemistry, transfusion of blood products such as packed red blood cells
(PRBCs) will alter blood composition and biomaterial interactions. Blood chemistry is the element
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of Virchow’s triad that is currently targeted to prevent coagulation during ECLS through
administration of anticoagulant drugs that affect the activity of key homeostatic regulators such as
thrombin (45). This will be discussed in detail in section 2.5.
2.3.2 Biomaterial surface characteristics. The first reaction that occurs when blood is
exposed to a foreign surface is rapid adsorption of plasma proteins (36). These adsorbed proteins
then induce thrombosis by providing binding sites to localize platelets at the material surface and
activating the platelets to a pro-coagulant state (46). The specific characteristics of the material
surface affect the type and quantity of proteins that are adsorbed and the exposure of functional
groups on the proteins that mediate thrombosis (46). Albumin, which accounts for over 50% of
total plasma protein content (35-55 g/L), does not readily mediate platelet adhesion or activation
and is thought to be relatively inert when adsorbed; whereas fibrinogen, which accounts for less
than 10% of total plasma protein content (1.5-4.5 g/L), is considered the central mediator of platelet
activation and aggregation on the biomaterial surface (47-49). Other plasma proteins such as
immunoglobulins, vWF, fibronectin and vitronectin also induce platelet activation and/or adhesion
to foreign surfaces (29). Sivaraman, and colleagues demonstrated that the degree of deformation
of adsorbed fibrinogen, rather than total quantity of fibrinogen adsorbed is more strongly
correlated with platelet activation and adhesion to the biomaterial surface (50). This demonstrates
the importance of 1) the type of protein adsorbed (pro-coagulant vs inert) and 2) the interaction of
the protein with the biomaterial surface to expose platelet binding sites in determining
thrombogenicity of the material. In addition to plasma protein adsorption and subsequent platelet
activation, biomaterial contact can activate plasma coagulation directly through activation of
Factor XII (51, 52). Complement proteins such as C3 can also adsorb and activate, promoting
coagulation and initiating inflammation (53, 54).
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The characteristics of the material surface that affect the type and degree of protein
adsorption and coagulation include the surface free energy, wettability, chemistry, topography and
roughness (46). Surface free energy contributes to the interfacial energy between the material and
the blood, determining if thermodynamics favor adsorption. It has been reported that protein
adsorption is greater on surfaces with lower free energy (55). The wettability of the surface,
described as the hydrophilicity, affects the strength of the interaction between the protein and the
surface. Hydrophobic surfaces generally increase protein adhesion, favoring stronger interaction
between the protein and the surface; whereas, hydrophilic surfaces form a layer of water that acts
as a buffer to inhibit protein adhesion and reduce the strength of the protein-surface interaction
(46, 56). Addition of functional groups and topographical features to the material surface can alter
protein adsorption regardless of wettability. For example, surface texturing can increase surface
hydrophobicity by trapping air between the topographical features, which inhibits protein contact
with the surface forming a blood-repellant “superhydrophobic” material (57). The effect of surface
roughness on protein adsorption is dependent on the size of the topographical features on the
material, where nanoscale features may suppress adsorption, but microscale features may increase
adsorption (58).
2.3.3 Blood flow, shear stress and hemolysis. The effects of blood flow, including rate
and distribution, determine both the rate of transport of blood elements to the biomaterials surface
and the level of shear stress at the surface. High flow rates cause “reaction controlled” surface
adsorption, where blood cells and proteins are readily delivered to the surface and adsorption is
highly dependent on surface characteristics (35). In low-flow systems, adsorption is “diffusion
controlled,” dependent on availability of proteins and cells at the material surface (35). Shear
stress can be understood by Poiseuille’s Law, which describes laminar flow of fluid in a cylindrical
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container, such as blood in a segment of vasculature or connective tubing in the ECLS circuit (59).
The velocity of the fluid is greatest in the center of the lumen and gradually decreases with
proximity to the wall. Shear stress is the force that the near-wall flow exerts on the wall. This force
is directly related to flow rate and fluid viscosity; and is inversely related to the vessel diameter
(59). Therefore, it is important to select ECLS catheters and tubing that will support the flow rate
needed for a specific type of ECLS therapy. Small catheters are easier to place but may cause
excessive hemolysis if the diameter of the catheter lumen is insufficient to support the required
flow. Shear stress damages red blood cells causing hemolysis, usually measured by the level of
free-hemoglobin in plasma, where a concentration greater than 50 mg/dL is considered significant
hemolysis (60). Shear stress can also damage white blood cells, platelets and proteins; and ADP
released from damaged cells triggers platelet activation (61). In addition to surface shear stress
described by the laminar flow model above, turbulent flow occurs throughout the ECLS circuit
due to varied lumen diameters at different connection points, varied pressure, and changes in blood
viscosity. Turbulent flow can cause blood trauma, hemolysis and is associated with a pro-coagulant
response (62, 63).
In addition to shear-induced hemolysis that occurs when blood contacts the circuit wall and
during turbulent flow, significant blood trauma and hemolysis can occur due to mechanical forces
and negative pressures generated by the blood pump (64). The degree of hemolysis depends on the
type of pump used, the pressure within the circuit and the number of revolutions per minute (rpms)
needed to support the desired flow rate. Centrifugal pumps generally have a lower hemolysis index
than peristaltic pumps when high flow rates (1-8 L/min) are used; however, when high rpms are
required to support a low flow rate such as during neonatal ECLS therapy when small catheters,
tubing and membranes create a low-flow, high-pressure circulation system, a roller pump is
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generally preferred (60). This is because the blood contact time with the pump is increased, and
red blood cell damage may occur at a faster rate with the centrifugal pump (60). The pump rpms
are adjusted during circulation to prevent negative pressures of less than -650 mmHg in the venous
line (line connecting the catheter outflow to the membrane inlet face), as significant hemolysis and
sudden pressure drops inducing cavitation in the lines will occur (65).
2.4 Coagulation management during ECLS
To address thrombosis resulting from foreign surface exposure, shear stress and altered
blood flow during ECLS, patients receive systemic anticoagulation therapy. Despite anticoagulant
administration, the Extracorporeal Life Support Organization reported that significant clotting
complications occurred in nearly 40% of all ECLS runs (60). A significant clotting complication
was defined as a thrombotic occlusion that required replacement of a component of the ECLS
circuit. The most common site of thrombus formation was the membrane. Additionally, circulation
of damaged, pro-coagulant blood can result in systemic thrombosis which can be a lethal
complication that often is unrecognized until postmortem assessment (60). For example, in a
single-center prospective trial comparing clinical and autopsy findings of 78 adult ECMO patients
over a 5 year period, deep venous thrombus formation occurred in 39.7% of patients, but was only
clinically identified in 7.7% of patients (66). Arterial and end-organ thromboembolisms were
found in 46.2% of patients but were clinically recognized in only 15.4% of patients.
The instance and severity of thrombotic complications presents a clear need for
anticoagulation therapy; however, the task of achieving and maintaining therapeutic
anticoagulation levels amidst constant blood stress from the extracorporeal circuit, frequent
transfusions and underlying coagulopathies from initial injury is extremely challenging. There is
currently no universal guideline for administration of anticoagulants or use of coagulation
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monitoring tests for ECLS patients, resulting in highly variable, center-specific hemostasis
management protocols (67, 68). Lack of consensus on the type of anticoagulant to use, the form
of monitoring test to be employed and the therapeutic target range for each test, results in
suboptimal outcomes and inconsistent patient care (67). The requirement for anticoagulation, in
combination with consumption of platelets and clotting factors during circulation, leads to a high
instance of bleeding complications, which occurs more frequently than thrombosis as described in
Chapter 1 (69). In this final section summarizing the challenge of hemostasis during ECLS, we
describe the clinically utilized anticoagulants for ECLS and introduce the concept of localized
anticoagulation using biocompatible materials and surface coatings.
2.4.1 Systemic anticoagulants for ECLS.
2.4.1.1 Unfractionated heparin. At present, unfractionated heparin is the most
consistently utilized anticoagulation method for ECLS and is considered the clinical
standard (70). Heparin binds irreversibly to antithrombin III (ATIII), inducing a
conformational change that increases ATIII inhibition of thrombin, Factor Xa and other
clotting enzymes by 1000-fold compared to ATIII alone. Additionally, unfractionated
heparin induces a 7-fold increase in release of TFPI from the endothelium, which inhibits
factor Xa and the factor VIIa/TF complex as described in section 2.3.4.1. Heparin will not
dissociate thrombin already bound to fibrin on material surfaces, and will not inactivate
platelets (71). Yet, platelet activation and consumption are leading causes of bleeding
complications in ECLS patients. Additionally, the activity of heparin is altered by the
presence of plasma proteins; and it is neutralized by high-molecular weight von Willebrand
factor multimers and platelet factor 4 (PF4), both released by activated platelets (72).
Cumulatively, this leads to an unpredictable drug response from patient to patient. Heparin
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induced thrombocytopenia (HIT) is an additional concern occurring in patients who
develop antibodies against heparin-bound PF4. Heparin is metabolized by the liver and the
reticuloendothelial system, with a half-life of approximately 60 minutes (73).
2.4.1.2 Direct thrombin inhibitors. Direct thrombin inhibitors (DTI), mainly bivalirudin
and argatroban, were initially utilized in ECLS patients that developed HIT; but are now
the anticoagulant of choice in certain centers due to more direct/linear pharmacokinetics
(70). Unlike heparin, these agents do not require a cofactor, are not readily neutralized by
plasma proteins, and can prevent thrombin induced platelet aggregation and inhibit
thrombin already bound to fibrin clots (70, 72). Extensive use of these agents for ECLS
across populations will require standardization of administration protocols and monitoring
techniques, as well as improved understanding of potential antidotes to be used in case of
overdose.
Bivalirudin is an analog of hirudin that binds both the active site and fibrinogen
binding site of thrombin (74). It is metabolized by proteolytic cleavage (80%) or renal
clearance (20%) and has a half-life of 25 minutes (60). Despite promising case reports, to
date there are no large randomized prospective trials to provide thorough evidence for the
role of bivalirudin anticoagulation during ECLS, and there are no Food and Drug
Administration approved indications for pediatric populations (74-76). Further, there are
no clear guidelines for optimal dosing and monitoring, and renal clearance may be
problematic as many ECLS patients have altered renal function. For example, in a
retrospective study bivalirudin dosing requirements increased by 75-125% in patients
receiving extracorporeal renal replacement therapy (77).
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Argatroban, a derivative of L-arginine, is a competitive thrombin inhibitor that
reversibly binds the active site (73). It undergoes hepatic metabolism and has a half-life of
15 minutes (70). Like bivalirudin, there are no clear guidelines for optimal dosing and
monitoring, and to date there are no prospective trials to demonstrate a clear therapeutic
benefit during ECLS (70, 73). Both argatroban and bivalirudin are significantly more
expensive in comparison to heparin; and both direct thrombin inhibitors lack a clear
reversal agent (60, 73).
2.4.1.3 Anti-platelet agents. Antiplatelet agents such as acetylsalicylic acid (ASA) and
prostacyclin have been utilized to supplement the use of unfractionated heparin or direct
thrombin inhibitors for various forms of ECLS in small, single-center trials (70, 78). For
example, ASA was used in combination with heparin in 15 patients receiving
extracorporeal therapy for respiratory failure where no increased bleeding activity or
transfusion demands were reported (79). ASA inhibits cyclo-oxygenase, reducing platelet
production of thromboxane A2 and inhibiting aggregation (70). Prostacyclin was used with
heparin in children (80) and adults (81) receiving extracorporeal renal replacement therapy
without adverse effects and shown to increase membrane life (time until replacement was
necessary due to occlusion) in both cases versus patients that received heparin alone (82).
Prostacyclin is an endogenous antithrombotic, described in section 2.3.4.6, that inhibits
platelet aggregation by binding platelet receptors and inhibiting adenylyl cyclase activity.
This leads to elevated cyclic adenosine monophosphate (cAMP) levels in the platelet,
inhibiting multiple mechanisms of activation and aggregation (70).
2.4.2 Localized anticoagulation in the ECLS circuit. In addition to systemic
anticoagulant drugs, local methods of anticoagulation have been introduced to inhibit clotting
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within the circuit while preventing systemic bleeding complications. This includes regional
infusion of anticoagulant drugs, such as citrate directly into the circuit (83), and development of
anti-thrombogenic circuit surface coatings which will be discussed in depth in the next chapter
(84). Regional citrate infusion is successfully utilized for ECLS application with low-flow
requirements such as extracorporeal hemofiltration; however, it is insufficient for the high flow
rates needed to support cardiopulmonary function (70). The leading surface coating strategy that
has passed the developmental stage and is utilized in clinical practice involves immobilization of
heparin on ECLS circuit surfaces. Immobilized heparin coatings are utilized for most current
generation ECLS devices (e.g. Bioline®, Carmeda®); however, these coatings alone are not robust
enough to prevent thrombus formation for an extended period, and supplementary use of systemic
anticoagulants remains clinical practice (45, 60, 85). Both laboratory investigations and clinical
studies have cautioned against the long-term stability of immobilized heparin coatings alone, or
when used with low-dose heparin administration, as with extended use accumulation of fibrin and
cellular deposits occurs, impairing gas exchange efficiency and causing resistance to blood flow
(86-88). Additional studies caution against the use of heparin coated devices when HIT is
suspected, as the HIT immune reaction has been observed to continue even after withdrawal of
systemic heparin, implying potential heparin leakage from the circuit surface (89).
2.5 Conclusions.
Despite improvements in circuit design and biocompatibility of circuit materials, contact
of blood with polymers in extracorporeal circulation systems causes extensive stress, thrombosis,
hemolysis and consumptive coagulopathy. The high instance of both thrombotic and bleeding
complications reported for ECLS demonstrates that current methods of coagulation management
using systemic anticoagulant drugs and heparin-coated circuits are insufficient. The complexity
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and delicate balance of coagulation management in the vascular endothelium suggests that a
localized, multi-faceted approach to prevent coagulopathy during ECLS may be necessary.
Understanding the factors defined by Virchow’s triad that determine blood-surface interactions is
key for development of biocompatible materials to reduce coagulopathy. In the next chapter we
discuss how scientists, clinicians, chemists and engineers are collaborating to create biocompatible
materials modelled after the endothelium to provide a localized, efficacious solution to the
challenge of coagulation during ECLS.
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Chapter Three:
Biomaterials for extracorporeal life support
3.1 Abstract.
Extracorporeal life support (ECLS) devices are utilized for diverse applications to include
acute support of neonates and children with congenital abnormalities, emergency support for
trauma-induced organ failure, transitional support for bridge to organ transplant and chronic
support for terminal organ failure. The major complication that limits use of these life-saving
devices across all disciplines is thrombosis, bleeding and inflammation caused by interactions of
the blood with the foreign-surfaces of the devices. To address this challenge, trans-disciplinary
efforts by scientists and clinicians look to the vascular endothelium as inspiration for development
of biocompatible materials for ECLS. Here we describe clinically approved and new
investigational biomaterial solutions for thrombosis such as immobilized heparin, nitric oxidegenerating polymers, slippery non-adhesive coatings, and surface endothelialization. We describe
how hemocompatible materials could abrogate the use of anticoagulant drugs during ECLS; and
discuss special considerations for development of biomaterials specifically for ECLS to include
preserving function of the artificial organ, longevity of use, and multifaceted approaches for the
diversity of applications and functions of the devices.
3.2 Introduction.
Extracorporeal life support (ECLS) therapy has evolved significantly since initial use in
1953 by Dr. John H. Gibbon, Jr. to provide 26 minutes of heart and lung support during surgical
repair of a cardiac defect (1). This initial device weighed over 1,000 kg and required multiple
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technicians and specialists to operate. Since this time, ECLS technology has become significantly
safer and less invasive, and has diversified to include capabilities for multi-organ failure including
cardiac, pulmonary, renal and hepatic support. ECLS is now commonly performed outside of
surgical suites, often in the intensive care unit, and can be utilized for weeks and even months of
support (2, 3). This extended duration of use has allowed for ECLS as a bridge-to-transplant
therapy (4). Further, ECLS has been used out of hospital during inter-hospital transport of unstable
patients (5, 6); and has been utilized by the military in combat hospitals and during transcontinental
aeromedical transport of combat casualties (7-9). Future applications include destination therapies
for chronic disease using miniaturized, wearable ECLS devices that could provide support out of
hospital in the patient’s home (10).
Despite the range of applications and patient populations for which ECLS has been utilized,
the major challenge that limits use and poses a safety threat to the patient is disturbance of
coagulation. The large surface area of interaction between blood and internal components of ECLS
devices subjects the circulating blood to various detrimental effects. (11). The result is both
thrombotic and hemorrhagic complications, which can often coexist simultaneously in the same
patient (12, 13). When blood contacts the foreign surfaces in the ECLS circuits, adsorption of
plasma proteins rapidly occurs (14). Platelets exposed to the proteins become activated, adhere to
the surface of the circuit and release procoagulant factors to recruit and activate other platelets
(15). Platelet and contact pathway activation initiates the coagulation cascade, leading to thrombin
generation and conversion of fibrinogen to insoluble fibrin, stabilizing the clot (Figure 3.1) (16).
Circulating red blood cells, platelets and leukocytes continuously become activated with exposure
to the developing thrombus, causing release of soluble pro-inflammatory mediators and activation
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Figure 3.1 Illustration of thrombus deposition on foreign material surface. The process is
initiated by protein adsorption, followed by contact activation and platelet
adhesion/activation. Coagulation activation leads to downstream activation of the
complement system and inflammatory reactions. Reproduced with permission of
ELSELVIER BV in the format Thesis/Dissertation via Copyright Clearance Center. Biran
R, Pond D. Heparin coating for improving blood compatibility of medical devices. Advanced
Drug Delivery Reviews. 2017; 112: 12-23.
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of complement factors (14, 17). As the activated blood is returned to the systemic circulation,
tissue factor release and pro-inflammatory factor expression occur within the endothelium (14, 18,
19). In addition to foreign surface contact, turbulent blood flow results from variability in the size
of catheter and circuit tubing lumens. Pressure drops, shear stress and turbulence are generated by
the blood pump and result in hemolysis, introduction of procoagulant microbubbles, endothelial
collagen exposure and von Willebrand factor release from damaged cells (17, 20). Cumulatively,
this causes severe risk of thrombus formation in the circuit and the patient, requiring administration
of blood thinners to all patients receiving this therapy.
Simultaneous with thrombus formation, the hypercoagulable state that results from
constant activation of blood and immune cells causes consumption of platelets and clotting factors,
resulting in a frequently unrecognized hypocoaguable state and significant bleeding complications
(21). Additionally, ECLS patients require continuous systemic anticoagulation therapy to prevent
circuit thrombosis, occlusion and systemic thrombus formation; however, maintaining therapeutic
anticoagulation is exceptionally challenging due to continuous blood trauma, high transfusion
requirements and underlying coagulopathies resulting from the initial injury (22). Because of this,
iatrogenic bleeding (secondary to anticoagulant administration and blood stress from circulation)
is one of the most common complications associated with ECLS therapy and has been cited as
problematic for >30% of patients, with recent reports suggesting this may occur in as many as 6080% of patients (23-27). Anticoagulation for ECLS is typically performed with unfractionated
heparin, direct thrombin inhibitors or combinations thereof; however, there are no universal
guidelines for administration of these agents resulting in highly variable, center-specific
hemostasis management protocols (22, 28). Lack of consensus on the type of anticoagulant to use,
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the form of monitoring test to be employed and the therapeutic target range for each test, results
in suboptimal outcomes and inconsistent patient care (28).
To address this challenge, research groups and industry partners are developing
biocompatible surface coatings to be applied to the ECLS circuit, providing localized
anticoagulation at the blood-biomaterial interface. Inspiration for these coatings is derived from
the vascular endothelium, the endogenous blood-contacting interface that covers over 3,000-6,000
m2 in adult humans (19, 29). The vascular endothelium serves as more than a passive barrier that
separates blood from foreign sources of activation. The endothelium actively regulates blood
fluidity and hemostasis by continuously modifying surface chemistry, excreted factors, flow
distribution and permeability (29, 30). Further, the surface chemistry and functional characteristics
of the endothelium are extremely heterogenous, varied to support tissue-specific needs and
fluctuating metabolic demands (31). The intricacy and adaptability of the endothelium emphasize
the complexity of developing an artificial hemocompatible surface.
Blood-biomaterial interactions during ECLS are dependent on several factors, to include
the composition and surface characteristics of the material, the rate and path of blood flow, the
duration of exposure, and the status and composition of the blood (32). These factors vary
depending on the type of organ support the device is designed to supply, and the specific
configuration of the circuit - which varies by manufacturer. For this reason, a universally
hemocompatible material currently does not exist; and further, a material that is biocompatible for
one ECLS application may not be compatible for another. In this review, we discuss
hemocompatible materials that are clinically utilized for ECLS, including the biological inspiration
that led to their development and the clinical and pre-clinical studies demonstrating their efficacy.
It is important to note that to date administration of systemic anticoagulants is standard practice
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for all forms of ECLS, regardless of biocompatible coatings, as current surface coatings alone are
insufficient to prevent coagulation disturbances (33, 34). We will also discuss investigational
surface coatings for ECLS and detail how these coatings are tested and optimized in the pre-clinical
development phase. Finally, we will highlight key considerations for development of biomaterials
specifically for ECLS, emphasizing current gaps in how materials are tested in the laboratory
versus how they are utilized in the field.
3.3 Biomaterials for ECLS – coatings in the clinic.
There are many important considerations when developing a biomaterial for ECLS, as the
devices vary significantly depending on the type of organ support and level of therapy they
provide. In general, ECLS circuits consist of vascular access catheters, a blood pump, a membrane
(modified for the specific type of organ support) and connective tubing. The circuits are generally
composed of hydrophobic materials including polyvinylchloride (PVC), silicone, polycarbonate,
polymethylpentene (PMP), polyurethane and/or polypropylene (11). Application of coatings over
the surface of these polymers or incorporation of bioactive substances into the polymer matrix
could alter the physical and mechanical properties of the polymer, potentially altering performance
of the device. Additionally, the intended blood flow rates the devices are designed to support vary
significantly depending on the application – for example, a rate of 3 mL/kg/min is recommended
for adult respiratory support; whereas, a rate of 60mL/kg/min is recommended for adult
cardiopulmonary support (35). The size of the devices is also an important consideration, as the
devices are modified to accommodate neonates, pediatrics and adult populations. Finally, the
duration of use of the device must be considered to ensure that the coating is functional for the
time of intended use. These important considerations are integral in development of biomaterials
for ECLS and will be discussed in context of the clinically available coatings described below.
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3.3.1 Heparin. Immobilized heparin, first described in 1963 by Dr. Vincent Gott, is one of
the first biomaterials applied to ECLS and is currently the most widely utilized (36). Heparin binds
to and accelerates the activity of antithrombin III (ATIII), an enzyme that inhibits thrombin, Factor
Xa and other clotting enzymes, and also performs numerous anti-inflammatory functions (37, 38).
Within the vascular endothelium, heparin sulfate residues with heparin-like activity are anchored
to the endothelium by a proteoglycan core (37, 39). These residues bind and localize ATIII on the
endothelial surface (40) and are key components of the glycocalyx – a protective barrier between
the blood and endothelial cells that performs mechanotransduction and micro-regulatory functions
(39).
Heparin coatings (Figure 3.2 A) have been utilized clinically for over 4 decades, initially
for cardiopulmonary bypass (CPB) and eventually for ECLS circuits and catheters (41). Clinical
trials and meta-analyses comparing heparin-coated circuits to uncoated circuits for both CPB and
ECLS showed that heparin coating reduced transfusion requirements (42-45), inflammatory cell
activation (44, 46), complement activation (47, 48) and ICU length of stay (42-45); however,
platelet count and activation were generally equivalent between heparin-coated and uncoated
circuits (49, 50). Studies that distinguished between covalently bound versus ionically bound
heparin found that covalent binding improved patient outcomes (42, 47), likely due to better
retention of the heparin molecule which can be displaced and eluted from the surface via ion
exchange (11).
While the above approach has made a significant impact on medical care, most reported
benefits have been observed with short-term (~6 hrs) use (11). This may be sufficient for CPB, but
ECLS can be continued for weeks to months at a time and requires a more robust solution.
Currently no data supports utilization of immobilized heparin for ECLS without supplemental

50

Figure 3.2 Illustration of clinically available biomaterial coatings for extracorporeal life
support. A) Immobilized heparin coating shown in green. Antithrombin III (ATIII) binds to
heparin inducing a conformational change in ATIII, increasing enzymatic activity by 1,000fold. ATIII binds and inactivates thrombin, inhibiting thrombus formation. B) Immobilized
albumin competitively inhibits adsorption of procoagulant proteins like fibrinogen,
providing surface passivation. C) Phosphorylcholine zwitterion coating modifies surface
hydrophobicity and resembles the surface of cell membranes.
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anticoagulation (51). In fact, even when used in combination with systemic anticoagulant drugs,
this approach may be insufficient. For example, Lehle and colleagues examined heparin-coated
membrane oxygenators from 28 ECLS patients receiving ECLS for respiratory failure for mean
duration of 11 days with supplemental continuous heparin infusion (52). They observed significant
thrombus formation and cellular deposits that formed “pseudomembranous” layers of 30-45 µm
(primary wall thickness of gas exchange fiber is 75 µm). These layers can impede gas exchange,
and in this study led to complete occlusion of 3 membranes, requiring circuit exchange during
treatment. Pre-clinical comparison of heparin-coated ECLS circuits used with and without
continuous heparin administration in an ovine model of oleic acid-induced lung injury
demonstrated no difference in platelet aggregation and activation, thromboelastography or
coagulation factors throughout 10 hours of circulation (53); however, after 10 hours greater
thrombus deposition was observed on membranes from the group that did not receive continuous
heparin infusion (54). Clinically, heparin-coated circuits have been utilized without systemic
heparin (or with low-dose heparin protocols) for hours to days in trauma patients with bleeding
complications; however, these patients are transitioned to heparin infusion protocols once bleeding
is resolved (55-57).
In addition to insufficient longevity and efficacy, other critical limitations to this approach
for ECLS are apparent. Heparin will not dissociate thrombin already bound to fibrin on material
surfaces and will not inactivate platelets, meaning once a clot has formed heparin will not dissolve
it (14). Additionally, extended exposure to heparin can invoke generation of antibodies against
platelet activating factor 4 complexed with heparin, causing pronounced platelet activation in a
condition called heparin induced thrombocyotpenia (HIT) (51). This condition is normally treated
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by discontinuation of heparin therapy; however, when a tethered-heparin circuit is in use, this may
require complete withdrawal and replacement of the circuit (58).
3.3.2 Albumin. Introduced in the 1980s, immobilized albumin has been applied to ECLS
materials and is most often used clinically when HIT is suspected (59, 60). In the vasculature,
albumin is incorporated in the endothelial glycocalyx via interactions with proteoglycans and
glycoproteins where it serves an important role in controlling the charge and permeability of the
glycocalyx (39, 61). Albumin is the most abundant plasma protein and is thought to be inert to
platelet activation and pro-thrombotic reactions when adsorbed on a biomaterial surface (62, 63).
This is because albumin lacks specific binding sequences for platelets, leukocytes and coagulation
enzymes (64). In this way, immobilized albumin acts as a “passivating agent” or competitive
inhibitor of pro-coagulant plasma proteins – primarily fibrinogen, but also vWF, fibronectin,
vitronectin and immunoglobins (Figure 3.2 B) (62). In a 2-hour ex vivo extracorporeal circulation
study, use of albumin coating reduced circulating plasma concentrations of activation markers of
platelets, complement, coagulation and immune cells. Furthermore, membranes had reduced
fibrinogen adsorption at the end of study compared to uncoated controls (65). While albumin
coated ECLS circuits have been successfully utilized in the clinic, primarily in the instance of HIT
(66, 67), specific data demonstrating efficacy and comparing this approach to other coatings is
lacking.
3.3.3 Phosphorylcholine (PC). PC is a neutral, zwitterionic phospholipid that composes
the surface of the lipid bilayer of cell membranes. PC biomaterial coatings have been developed
to modify the surface charge and hydrophilicity of foreign polymers to resemble that of endothelial
cells (Figure 3.2 C) (11, 68). In addition to serving as a physical barrier, phospholipids play an
important role in cell-to-cell communication through alteration in their charge and composition
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(69). For example, erythrocytes and platelets have asymmetric cell membranes, where in the
native/resting state a greater proportion of neutral charge PC is exposed on the outer cytosolic
leaflet and a greater proportion of negatively charged phosphatidylserine (PS) is present on the
inner/cytoplasmic leaflet (68). When these cells become activated/pro-coagulant, phospholipid
scrambling occurs, and negatively charged PS is exposed on the outer cytosolic leaflet at a greater
proportion (68, 69). In-vitro assessment of a PC coating applied to hollow-fiber oxygenator
segments using ovine blood and 3 hour exposure time did not show an appreciable reduction in
platelet deposition compared to heparin coating (70). When PC coating was compared to uncoated
materials during CPB, the coating preserved platelet count, reduced platelet activation and reduced
transfusion requirements (71, 72); however, when compared to heparin and albumin-coated
materials, PC-coating was similar and did not show additional benefit in terms of biocompatibility
during use or in post-operative outcomes (73, 74). One CPB study suggested that heparin and PC
coatings may reduce inflammation when compared to albumin (75). Like albumin, while
successful use of PC coatings during ECLS has been reported (76-78), there is no evidence to
support use without continuous systemic anticoagulation therapy.
3.3.4 Other synthetic polymer surfaces. A number of synthetic polymer surfaces have
been developed to increase hydrophilicity and biocompatibility of ECLS surfaces – these surfaces
have hemocompatible properties but are not directly modelled after biological molecules. This
includes poly(ethylene) oxide (PEO), poly 2-methoxyethylacrylate (PMEA) and surface
modifying additives (SMAs) (11). PEO, which alone has been shown to increase hydrophilicity
and decrease protein adsorption (79), is incorporated in the Trillium® coating (Medtronic; Dublin,
Ireland) which has a functional layer of PEO, sulfate/sulfonate groups and heparin. Applied to
CPB, Trillium® was comparable to other heparin-coated materials (80-82) and preserved platelet
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count (81, 83), reduced platelet and granulocyte activation (80), and reduced complement
activation versus uncoated controls (83). PMEA is generated on PVC and polypropylene via
plasma activation (11) and is composed of a hydrophobic backbone along the polymer surface and
a weakly hydrophilic surface on the blood-contacting face (84). The hydrophilic face attracts a thin
boundary layer of water that prevents adsorption and deformation of proteins (84). SMA, which
can be blended into the base polymer or applied to the surface, is a triblock copolymer with
alternating hydrophobic and hydrophilic regions thought to compete for platelet binding sites on
adsorbed proteins (84). PMEA and SMA materials have demonstrated questionable efficacy in the
CPB literature, with some authors reporting comparable results to heparin-coated circuits (85),
others reporting modest preservation of platelet count (86) and/or decreased transfusion
requirements compared to uncoated controls (87), and still others reporting no appreciable benefit
(84, 88). Additionally, in a pediatric CPB study, investigators reported transient leukopenia,
elevated respiratory quotient and C-reactive protein levels when using PMEA membranes versus
heparin membranes, which may have caused post-operative systemic inflammatory respiratory
syndrome (89). Use of these synthetic surfaces without supplemental anticoagulation therapy is
not advised.
3.4 Biomaterials for ECLS: investigational coatings.
A multitude of hemocompatible surface coatings are under development and have been
applied to catheters and tubing segments. Many of these coatings demonstrate promising qualities
that could be beneficial if applied to ECLS materials; however, in this review we summarize only
surfaces that have reached a developmental stage where they have minimally been evaluated in a
flow model.
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3.4.1 Slippery, non-adhesive surfaces. One novel approach to inhibit protein adsorption
and thrombus formation is utilization of liquid lubricant layers that have slippery, “omniphobic”
characteristics. One such coating is tethered liquid perfluorocarbon (TLP), which is a bilayer
coating that utilizes 1) a covalently bound flexible perfluorocarbon tether layer applied to the
substrate/native polymer and 2) a thin, mobile liquid surface layer of perfluorocarbon lubricant
(90). The tether layer attracts and anchors the liquid lubricant, preventing washout into overlaying
fluid under flow. TLP is a modification of a coating approach called “SLIPS” or “slippery, liquidinfused, porous surfaces.” SLIPS were inspired by the Nepenthes pitcher plant which has a
roughened, porous rim that attracts a liquid water layer via capillary forces to create a slippery
surface that prevents insect attachment, causing them to slide into the pitcher of the carnivorous
plant (91). Leslie, et al showed that TLP applied to acrylic and polysulfone reduces fibrinogen
adsorption and platelet adhesion following incubation in whole blood (90). In vivo they examined
TLP using an 8 hour porcine AV-shunt model and demonstrated that TLP-coated PVC tubing
maintains patency under maximum flow rate of 300 mL/min without administration of heparin;
whereas, four of five uncoated control tubing segments became occluded (90). Interestingly, they
also found that TLP reduced biofilm formation 8-fold when applied to PVC versus uncoated PVC
when Pseudomonas aeruginosa bacteria were grown on the surface for 8 weeks.
A limitation to the aforementioned studies is that in vitro tests were performed for 0.5 - 1.5
hours and in vivo assessment was conducted for 8 hours, so it remains unclear whether the liquid
layer is retained on the material surface at a functional level beyond this time. Howell, et al showed
that similar immobilized perfluorinated lubricant layers were stable following 16 hours circulation
using deionized water at dialysis-like flow rates of 10-90 mL/hr (92). These studies also only
evaluate TLP applied to tubing, without assessing the feasibility or functional impact of applying
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the coating to ECLS membranes, which is the most common location where clotting occurs. Liquid
lubricant layers have been applied to ECLS circuit materials using other methods, such as chemical
vapor deposition of a perfluorinated organosilane on coronary catheters (93) and swelling of
silicone oil into the polymer matrix of silicone tubing (94); however these materials have yet to be
evaluated under flow conditions that replicate clinical ECLS conditions.
3.4.2 Nitric oxide (NO) releasing materials. Another bioinspired approach to prevent
foreign surface mediated thrombosis during ECLS is development of NO-releasing materials that
produce NO at the blood-biomaterial interface at a similar flux as occurs from healthy endothelial
cells in the vasculature, estimated to be 0.5-4 x10-10 mol cm-2 min-1 (95). In the endothelium NO
is a potent vasodilator, prevents platelet aggregation and adhesion, inhibits monocyte activation,
and also has bactericidal and antimicrobial properties (96-98). Various NO donor species such as
diazeniumdiolated

dibutylhexanediamine

(DBHD/N2O2)

(99-101)

and

S-nitroso-N-

acetylpenacillamine (102-104) have exhibited anithrombogenic properties when incorporated into
medical polymers and evaluated in a 4-hour extracorporeal circulation model in rabbits. In this
model, the coatings are applied to PVC tubing that forms an arterio-venous shunt when connected
to the carotid artery and jugular vein via two angiocatheters. Thrombus deposition area, platelet
count and activity (platelet P-selectin expression and aggregometry) and plasma clotting time are
assessed (105). To investigate the NO-release capacity of these materials in vivo beyond the 4hour circulation time frame, Brisbois and colleagues evaluated cannulas fabricated from SNAPdoped Elast-eon™ E2As polymer following implantation in the jugular veins of sheep for 7 days
(106). Thrombus area was reduced in the SNAP-doped group, and bacterial adhesion was reduced
by 90% compared to controls. Additionally, at the end of use, NO flux from the SNAP-doped
catheters was 0.6 ± 0.3 x 10-10 mol cm-2 min-1, still within the range of endothelial NO-flux. A
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limitation to this approach is that only a finite amount of NO donors can be incorporated into the
polymer matrix; and the longevity and efficacy of this approach remains to be evaluated using
flow rates and study durations that simulate the clinical condition for specific forms of ECLS.
Another solution to extend performance of NO-releasing materials is utilization of a nitric
oxide catalyst to generate NO from bio-available NO-donors, such as S-nitroshothiols (RSNOs)
(107). Metal-organic frameworks (MOFs) such as the copper-based H3[(Cu4Cl)3-(BTTri)8]
(H3BTTri = 1,3,5-tris(1H-1,2,3-triazol-5-yl)benzene), or CuBTTri, are capable of generating NO
from endogenous sources to provide a continuous source of NO as long as bioavailable donors are
present - rather than pre-loading circuit materials with finite levels of synthetic donors (107).
CuBTTri accelerated NO release from S-nitrosoglutathione (GSNO) nearly 65-fold relative to
thermal decomposition of GSNO (108) and CuBTTri impregnated polymers have shown
significant NO release from a variety of RSNOs (107-109). CuBTTri polymers have yet to be
evaluated in vivo under flow. In addition to copper-based MOFs, NO-generating copper
nanoparticles have been incorporated into polyurethane and applied to PVC tubing and
angiocatheters for evaluation in the 4-hour rabbit circulation model (110). The coating preserved
platelet count and function, reduced thrombus area and fibrinogen Aү dimer formation and
prevented monocyte activation, so long as a continuous infusion of an exogenous RSNO was used
in combination with the coating. These effects were not observed without supplemental RSNO
administration, suggesting endogenous RSNO concentration may be insufficient for this approach.
Combination coatings that incorporate both NO-generating copper nanoparticles with a synthetic
donor (SNAP) into a polymer composite produce NO-flux as high as 11.7 ± 3.6 x 10-10 mol cm-2
min-1, causing a 99.8% reduction in bacterial adhesion and 92% reduction in platelet adhesion in
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vitro compared to controls (111). This approach requires further evaluation in vivo using ECLSrelevant flow conditions.
3.4.3 Immobilized direct thrombin inhibitors (DTIs). Similar to immobilization of
heparin, immobilized DTIs like bivalirudin and argatroban could prevent thrombus formation at
the biomaterial surface, while reducing systemic complications. Unlike heparin, these agents do
not require a cofactor and can inhibit thrombin already bound to fibrin clots (112). For example,
argatroban has been applied to polyurethane angiocatheters and PVC tubing and evaluated in vivo
in the 4-hour rabbit arterio-venous shunt model described above (113) with blood flow rate ranging
from 59-80 mL/min. The argatroban coating reduced the total area of thrombus formation on the
tubing but did not preserve platelet count, as argatroban does not inhibit platelet activation.
Thrombin clotting time in circulating blood was elevated in the argatroban group, suggesting some
leaching may occur (113). The efficacy and longevity of these materials at flow rates typically
observed during ECLS (0.5-7 L/min) have yet to be assessed, and application of the coating to the
membrane will require further investigation.
3.4.4 Glycosaminoglycan polymer brushes. The endothelial glycocalyx consists of an
extensive layer of glycosaminoglycan containing proteoglycans organized into “bush-like”
structures of 100-200 nm that provide a physical barrier to protein adsorption. Attempts to recreate
organized glycosaminoglycan-rich structures is challenged by the fact that these residues are
strongly polyanionic, making assembly electrostatically unfavorable (114). To overcome this, a
technique was developed to form polyelectrolyte multilayers that couple polycations like chitosan
with polyanions like hyaluronan (115). This technique was used to form polymer brushes rich with
sulfated glycosaminoglycans found in the glycocalyx, organized into structural domains as they
are in the endothelium. The materials successfully inhibited protein adsorption and fibrin
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formation but require further evaluation in vitro and under ECLS-relevant flow conditions (114).
Additionally, this approach has been coupled with nitric oxide releasing donor species to combine
multiple thrombo-regulatory mechanisms as occurs in the endothelium (116).
3.4.5 Factor XIIa inhibitor. Coagulation fXIIa is instrumental in thrombosis during blood
exposure to foreign surfaces, initiating contact pathway activation (62). To target this, application
of corn trypsin inhibitor (CTI), a selective fXIIa inhibitor, was applied to polyurethane catheters
using polyethylene glycol (PEG) conjugation to immobilize CTI on the catheter surface (117).
These catheters were evaluated in a rabbit model where time to occlusion was extended 2.5-fold
compared to uncoated controls. There was no difference in prothrombin time or activated partial
thromboplastin time from circulating blood in either group, suggesting that CTI does not leach
from the material surface. Others reported reduced fibrinogen adsorption using PEG conjugated
CTI on polyurethane following incubation in plasma (118). Further studies are needed to evaluate
this approach applied to other circuit components under flow conditions and exposure times that
resemble ECLS.
3.4.6 Endothelial cell seeding. Rather than replicate a specific thrombo-regulatory aspect
of the endothelium, the idea of applying a layer of endothelial cells over the surface of medical
polymers to achieve a completely hemocompatible surface has been investigated. This is
accomplished by seeding cells onto the surface directly (in vitro pre-endothelialization) or by
formulating a surface that will promote attachment and differentiation of circulating endothelial
progenitor cells on the biomaterial surface to self-assemble an endothelial layer in vivo (in situ
endothelialization (119). The pre-endothelialization approach, which has been utilized for vascular
grafts and stents, is now being adapted for ECLS applications. For example, Pflaum, et al applied
endothelial cells isolated from human umbilical cord blood to segments of polymethyl pentene
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(PMP) from a hollow-fiber gas exchange membrane for ECLS (120). Because endothelial cells
will not adhere to a strongly hydrophobic surface like PMP, a layer of titanium dioxide was applied
to allow for cell seeding; however, the titanium dioxide coating alone reduced the oxygen transfer
rate of the fibers by 22% compared to controls, prior to addition of the endothelial cell layer.
Endothelial cells adhered to the titanium dioxide coated fibers forming a monolayer, and withstood
shear stress at physiological levels (30 dyn/cm2). Additionally, the seeded endothelial cells
remained in a non-activated state, determined by expression of pro-inflammatory/prothrombotic
markers (ICAM-1, VCMA-1, E-selectin, tissue factor, thrombomodulin). While this is a
provocative approach, the feasibility of manufacturing such a product – including shelf-life,
sterilization, cell source, cost, etc., and the ability to apply the cells to complete components of the
ECLS circuit rather than small membrane segments tested thus far must be established.
3.5 Conclusions.
The vast number of strategies aimed to develop a hemocompatible surface for ECLS
emphasizes the importance and complexity of this problem. After reviewing the limitations of
clinically available coatings and understanding how investigational coatings are assessed, it is
apparent that there is a disconnect between how these coatings are utilized in clinic and how
coatings are developed and optimized in the lab. For example, while it is important and feasible to
assess novel coatings using stationary laboratory assays in whole blood or plasma during the initial
optimization phase, it is necessary to establish if a coating will perform with similar efficacy and
durability under in vivo flow conditions in animal models that closely resemble the physiologic
complexity of a patient and account for the intricacies of patient care. Use of arterio-venous shunt
models in small animals does not generate flow rates that would be utilized for most forms of
ECLS, and also does not account for hemolysis and shear induced by the blood pump.
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Additionally, the majority of studies evaluate coatings applied to tubing only, while the membrane
is the most common site of clotting complications (34). This is likely the most challenging
component of the circuit to coat due to the large surface area, complex structure and possibility of
altering performance of the native polymer – such as gas transfer and permeability of membrane
fibers designed for extracorporeal pulmonary support. The condition of the blood in investigational
studies is also very important as injury status, species, hydration, anesthesia medications,
anticoagulation drugs, presence of bacteria etc. will alter the coagulation response of the blood.
Finally, and potentially most importantly, many of the studies mentioned in this review were
conducted for only a few hours, as many coatings for ECLS were initially developed and evaluated
for cardiopulmonary bypass utilizing a 6-hour time frame. Studies of extended duration specific
to certain ECLS applications are necessary to ensure that the biomaterials can perform for the
duration of intended use. For example, the average duration of ECLS for adult respiratory support
is 271 hours, which is more than 45 times the current 6-hour testing protocol (3). In summary, it
is important for biomedical scientists, chemists, engineers, clinicians and industry to work together
to understand the complexity of clinical care and patient management, the fundamentals and
properties of materials science, the intricacies of coagulation and thrombogenesis, and the
challenges of developing and manufacturing a medical product. The future of ECLS will depend
on these types of interactions to develop a robust solution for ECLS without anticoagulation.
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Chapter Four:
A metal organic framework reduces thrombus formation and platelet aggregation ex vivo
4.1 Abstract.
4.1.1 Background. Management of hemostasis is a key challenge during extracorporeal
life support (ECLS). Metal organic frameworks are being investigated for use as nitric oxide
(NO) catalysts for incorporation into ECLS circuitry to prevent thrombosis at the bloodbiomaterial interface. A specific metal organic framework, CuBTTri, has been shown to
accelerate NO-release from bioavailable donors like S-nitrosoglutathione (GSNO). We
hypothesized that CuBTTri would reduce thrombus formation in whole blood (WB) and inhibit
platelet aggregation.
4.1.2 Methods. CuBTTri particles were added to WB and analyzed by
thromboelastography (TEG). Biostable metal-based frameworks (MIL-100, Zeolite USY) were
added to blood as controls, in addition to a saline vehicle control. Reaction time (R), clot
formation time (K), alpha-angle, clot strength (MA), and percent fibrinolysis (LY30/LY60) were
recorded. The effect of CuBTTri on platelet aggregation was assessed in WB and platelet rich
plasma (PRP), both with and without addition of GSNO.
4.1.3 Results. CuBTTri significantly prolonged R and K and decreased alpha-angle and
MA relative to the metal framework controls. Dose escalation results suggest that the control
metal-based particles induce thrombus formation, as R and K were significantly reduced

Portions of this chapter were previously published and have been used with permission from the
publisher. Roberts TR, Neufeld MJ, Meledeo MA, Cap AP, Reynolds MM, Cancio LC, Batchinsky, AI.
A metal organic framework reduces thrombus formation and platelet aggregation ex vivo. Journ of
Trauma and Acute Care Surg. 2018;85(3):572-579.
74

compared to the saline control; however, this did not occur in the CuBTTri group. LY30/LY60
were elevated in the CuBTTriroup versus saline (p = 0.014) but were not different from metal
framework controls. CuBTTri alone and with GSNO reduced platelet aggregation in WB (p
<0.0001), while GSNO alone had no effect. In PRP, GSNO and CuBTTri inhibited platelet
aggregation separately, and together decreased aggregation by 35% relative to GSNO alone (p =
0.004).
4.1.4 Conclusions. CuBTTri reduced thrombus formation and inhibited platelet
aggregation. CuBTTri enhanced platelet inhibition with GSNO, which was consistent with
reports that CuBTTri accelerates NO release from endogenous NO-donors. This initial
characterization of CuBTTri demonstrated its potential as an anti-thrombogenic agent to be
further evaluated with incorporation into ECLS circuitry.
4.2 Background.
The use of extracorporeal life support (ECLS) is increasing in trauma populations for
severe cardiopulmonary failure, as advancements in device circuitry and ease of cannulation have
improved feasibility (1). Trauma patients are optimal candidates for ECLS as they are generally
young and may have a reversible disease process without co-morbidities (2). In a systematic review
of ECLS for trauma from 1994-2015, survival to discharge ranged from 50-79%, demonstrating
the potential of this therapy in trauma populations (3). Additionally, data from recent military
conflicts show that a large number of casualties incur combined injuries of increasing severity
which necessitates utilization of various forms of ECLS (4, 5). Several forms of ECLS have been
used in combat zones and include renal support, extracorporeal membrane oxygenation (ECMO)
and combinations thereof (4, 6).
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Despite technological advances, bleeding remains a major ECLS complication, often
requiring surgical intervention and extensive transfusion. At the same time, systemic
anticoagulation is recommended for all current forms of ECLS to minimize thrombosis (7). Both
thrombotic and hemorrhagic complications take place during ECLS, resulting from blood contact
with foreign polymers in the circuitry, platelet loss, consumption of clotting factors, hemodilution,
tubing size to membrane surface ratio and shear-stress (8, 9). Use of systemic anticoagulants, while
potentially mitigating thrombosis, increases risk of bleeding (10, 11). Systemic anticoagulation
with unfractionated heparin (UFH), is the leading clinical strategy to prevent thrombotic
complications with ECLS (7); however, no universal guideline for heparin administration or
consensus on coagulation monitoring exists outside of variable, center-specific management
protocols (8, 12). In summary, thrombotic and bleeding complications present challenges to
management of ECLS and limit its utilization in trauma patients due to ongoing bleeding risk.
Several research efforts investigated localized, circuit-focused anticoagulation strategies,
including regional infusion of anticoagulants such as citrate directly into the ECLS circuit (13) and
development of anti-thrombogenic surfaces (5, 11). Some examples of modified surfaces include
tethering heparin or plasma proteins to the circuit surface (14-16), imparting hydrophilic or
omniphobic characteristics on circuit materials (17-19) and development of biomimetic materials
inspired by the endogenous endothelium, such as nitric oxide (NO) releasing materials (20-22). Of
these efforts, NO, is a promising therapeutic candidate as an endogenous substance with a short
half-life, reversible action on platelets and localized action at the material and blood interface (22).
A new approach to anticoagulation is utilization of an additive that allows for enhanced
NO generation from endogenous NO donors within the body. Metal-organic frameworks (MOFs)
such as the copper-based H3[(Cu4Cl)3-(BTTri)8] (H3BTTri = 1,3,5-tris(1H-1,2,3-triazol-5-
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yl)benzene), or CuBTTri, are capable of generating NO from NO donors, such as S-nitrosothiols
(RSNOs), which are biologically available in the blood (23). In this way, CuBTTri serves as an
NO catalyst, generating NO from endogenous sources rather than pre-loading circuit materials
with finite levels of NO donors. Incorporation of NO producing MOFs like CuBTTri into blood
contacting biomedical polymers could provide a continuous source of NO so long as endogenous
donors are present (Figure 4.1 A). This may impart platelet quiescence at the blood and
biomaterial interface without the untoward systemic effects of systemic anticoagulants. At present,
CuBTTri is the most promising candidate for biomedical applications due to the excellent stability
of this material in biological media, including blood (23). The ability of CuBTTri to generate NO
from a variety of RSNOs has been confirmed for both free CuBTTri particles and upon
incorporation into polymers (23-25). Whereas CuBTTri particles and the impregnated CuBTTri
polymers enhanced NO generation from multiple different RSNOs, its effects in blood on realtime clot formation and platelet aggregation have not been investigated. The objective of this study
was to test the anti-thrombogenic potential and bioactivity of CuBTTri using thromboelastography
(TEG) (Figure 4.1 B) which has been used to investigate the impact of various biomaterials at the
blood/biomaterial interface (24-26). Additionally, we investigate the effect of CuBTTri on
platelets directly via platelet aggregometry, utilizing the bioavailable NO donor Snitrosoglutathione (GSNO) as a positive control to demonstrate the catalytic activity of CuBTTri.
We hypothesized that CuBTTri particles reduce clot strength and decrease platelet aggregation in
ex-vivo human blood. Additionally, we hypothesized the CuBTTri would further reduce platelet
aggregation in the presence of GSNO, in comparison to GSNO alone.
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Figure 4.1 A) Metal organic framework (MOF) coated Tygon segment. The specific MOF is designed to
generate nitric oxide (NO) from biologically available donors, such as S-nitrosothiols (RSNO), releasing a
disulfide byproduct (RSSR). B) Schematic of nitric oxide catalysis by metal organic framework
suspended in blood for thromboelastography (TEG) analysis.
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4.3 Methods.
4.3.1 Preparation of MOF. CuBTTri was synthesized following a previously reported
method (23). Briefly, 225 mg of H3BTTri was added to 40 mL of DMF; the solution was then
adjusted to a pH of 4 using hydrochloric acid to dissolve H3BTTri into solution. Separately 335
mg of CuCl2*2H2O was dissolved in 5 mL of DMF. The solution was then added to the H3BTTri
solution and placed in the oven at 100 oC for three days, during which crystal growth occurred
resulting in the formation of a deep purple powder. Subsequently, upon solvent removal via
centrifugation, the powder was rinsed several times with additional DMF followed by Millipore
water (18 MΩ•cm). The rinsed CuBTTri was then added into a vial containing Millipore water and
placed in the oven at 80oC for an additional day to allow for solvent exchange, resulting in a light
purple powder. The MOF was then centrifuged to remove water and allowed to air dry for several
days. Confirmation of CuBTTri was performed by powder x-ray diffraction on a Bruker D-8
Discover DaVinci X-ray diffractometer (Cu Kα X-ray source, line focus) (Bruker, Billerica, MA,
USA). All measurements were performed at 4-35θ with a step count of 1.0 (Appendix C).
4.3.2 Preparation of S-nitrosoglutathione. GSNO was prepared following an adapted
method of a previously reported synthesis by Hart (27). In brief, glutathione (1.56g, 5 mmol) was
added to a round bottom flask containing 8 mL of Millipore water and 2.5 mL of 2 M hydrochloric
acid. Following addition of glutathione, the flask was placed in an ice bath and cooled to 0ᵒ C, to
which sodium nitrite (0.342 g, 5 mmol) was added. The resulting mixture was covered, protected
from light and allowed to stir for approximately 40 min. The red solution was then treated with 10
mL of ice-cold acetone and stirred for an additional 10 min. The resulting red precipitate was
isolated using filtration and subsequently washed with 5 × 5 mL of ice-cold water, 3 × 5 mL icecold acetone, and 3 × 5 mL ice cold diethyl ether. The precipitate was then allowed to dry followed
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by placement under vacuum to remove the presence of trace solvent and stored at -20ᵒ C in the
absence of light. UV-vis spectroscopy was used to confirm GSNO formation in water by the
appearance of peaks at 335nm (π → π*) and 545nm (nN → π*). A GSNO stock solution was
prepared approximately 10 min prior to all runs by dissolving 10 mg GSNO in 10 mL saline prior
to use on each study day. The resulting solution was then covered to protect from light and used
within 3 hours or preparation.
4.3.3 Blood collection and preparation. Whole blood was collected in a de-identified
fashion at the U.S. Army Institute of Surgical Research Blood Bank from a total of 20 healthy
male and female donors between 18-40 years of age under an approved standard operating
procedure at the U.S. Army Institute of Surgical Research Blood Bank. Donors were non-smokers
with no known coagulopathies. Blood from the same donor was used for both TEG and platelet
aggregometry, provided both experiments could be completed within 2 hours post-collection time
(for TEG, n = 20; platelet aggregometry, n = 12). Due to the unprecedented nature of this work an
effect size could not be estimated, and the sample size was chosen based on previous studies
utilizing similar methods. Blood was collected in 3.8% citrated BD Biosciences vacutainers
(Franklin Lakes, NJ, USA) and analyzed within 2 hours of collection time at 37o C. Platelet rich
plasma (PRP) was prepared by centrifugation (200-g for 10 min without braking). PRP platelet
counts were standardized to 250 x 109/mL by dilution with the donor’s platelet-poor plasma
(obtained by secondary centrifugation at 2000-g for 20 min without braking). Counts were
determined using an ABX Micros 60 hematology cell counter (Horiba Medical; Irvine, CA, USA).
4.3.4 Preparation of MOF solutions. A CuBTTri solution was prepared by suspending
CuBTTri in phosphate buffered saline (PBS), pH=7.4, to final concentrations of 2 mg / mL
(CuBTTri High) and 0.2 mg / mL(CuBTTri Low). As controls, solutions of the same concentration
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were prepared utilizing commercially available metal-based frameworks MIL-100 (Strem
Chemicals, Inc.; Newburyport, MA, USA) and Zeolite USY (Zeolyst International;
Conshohocken, PA, USA) to account for the effects of crystalline metallic particles in solution.
Mil-100 is an iron 1,3,5-tricarboxylate based MOF, which has been utilized for drug carrying
applications (28, 29). Zeolite USY is an aluminum-based inorganic framework commonly used
for solid acid catalysis. These specific metal frameworks were chosen to serve as metal-framework
variants of the CuBTTri as they remain highly stable in aqueous conditions and will not undergo
substantial decomposition in blood.
4.3.5 Thromboelastography. For each donor (n = 20), 100 µL of each MOF solution
(CuBTTri, Mil-100 and Zeolite) was added to 300 µL of citrated whole blood. For 10 donors, a
high concentration of each MOF solution (2 mg/mL) was added, and for the remaining 10 donors,
a low concentration (0.2 mg/mL) of MOF solution was utilized. As a vehicle control, 100 µL of
PBS was added to 300 µL citrated whole blood. Each mixture was gently inverted, and 340 µL
was transferred to a standard TEG clear cup to which 20 µL CaCl2 had been added. TEG was
performed between 20 – 30 min post-collection time without activating reagents using the TEG
5000 Hemostasis Analyzer System (Haemonetics Corporation; Braintree, MA, USA). The
following variables of interest were recorded: reaction time (R), initial clot formation time (K),
amplification rate (α-angle), clot strength (MA), and percent fibrinolysis at 30 min and 60 min
after MA was detected (Ly30 and Ly60). Samples were run in duplicate for each treatment, and
the average of the duplicates was taken for each donor. Duplicate TEG tracings that were
inconsistent (i.e. instrument error, early splitting of TEG tracing) were excluded from analysis.
4.3.6 Platelet aggregometry. Collagen stimulated platelet aggregation was determined
using impedance aggregometry (Multiplate 5.0, Verum Diagnostica; Munich, Germany). For each
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donor (n = 12), 300 µL whole-blood (WB) was diluted with 200 µL of 3 mM CaCl2 in 0.9% NaCl
and incubated at 37o C for 3 min. 50 µL of CuBTTri solution (0.4 mg / mL saline) (CuBTTri
Group and CuBTTri+GSNO Group), 50 µL Zeolite USY solution (0.4 mg / mL saline) (Zeolite
Group) or 50 µL saline (Saline and GSNO groups) was added. Immediately following addition of
MOF solution or saline, 50 µL GSNO in saline (50 µM) was added to the GSNO Group and
CuBTTri+GSNO Group, and 50 µL saline was added to all other groups (Saline, CuBTTri and
Zeolite Groups). Samples were incubated for 1.5 min, prior to addition of 20 µL collagen reagent
(3.2 µg / mL) which initiated the 12 min data collection period. This process was repeated using
platelet rich plasma (PRP) from the same donors. Per manufacturer’s instruction, if the internal
control (duplicate sensors) was outside the acceptance range (≥ 20% difference), the result was
excluded from analysis.
4.3.7 Statistical analysis. Statistical analysis was conducted using SAS 9.4 (Cary, North
Carolina, USA). A two-tailed test was performed with an alpha = 0.05 for significance. Results
are expressed as mean ± standard deviation. The distribution of the data was tested using a ShapiroWilk test. A mixed model with a random effect on donor was used to look for group differences.
For the TEG results, between group comparisons were made separately for the low dose groups
and high dose groups. The low and high doses were then compared within the same group. Tukey’s
adjustment was made for multiple comparisons.
4.4 Results.
4.4.1 Thromboelastography. The metal-framework controls (Zeolite and Mil-100) had
accelerated clot reaction (R) and formation times (K), as well as more rapid clot amplification rate
(α-angle) in comparison with the vehicle control (Figure 4.2). In the Mil-100 Group, this was
significant at both the low and high dose for reaction time (low = 25% decrease, high = 48%
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Figure 4.2 Figure represents mean ± standard deviation of the (A) reaction time, (B) clot formation time
and (C) amplification angle determined by thromboelastography of human donor blood (n ≥ 6 / group)
treated with free particles of a nitric-oxide catalyzing metal organic framework (CuBTTri). CuBTTri is
compared to metal-based framework control particles (Zeolite and MIL-100) and phosphate buffered saline
as a vehicle control (PBS). Particles were added at a low (0.2mg/mL) and high (2mg/mL) dose. Between
group comparisons for particle additives were made for particles of the same dose (low dose additives
compared separately from high dose). *Represents significant difference between groups (p < 0.05).
**Represents significant difference between low dose and high dose within the same group (p < 0.05).

83

decrease) and amplification rate (low = 11% increase; high = 26% increase), where the percent
change from the vehicle control was greater in the high dose group. In the Zeolite group, deviation
from the vehicle control was significant in the high dose group (R = 32% decrease, K = 23%
decrease, α-angle = 16% increase). This effect was not observed in the CuBTTri group, which did
not differ from the vehicle control for clot reaction and formation time or amplification rate
(Figure 4.2). Additionally, clot reaction and formation times were significantly longer in the
CuBTTri group versus both the Zeolite and Mil-100 groups at both the low and high dose (Figure
4.2 A and B). Amplification rate was significantly reduced in the CuBTTri group in comparison
with the Mil-100 Group at both doses and the high dose Zeolite Group (Figure 4.2 C). Clot
strength was significantly reduced in the CuBTTri group versus the metal framework controls and
the vehicle control in both the low and high dose groups (Figure 4.3 A). This reduction in clot
strength was more pronounced in the high dose group, where CuBTTri exhibited an 8% decrease
in comparison with both the Mil-100 and Zeolite group, and a 4% decrease from the vehicle
control. LY30 and LY60 were significantly elevated in the high dose CuBTTri group relative to
the vehicle control group but was not different from the Mil-100 or Zeolite Groups (Figure 4.3 B
and 4.3 C). This difference was not observed in the low dose CuBTTri group.
There were no differences for any TEG variables between the low and high doses of the
same additive (e.g. CuBTTri low vs CuBTTri high), with the exception that α-angle was
significantly higher (+8˚) in the high dose Mil-100 Group vs the low dose Mil-100 Group. There
was a numerical trend suggesting a pro-coagulant response to elevated concentrations of the metal
framework additives, as the high dose groups had shorter R and K times, as well as elevated αangles and MA in comparison with the low dose groups.

84

Figure 4.3 Figure represents mean ± standard deviation of the (A) clot strength, (B) clot lysis (LY30%)
and (C) clot lysis (LY60%) determined by thromboelastography of human donor blood (n ≥ 6 / group)
treated with free particles of a nitric-oxide producing metal organic framework (CuBTTri). CuBTTri is
compared to metal-based framework control particles (Zeolite and MIL-100) or phosphate buffered saline
as a vehicle control (PBS). Particles were added at a low (0.2mg/mL) and high (2mg/mL) dose. Between
group comparisons for particle additives were made for particles of the same dose (low dose additives
compared separately from high dose). *Represents significant difference between groups (p < 0.05).
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4.4.2 Platelet aggregation. In whole blood (Figure 4.4 A), CuBTTri reduced platelet
aggregation compared to the Zeolite (22% decrease) and Saline (23% decrease) Groups. A similar
reduction was observed in the CuBTTri+GSNO group (21% decrease vs. Zeolite; 22% decrease
vs. Saline), and there was no difference between the CuBTTri and CuBTTri+GSNO groups.
GSNO alone had no effect on platelet aggregation relative to the Zeolite and Saline Controls. In
PRP (Figure 4.4 B), CuBTTri again inhibited aggregation in comparison to Zeolite (19% decrease)
and Saline (21% decrease) Groups. GSNO alone significantly reduced platelet aggregation in
comparison to the Saline (58% decrease), Zeolite (57% decrease) and CuBTTri (47% decrease)
Groups. Aggregation was further inhibited (35% decrease) in the CuBTTri+GSNO group in
comparison with the GSNO group.
4.5 Discussion.
ECLS has become more widely used since its efficacy was proven during the H1N1
pandemic (30, 31) and significant miniaturization, safety and design improvements in modern
devices, many of which can be initiated percutaneously and with dialysis-like invasiveness (4, 7,
32, 33). The cumulative volume of ECLS cases for cardiac, respiratory and dialysis indications is
ever increasing and the indications for ECLS use in trauma are expanding (3, 7). The primary
hurdle to wider adoption of ECLS as a life-saving capability in severely injured patients is the
unresolved problem of blood/polymer interactions in ECLS circuitry. This study investigated a
new approach to anticoagulation management, which may have fundamental implications on how
we manage patients undergoing ECLS. We utilized an ex vivo set-up and accepted coagulation
monitoring assays to investigate local effects of a copper-based NO catalyst on whole blood and
PRP. Our primary finding is that the MOF NO-catalyst CuBTTri weakened clot strength in whole
blood and reduced platelet aggregation in both whole blood and PRP. CuBTTri also had a
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Figure 4.4 Figure represents mean ± standard deviation of collagen-stimulated platelet aggregation
measured by impedance aggregometry. Results expressed in aggregation units (AU). Aggregation was
measured in (A) whole blood (n ≥ 10 / group) and (B) platelet rich plasma with a standardized platelet count
of 250 x 109/mL by dilution in donor’s platelet-poor plasma (n ≥ 10 / group). Prior to addition of collagen
reagent, blood was incubated for 1.5 min with particles of a nitric-oxide catalyzing metal organic framework
(CuBTTri). CuBTTri was compared to a biologically-stable metal-based framework control (Zeolite) and
saline as a vehicle control (PBS). Immediately following addition of CuBTTri or controls, GSNO (50 µM)
was added to blood directly (GSNO Group) and to blood containing CuBTTri particles (CuBTTri + GSNO
Group). *Represents significant difference vs. Saline Control (p < 0.05). **Represents significant
difference vs. Zeolite Control (p < 0.05). ***Represents significant difference vs. CuBTTri (p < 0.05)
****Represents significant difference vs. GSNO (p < 0.05).
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potentiating effect on platelet inhibition in PRP when combined with the NO-donor GSNO. This
ex vivo experiment suggests that incorporating CuBTTri into ECLS circuitry may reduce the need
for systemic anticoagulation and reduce platelet consumption; further study is indicated.
Our TEG results demonstrate the specific antithrombogenic effects of CuBTTri in whole
blood, relative to the other metal-based frameworks, used as controls. CuBTTri increased R and
K and decreased α-angle and MA. This finding is consistent with TEG results reported previously
in which the NO-donor Deithylamine NONOate (DEA/NO) was added to whole-blood and
platelet rich plasma (34). In the aforementioned study, addition of increasing concentrations of the
NO-donor (0.1 - 1.0 µM) prolonged the R time and decreased α-angle and MA when adenosine
diphosphate and arachidonic acid were used to activate platelet membrane receptors (34). We did
not observe a significant dose-dependent response to CuBTTri in this study; however, CuBTTri
acts as a catalyst, so NO-derived effects may be limited by availability of endogenous NO-donors
in the small blood volumes utilized in this study.
The dose escalation results in the control metal-framework groups (Zeolite and Mil-100)
suggest that, in general, addition of metal-based framework particles causes a pro-coagulant
response by reducing R and K and increasing α-angle relative to the vehicle control. This effect
may be attributed to the particles serving as sites for plasma protein binding, activating platelets
and inducing the intrinsic pathway, as has been reported in multiple studies investigating
nanoparticle thrombogenicity (35). This response, however, was blunted in the CuBTTri Group.
This suggests that CuBTTri has specific antithrombogenic properties that offset the prothrombotic
effects of metal-based framework particles in blood. It is important to note that for biomedical
applications, the intent is to immobilize CuBTTri within a polymer matrix of the ECLS circuitry
rather than suspending particles into blood directly, - which alongside the ex-vivo nature of our
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work are important limitations of our study. Embedding CuBTTri into the ECLS circuitry
polymers will eliminate the procoagulant effects of metal framework particles suspended directly
in blood as observed here, but also may modify the interaction of the CuBTTri NO catalyst with
endogenous NO donors. It was previously demonstrated, however, that there is no significant
difference in NO catalysis in the presence of GSNO from free CuBTTri particles versus CuBTTri
immobilized in a chitosan matrix as determined by chemiluminescence (36). This suggests that
NO-related anithrombogenic effects will be preserved when CuBTTri is incorporated into a
polymer, pending the ability of the NO-donors to diffuse through the polymer matrix.
We hypothesized that CuBTTri would reduce MA specifically as the TEG MA has a strong
linear relationship with platelet count and activity; and CuBTTri catalyzes NO which is a known
platelet inhibitor (37). While this effect was assessed by TEG, we also investigated the impact of
CuBTTri on platelets more directly using platelet aggregometry. Additionally, to demonstrate the
catalytic activity of CuBTTri we added GSNO (50 µM) as a positive control to see if CuBTTri
would enhance platelet inhibition in the presence of this endogenous NO-donor. In whole blood,
GSNO alone had no effect on platelet aggregation which is likely due to the NO-scavenging effects
of hemoglobin (Hb). Both cell-free and intraerythrocytic Hb have been shown to abolish the
inhibitory effects of GSNO on collagen induced platelet aggregation in platelet rich plasma (38,
39). Interestingly, CuBTTri both with and without GSNO decreased platelet aggregation in whole
blood. Accelerated NO release from GSNO in the presence of CuBTTri has been reported in realtime using chemiluminescence, where CuBTTri particles caused nearly a 65-fold increase in NO
release relative to the thermal decomposition of GSNO alone (36). The ability of CuBTTri to
accelerate NO release from GSNO could explain why platelet inhibition was observed in the
CuBTTri+GSNO group, but not in the GSNO group. Others have reported that high concentrations
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of NO-donors such as DEA/NO can inhibit platelets despite the presence of Hb if the heme ligands
become saturated (40). By accelerating NO release through catalysis, CuBTTri may sufficiently
increase NO levels so that NO is available to interact with platelets despite the scavenging effects
of Hb. Alternatively, the fact that there was no difference in platelet aggregation between the
CuBTTri and CuBTTri+GSNO groups could imply that GSNO-derived NO was less substantive
or effective in platelet inhibition relative to NO catalyzed from other endogenous donors. It has
been reported that the NO release profile of structurally distinct NO-donors varies from donor to
donor, and that platelet inhibition can occur by independent mechanisms for different donors (40).
For example, addition of a selective guanylate cyclase inhibitor, quinaxallin-1-one, limited but did
not abolish inhibition of collagen stimulated platelet aggregation in PRP with GSNO and RIG200
(a novel S-nitrosothiol), but did not significantly reduce the inhibitory effect of DEA/NO. Presence
of Hb reduced the inhibitory effects of GSNO, RIG200 and DEA/NO, but had a less pronounced
effect in the DEA/NO group (40).Alternatively, the platelet inhibition observed may be due to
another property of the CuBTTri that cannot be definitively determined in this study. We do not
believe that the observed platelet inhibition is due to the particulate nature of the CuBTTri, as there
was no change in platelet aggregation in the metal-based framework control group versus the
Saline group, and CuBTTri substantially inhibited platelet aggregation relative to both groups.
We repeated the platelet aggregometry investigation in PRP to eliminate the scavenging
effects of Hb. CuBTTri again inhibited aggregation relative to the controls; and there was no
difference between the Saline and Zeolite groups, again suggesting that the presence of the
inorganic-organic particulate species was not a significant contributor to the observed decrease in
platelet aggregation. GSNO alone inhibited platelet aggregation, which is consistent with previous
reports (40). The addition of CuBTTri to GSNO had an enhanced effect on platelet aggregation,
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which as previously mentioned may be due to the demonstrated ability of CuBTTri to enhance NO
release from GSNO (41). This effect may be amplified in the PRP due to the absence of an NOscavenging agent, therefore eliminating any competitive interactions.
We observed an accelerated rate of fibrinolysis (elevated LY30 and LY60) in the high dose
CuBTTri group, relative to the vehicle control group, which may be attributed to the role of NO in
promoting dissolution of small platelet aggregates (42). NO derived from endogenous donor
species has been shown to decrease surface expression of the platelet fibrinogen receptor
GPIIb/IIIa, which is essential for sustained platelet aggregation (43); however, we did not observe
platelet disaggregation during platelet aggregometry. We also observed numerically elevated
LY30 and LY60 values in the Zeolite and Mil-100 Groups, which were not significantly different
from the CuBTTri group. This suggests that the increase in LY30 and LY60 we observed is likely
not specific to CuBTTri per se but rather is attributable effects of particulate organic-inorganic
materials.
While this initial study has provided valuable information towards understanding
fundamental effects of CuBTTri, a limitation is that it cannot be assumed that CuBTTri will have
identical effects when incorporated into a polymer. Utilization of CuBTTri for medical
applications will be dependent upon preservation of the anti-thrombogenic effects observed once
the particles are incorporated into ECLS circuitry components. Once incorporated into medical
polymers, the ability of NO-donors to diffuse into the polymer matrix, as well as the ability of NOdonors to interact with the catalyst under flow conditions will be key questions to address.
Importantly, the scale of potential NO effects in-vivo cannot be conjectured from this report
without targeted multi-day studies in large animals with human-like physiology. Such studies
previously demonstrated the beneficial effects of partial (33) and full ECLS for reduction of
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ventilator settings and as adjuncts to mechanical ventilation in severe ARDS (44) but were
performed using systemic heparinization. This ex vivo experiment paves the way for incorporating
CuBTTri into ECLS circuitry. Pending future in vivo experiments utilizing CuBTTri embedded
polymers, this approach may reduce or eliminate anticoagulation requirements for ECLS and shift
the current practice of anticoagulating the patient to an approach in which the circuit is constructed
from antithrombogenic components. Future studies will require evaluation of blood exposure to
CuBTTri incorporated into biopolymers at physiologically relevant ECLS flow rates (0.5
L/min/m2 – 5 L/min/m2). In vivo circulation studies will also provide further insight as to potential
systemic effects of prolonged blood exposure to an NO catalyst during extracorporeal circulation;
although the reversible nature of binding and short half-life of NO lend confidence that pronounced
systemic effects are unlikely (45, 46).
In conclusion, ex-vivo exposure of CuBTTri to blood led to reduced clot strength and
platelet aggregation which provides preliminary evidence of the potential utility of this MOF as
an antithrombogenic agent during ECLS. Pending further preclinical large animal testing this
approach may revolutionize critical care eliminating the need for systemic anticoagulation of the
patient by mitigating contact activation of the coagulation cascade in the circuit.
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Chapter 5:
Tethered-liquid omniphobic surface coating reduces surface thrombogenicity, delays clot
formation and decreases clot strength ex vivo
5.1 Abstract.
5.1.1 Aims. Hemocompatible materials for extracorporeal life support (ECLS) technology
are investigated to mitigate thrombotic complications associated with this therapy. A promising
solution is an omniphobic bilayer coating, tethered liquid perfluorocarbon (TLP), which utilizes
an immobilized tether to anchor a mobile, liquid surface lubricant that prevents adhesion of blood
components to the substrate. In this study, we investigated the effects of TLP on real-time clot
formation using thromboelastography (TEG). TLP was applied to TEG cups, utilizing
perfluorodecalin or FluorLube63 as the liquid layer, and compared to uncoated cups. Human blood
(n=10) was added to cups; and TEG parameters (R, K, α-angle, MA, LY30, LY60) and adherent
thrombus weight were assessed.
5.1.2 Findings. TLP decreased clot amplification (α-angle), clot strength (MA) and
adherent clot weight (p<0.0001). These effects were greater with FluorLube63 versus
perfluorodecalin (α-angle p<0.0001; MA p=0.0019; clot weight p<0.0001)). Reaction time (R)
was longer in TLP-coated cups versus control cups with liquid lubricant added (p=0.0377). Percent
fibrinolysis (LY30 and LY60) was greater in TLP versus controls at LY30 (p<0.0001), and in
FluoroLube63 versus controls at LY60 (p=0.0021).
Portions of the chapter have been submitted for publication to Journal of Biomedical Materials Research
Part B: Applied Biomaterials. Roberts TR, Leslie DC, Cap AP, Cancio LC, Batchinsky AI. Tetheredliquid omniphobic surface coating reduces surface thrombogenicity, delays clot formation and decreases
clot strength ex vivo. J Biomed Mater Res B. (submitted November 2018).
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5.1.3 Conclusions. TLP significantly altered clot formation, exerting antithrombogenic
effects. This reduction in surface thrombogenicity supports TLP as a candidate for improved
biocompatibility of ECLS materials, pending further validation with exposure to shear stress.
5.2 Introduction.
Since the earliest reported cases in the 1970s extracorporeal life support (ECLS)
technology has made marked advances in survivability from severe trauma and renal and
respiratory failure (1). ECLS circuitry consists of vascular access catheters, connective tubing, a
treatment membrane and mechanical pump. Blood is pumped to and from the patient through
connective tubing to the treatment membrane which supplements the function of the failing organ.
The membrane off-loads the work of the native organ, allowing it to rest and recover. New
applications, including bridge to transplantation, extended support for chronic lung failure, and
personalized or “dynamic” renal replacement therapy are in early use or are under development
(2, 3). As the scope of application of these devices is developed, one unresolved limitation
continues to be debated: a solution to coagulation management.
Interaction of blood with plastic components of ECLS circuitry causes both hemostatic and
hemorrhagic complications, which can coexist simultaneously in the same patient. Contact of
blood with foreign surfaces in the circuitry leads to protein adsorption and fibrin deposition.
Platelets and leukocytes become activated with exposure to fibrin deposits, causing release of
soluble pro-inflammatory mediators and activation of complement factors (4, 5). Additionally,
shear stress, turbulence and pressure drops generated by the circuit pump cause hemolysis, blood
activation and introduction of procoagulant microbubbles into the circulation. To maintain circuit
patency and prevent thrombus formation, anticoagulation is required (6).
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Systemic anticoagulation with unfractionated heparin is the clinical standard for
coagulation management of patients (6). Heparin, however, does not effectively address the
coagulation disturbances that occur during ECLS, such as platelet activation and consumption, and
protein adsorption (7). Additionally, systemic heparin alters native blood parameters causing
untoward effects; and highly individualized patient responses significantly complicate care
management (4, 6).
An alternative approach to coagulation management is to improve the biocompatibility of
the circuit materials. This strategy directly addresses the coagulopathic impact of the foreign
circuit surfaces, which would decrease the need for systemic anticoagulation. Such a material
would not only improve patient care for ECLS, but also have applications for indwelling line
placement and intravascular interventions. It would also extend ECLS therapy to patients in whom
systemic anticoagulation is contraindicated, such as those with trauma or burns.
A promising solution is the omniphobic surface coating, tethered liquid perfluorocarbon
(TLP). This coating was inspired by the Nepenthes pitcher plant, which has a roughened, toothlike surface that holds in place a thin layer of liquid water. This super-hydrophilic surface inhibits
adhesion of insects, causing them to slide down the pitcher rim and become trapped by the
carnivorous plant (8). TLP is a bilayer coating consisting of the following components: 1) a
tethered perfluorocarbon (TP): an immobilized perfluorocarbon layer that is covalently bound to
an underlying substrate and acts as a tether; and 2) liquid perfluorocarbon (LP): a mobile, liquid
surface layer that is retained on the substrate surface by the immobilized tether layer, imparting
anti-adhesive properties to the substrate. This omniphobic liquid-infused coating repels both
hydrophilic and hydrophobic materials, including clotting components of blood. It has been
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demonstrated that TLP prevents the attachment of thrombus and pathogenic microbes to the
surface of an array of medical grade materials, including plastics, glasses and metals (9).
The objective of this study was to investigate the effect of TLP on real-time clot formation
in whole human blood exposed to TLP coated materials using thromboelastography (TEG). We
compared two different LPs for the mobile surface layer: perfluorodecalin (PFD) and Fluorolube
63 (FL63). TEG is a viscoelastic clotting test that has been used to investigate the impact of various
biomaterials at the blood/biomaterial interface in ex vivo blood preparations (10-13). It has been
identified as a useful screening tool to select promising biomaterial candidates for in vivo testing
(14). This method generates the following clinically relevant clot formation measures: reaction
time (R), which is the time from start of test to first detection of clot formation (corresponding to
2 mm amplitude); initial clot formation time (K), which is the time from R to formation of a 20
mm amplitude clot; amplification rate (α-angle), which is related to the speed of fibrin formation
and cross-linking; clot strength (MA), which is the maximum amplitude detected and is related to
clot stability; and percent fibrinolysis at 30 min and 60 min after MA is detected (Ly30 and Ly60)
(see Figure 5.1 for diagram of TEG values). We hypothesized that the TLP coating increases clot
formation time and reduces clot strength by inhibiting surface adhesion of blood components.
5.3 Methods.
5.3.1 Preparation of TEG cups: Standard clear TEG cups (Haemonetics Corp.; Braintree,
MA) were exposed (45 s) to low-pressure (150-250 mTorr) radio frequency (13.56 MHz) oxygen
plasma at 100 W. Cups were then immersed in liquid silane solution of 5% v/v tridecafluoro1,1,2,2 – tetrahydrooctyl trichlorosilane for 24 h, then rinsed and dried to covalently attach a
perfluorinated layer. Before TEG analysis, a thin layer of liquid perfluorodecalin (PFD group) or
liquid Fluorolube 63 (FL63 group) was applied to the cups using a plastic transfer pipette.
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Figure 5.1 Diagram of thromboelastography parameters. Reaction Time (R) is the time from sample
placement and start of test until detection of a 2mm amplitude clot. Initial Clot Formation Time (K) is the
time from R until a specific clot strength is achieved (20 mm amplitude). Amplification rate (α Angle),
measures the speed of fibrin formation and cross-linking. Clot Strength (MA) is the maximum amplitude
of the tracing, representing strength and stability of the clot. LY30 is a measure of fibrinolysis and clot
retraction, which is determined by the percent reduction in MA after 30 minutes. LY60 (not shown) is the
percent reduction in MA after 60 minutes.
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Uncoated standard TEG cups were used as a control (CTR group). As an additional control, liquid
perfluorodecalin was applied to standard TEG cups without the perfluorcarbon tether layer
(CTR+LP group) to account for volume changes.
5.3.2 Experimental procedures. Whole blood was collected in a de-identified fashion at
the U.S. Army Institute of Surgical Research Blood Bank from healthy male and female donors
between 18-40 years of age (n=10). Donors were non-smokers with no known coagulopathies.
Blood was collected in 3.8% citrated BD Biosciences vacutainers (Franklin Lakes, NJ, USA) and
analyzed within 2 hours of collection time at 37 oC. All coated and uncoated TEG cups were
weighed before addition of blood, and after TEG was complete and non-adherent blood materials
were removed by gentle inversion, to determine the adherent clot weight. 340 µL of citrated donor
blood was added to each of the cups (CTR, CTR+LP, PFD, FL63) with 20 µL CaCl 2. Samples
were run in duplicate for each treatment, and the average of the duplicates was taken for each
donor.
5.3.3 Thromboelastography. Thromboelastography was performed without activating
reagents using the Haemonetics Corporation TEG 5000 Hemostasis Analyzer System
(Haemonetics Corp., Braintree, MA). The following variables of interest were recorded: reaction
time (R), initial clot formation time (K), amplification rate (α-angle), clot strength (MA), and
percent fibrinolysis at 30 min and 60 min after MA was detected (Ly30 and Ly60).
5.3.4 Statistical analysis. Statistical analysis was conducted using SAS 9.4 (Cary, North
Carolina, USA). Tests were two-sided with an alpha = 0.05 for significance. The distribution of
the data was tested using a Shapiro-Wilk test. The same donors were used in each group, so a
mixed model with a random effect on donor was used to look for group differences. If a group
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difference was significant, a Tukey adjustment was made for multiple comparisons. Results are
expressed as mean ± standard deviation.
5.4 Results.
The reaction time, which is the time to start of clot formation (smallest detectable clot is 2
mm amplitude), was prolonged in the FL63 (9.77 ± 0.38 min) and PFD groups (9.79 ± 0.59 min)
when compared to the CTR+LP group (8.42 ± 0.46 min); however, there was no statistical
difference from the CTR group (9.07 ± 0.42 min) (Figure 5.2 A). The clot formation time, which
is the time for the clot amplitude to increase from 2 mm to 20 mm, could not be determined for
the FL63 group because the clots never reached 20 mm amplitude. In the PFD group, only 2
samples reached a 20 mm amplitude, with an average clot formation time of 10.1 ± 0.2 min. This
was notably longer than the average clot formation time for CTR (2.5 ± 0.2 min) and CTR+LP
(2.6 ± 0.5 min). The alpha angle, which represents the propagation phase of clot formation, was
significantly reduced in the PFD (32 ± 1º) and FL63 groups (19 ± 3º) versus the controls (CTR =
56 ± 1º; CTR+LP = 51 ± 2º). Additionally, the alpha angle was significantly lower in the FL63
group versus PFD (Figure 5.2 B). The MA, which represents the clot strength, was significantly
decreased in the FL63 group (9 ± 1 mm) versus the PFD group (15 ± 2 mm), and both were
decreased versus the CTR (55 ± 2 mm) and CTR+LP (60 ± 1 mm) groups (Figure 5.2 C). LY30,
which is the percent reduction in clot strength after 30 minutes, was greater in the FL63 group
(27.7 ± 5.6 %) versus the CTR (3.9 ± 1.2 %) and CTR+LP groups (1.6 ± 0.6 %); it was also greater
in the PFD group (11.2 ± 3.8 %) versus CTR+LP. LY60, which is the percent reduction in MA
after 60 minutes, was greater in the FL63 group (40.4 ± 7.1 %) when compared to CTR (8.7 ± 1.8
%), CTR+LP (4.5 ± 0.9 %) and PFD (14.4 ± 4.7 %) (Figure 5.3 A and B).
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Figure 5.2 Box plots depict (A) reaction time, (B) amplification rate and (C) clot strength determined by
thromboelastography of human donor blood (n = 10 / group) using standard clear cups (CTR), standard
clear cups with a thin liquid layer of pefluorodecalin (CTR + LP), tethered liquid perfluorocarbon (TLP)
coated cup with a pefluorodecalin liquid layer (PFD), and TLP coated cup with a Fluorolube 63 liquid layer
(FL63). The boundaries of the box indicate the 25th and 75th percentiles, with the median denoted within
the box. The whiskers above and below the box indicate the 10th and 90th percentiles. Minimum and
maximum values are shown (+). Statistical differences are noted as *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 5.3 Box plots depict the percent fibrinolysis at (A) 30 min (LY30) and (B) 60 min (LY60), as
determined by thromboelastography of human donor blood (n = 10 / group) using standard clear cups
(CTR), standard clear cups with a liquid layer of pefluorodecalin (CTR + LP), tethered liquid
perfluorocarbon (TLP) cup with a pefluorodecalin liquid layer (PFD), and TLP coated cup with a
Fluorolube 63 liquid layer (FL63). The boundaries of the box indicate the 25th and 75th percentiles, with
the median denoted within the box. The whiskers above and below the box indicate the 10th and 90th
percentiles. Minimum and maximum values are shown (+). Statistical differences are noted as *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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The adherent clot weight determined after the TEG run was significantly lower in the FL63 group
(8.5 ± 2.4 mg) than PFD (95.7 ± 21.3 mg), and both were lower vs. the CTR (279.0 ± 7.0 mg) and
CTR+LP groups (258.0 ± 46.0 mg) (Figure 5.4). Images of the TEG cups were taken after they
had been inverted to demonstrate the reduction in adherent blood material in the TLP coated cups
(Figure 5.5). The FL63 cups were nearly clean upon inspection at the end of the TEG run. Similar
results were observed for the PFD cups, although adhesion to the pin cover was observed in
approximately half of the PFD coated cups. Both the cup and pin cover portions of the CTR and
CTR+LP cups were consistently covered in adherent blood material.
5.5 Discussion.
The principal findings of this study were: (1) TLP reduces clot formation and has antiadhesive properties under the low shear conditions during TEG; (2) TLP reduces surface
thrombogenicity in the TEG cup; and (3) the non-adhesive properties of the coating only occur
when the LP is tethered to the material surface forming a bilayer. Additionally, using a quantitative
analytical method we established that the FL63 LP performed better than the PFD in terms of
decreasing blood adhesion and thrombus formation.
The reduced alpha angle in the TLP groups may be attributed to the anti-adhesive
properties of the coating. Protein adsorption is a critical early step that mediates thrombus
development on material surfaces. Specifically, fibrinogen is a key mediator of platelet adhesion
to biomaterials under low shear stress (15). The surface properties of TLP inhibit fibrinogen
adsorption, which prevents fibrin cross linking between the cup surface and pin. The reduction in
MA is due to an inability of platelets to adhere or become activated when exposed to the TLP
coating. Sun, et al investigated platelet adherence to nanostructured superhydrophobic films
composed of poly(carbonate urethane)s with fluorinated alkyl side chains (16). They demonstrated
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Figure 5.4 Box plots depict the adherent clot weight of human whole blood (n = 10 / group) measured by
weighing thromboelastography (TEG) cups before addition of blood and after TEG was complete and cups
were gently inverted. Standard clear cups (CTR), standard clear cups with a liquid layer of pefluorodecalin
(CTR + LP), tethered liquid perfluorocarbon (TLP) cup with a pefluorodecalin liquid layer (PFD), and TLP
coated cup with a Fluorolube 63 liquid layer (FL63) were compared. The boundaries of the box indicate
the 25th and 75th percentiles, with the median denoted within the box. The whiskers above and below the
box indicate the 10th and 90th percentiles. Minimum and maximum values are shown (+). Statistical
differences are noted as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 5.5 Representative image of thromboelastography (TEG) cups after TEG was complete and cups
were gently inverted to remove non-adherent blood. Standard clear cups (CTR), standard clear cups with a
liquid layer of pefluorodecalin (CTR + LP), tethered liquid perfluorocarbon (TLP) cup with a
pefluorodecalin liquid layer (PFD), and TLP coated cup with a Fluorolube 63 liquid layer (FL63) were
compared.
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that following exposure to platelet rich plasma these films had minimal platelet adhesion (fewer
than 10 per sample), and observed platelets were in a rounded, inactive conformation. This was a
stark contrast to control films where platelet adhesion estimated from SEM images was 7 - 8 x 105
cm2 with the majority of platelets in a deformed/active conformation with pseudopods clearly
observed.
Our results add to the evidence presented by Leslie, et al, demonstrating the reduced
surface thrombogenicity of TLP (with PFD as the mobile, liquid layer) in a series of blood
preparations (9). In this study, blood adhesion to material surfaces was quantified by determining
the minimum angle required for a droplet of citrated blood to slide across the surface of the
material. For TLP treated acrylic, the minimum angle required for the blood to slide was less than
1 degree, as compared to 90 degrees for the control uncoated materials. These results were
maintained even after the materials had been exposed to fluid shear strain (1,000 s-1) for 16 hours.
When heparinized blood (0.25 U/mL) was exposed to TLP-treated and untreated acrylic and
polysulfone segments for 90 minutes, percent fibrin-covered area and platelet adhesion were
significantly reduced with the TLP coating. Additionally, to investigate the performance of the
tubing in an in vivo flow setting, TLP coated polyvinyl chloride (PVC) blood perfusion tubing was
assembled into a femoral arteriovenous shunt for 8 hours. In unheparinized pigs, 100% of the TLP
circuits maintained patency over the 8 hour period compared to only 20% of control circuits. There
was also a 2.5-fold reduction in circuit occlusion, as determined by computerized image analysis
of the lumens.
In our current study, the anti-adhesive effects observed in the TLP groups (both FL63 and
PFD) did not occur in the CTR+LP group, indicating that the LP must be tethered to the substrate
for these effects to occur. The liquid perfluorodecalin alone did not impart any reduction in clot
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formation parameters or adherent material. The clean appearance of the TEG cups and reduction
in adherent clot material in the TLP groups suggests that the bilayer remains intact with exposure
to blood under low shear conditions during the >75 min TEG run. Immobilized PFD has been
shown to remain in place under flow with minimal leaching of the LP layer, which is important
for application on extracorporeal circuits. This was demonstrated with PFD applied to a fluorinated
surface on the interior of PVC tubing (17). The tubing was incorporated into a closed circuit filled
with deionized water driven by a peristaltic pump and exposed to flow rates of 10-90 mL/min for
16 hrs. Gravimetric and sliding angle analyses demonstrated that the tubing retained the PFD
lubricant, and gas chromatography with electron capture detection of the water samples collected
from the circuit showed minimal leaching of lubricant from the material surface. Further studies
are needed to examine the stability of the coating with exposure to flow rates utilized for
extracorporeal circulation (100 mL/min to 1 L/min for dialysis and partial lung support, up to 3-7
L/min for extracorporeal membrane oxygenation/full lung support).
The superior performance of FL63 LP versus PFD may be due to the lower volatility of
FL63 compared with PFD. This increases ease of handling by reducing evaporation of the lubricant
during the coating process. PFD is also less viscous (2.94 cSt at 25 oC) than FL63 (12.0 cSt at 25
o

C), meaning less energy is required to move the PFD liquid along the surface with the same

amount of shear force. This could result in a thinner layer of lubricant and potential lubricant
stripping of PFD in comparison to FL63; however, PFD is a desirable candidate for medical
applications due its clinical use and familiarity as a blood substitute (18).
An important limitation of this study is that the low-shear environment in the TEG cups
does not account for the impact of shear-stress on blood-biopolymer interactions. This is an
important consideration for application of TLP to biomaterials under flow, and future studies are
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needed to investigate the performance of TLP coating under ECLS-relevant flow conditions. An
additional limitation is that the measure of adherent clot weight did not include a characterization
of the non-adherent blood that was removed from the cup during inversion. Further analysis is
needed to assess the coagulability of the liquid blood removed from the TLP cups.
Development of hemocompatible surfaces for ECLS is vital, as systemic heparin
administration does not effectively address surface mediated coagulation disturbances and
complicates patient management. Heparin binds to antithrombin III (ATIII), inducing a
conformational change that increases ATIII inhibition of thrombin and other clotting enzymes;
however, heparin will not dissociate thrombin already bound to fibrin or material surfaces, and
will not inactivate platelets (4). Additionally, the activity of heparin is altered by the presence of
plasma proteins; and it is neutralized by high-molecular weight von Willebrand factor multimers
and platelet factor 4 (PF4), both released by activated platelets (19). Cumulatively, this leads to an
unpredictable drug response from patient to patient. Heparin induced thrombocytopenia (HIT) is
an additional concern occurring in patients who develop antibodies against heparin-bound PF4.
Other anticoagulants, such as direct thrombin inhibitors, are gaining favor in certain centers due
to more predictable pharmacokinetics and ability to inhibit thrombin bound to fibrin clots (19);
however, extensive use of these agents requires standardization of administration protocols and
monitoring techniques, as well as improved understanding of reversal agents. There is currently
no universal guideline for administration of anticoagulants or coagulation monitoring for ECLS
patients, resulting in highly variable, center-specific hemostasis management protocols (20, 21).
Current generation ECLS devices utilize immobilized heparin surface coatings (e.g.
Bioline®, Carmeda®) to decrease the risk of thrombus development and need for systemic
anticoagulation; however, these coatings alone are not robust enough to prevent thrombus
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formation, and supplementary use of systemic anticoagulants remains clinical practice (22, 23).
This is in part due to the fact that heparin cannot eliminate platelet adhesion and aggregation on
the circuit surface, which is a leading cause of circuit clotting (2). Additionally, studies caution
against the use of these devices when HIT is suspected, as the HIT immune reaction has been
observed to continue, even after withdrawal of systemic heparin, when a heparin-immobilized
surface is used (24).
The anti-adhesive effects observed in this study, along with the previously reported data,
identify TLP as promising candidate for surface coating of ECLS devices. Numerous studies have
identified the clinical need for such a biocompatible coating to replace the use of heparin (25). As
ECLS devices become more sophisticated and specialized for long-term support, coagulation
management and improved material biocompatibility are hurdles that must be solved. This
necessitates the study of materials in benchtop models such as TEG and translational animal
studies for development to clinical trials. Understanding the interaction of TLP with blood at the
material interface provides important insight for development of this coating for ECLS application.
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Chapter Six:
Heparin-free extracorporeal life support using tethered liquid perfluorocarbon: a
feasibility and efficacy study
6.1 Abstract
6.1.1 Objective. Coagulation management is the leading challenge during extracorporeal
life support (ECLS). A non-adhesive, slippery coating called tethered liquid perfluorocarbon
(TLP) has been developed to prevent adhesion of blood and pathogens on medical devices and
materials. In this study, we investigated the efficacy of TLP compared to immobilized-heparin
during 6 hours in vivo circulation without systemic heparin. We hypothesized that TLP coating
permits heparin-free circulation without untoward systemic effects, while reducing thrombus
deposition on ECLS circuitry when compared to standard immobilized-heparin coating.
6.1.2 Design. Translational Animal Study.
6.1.3 Setting. Animal Intensive Care Unit Research Facility.
6.1.4 Subjects. Six anesthetized, spontaneously breathing swine.
6.1.5 Interventions. ECLS circuits were coated tip-to-tip with TLP antithrombogenic
coating and compared to industry standard heparin-coated circuits. A 19-F dual-lumen catheter
was inserted for veno-venous ECLS (1L / min blood flow rate). Subjects were monitored for 6
hours of circulation without systemic heparin anticoagulation therapy.
6.1.6 Measurements and main results. Key vital signs and respiratory parameters, gas

Portions of this chapter have been submitted for publication to Acta Biomaterialia and are under peerreview. Roberts TR, Harea GT, Singha P, Sieck KN, Beely BM, Wendorff D, Choi J, Ande S, Handa H,
Batchinsky AI. Heparin-free extracorporeal life support using tethered liquid perfluorocarbon: a
feasibility and efficacy study. Acta Biomater. (submitted Jan 2019).
115

transfer across the ECLS membrane lung, coagulation panel and histology were evaluated to assess
the safety and functionality of the TLP coating during ECLS without heparin. Scanning electron
microscopy (SEM), elemental mapping and digital imaging were used to assess thrombus
deposition on materials after use. There were no group differences in key vital signs, gas exchange
efficiency, coagulation and histology. In both groups, ECLS enabled a decrease in minute volume
and end-tidal CO2, with concomitant increase in pH versus baseline (p<0.05). SEM and digital
imaging revealed significant thrombus deposition on membrane lungs from control heparin-coated
materials, which was reduced or absent on TLP-coated materials.
6.1.7 Conclusions. TLP coating permitted heparin-free circulation without altering ECLS
device safety or function. TLP also prevented thrombus deposition in comparison with the industry
standard immobilized-heparin coating. Pending multi-day in vivo testing, TLP could serve as a
promising biomaterial solution to eliminate anticoagulation requirements during ECLS.
6.2 Introduction.
Coagulation management is the leading challenge during extracorporeal life support
(ECLS). Despite advances in ECLS technology in the past decades that improve safety and
simplicity, the issue of coagulation management remains unresolved (1, 2). Both bleeding and
thrombotic complications limit the duration of use and range of applications of this life-saving
therapy (3). All current forms of ECLS require systemic anticoagulation to prevent thrombotic
complications; however, anticoagulation protocols are highly variable among centers with no
accepted universal guidelines (4).
An alternative approach to systemic anticoagulation during ECLS is to improve the
hemocompatibility of the device materials. A variety of strategies are under investigation, with the
leading approach being immobilization of heparin on circuit surfaces (4). Other surface
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modifications include hydrophilic materials that repel blood cells and proteins (5); immobilized
albumin to competitively occupy sites for protein adsorption (6); zwitterionic surfaces containing
phosphorylcholine-like residues (7, 8); and nitric oxide (NO) releasing materials that produce NO
with similar flux as in the endothelium, inhibiting platelet activation (9, 10). While these
approaches have been shown to improve surface hemocompatibility, an optimal solution to address
both the protein adsorption and platelet activation that drive foreign surface-induced thrombosis
has yet to be fully developed.
A novel approach to prevent thrombus formation on medical devices is a coating called
tethered liquid perfluorocarbon (TLP) (11). This bilayer coating consists of a tether layer that is
covalently bound to the material surface, and a non-adhesive liquid surface layer that prevents
adhesion of blood and thrombus formation (Figure 6.1). The liquid lubricant is highly attracted to
the immobilized tether, preventing wash-out of the lubricant into the blood as it passes over the
surface. This coating has been applied to an array of medical polymers and shown to reduce
adhesion and activation of blood components including fibrinogen and platelets ex vivo (11).
Additionally, TLP coating reduced thrombus formation and maintained patency in an 8 h porcine
arterio-venous shunt model (11). While this coating has demonstrated promising antithrombogenic effects during low-flow circulation (~10 – 20 L/hour), the coating has not been
evaluated when applied to a standard ECLS circuit at clinically-relevant flow rates for
extracorporeal CO2 removal (ECCO2R) (0.5 – 2 L/min).
The objective of this study was to evaluate the feasibility, efficacy and safety of TLP
coating applied to ECLS circuits and catheters during ECCO2R in spontaneously breathing
anesthetized swine. We hypothesized that TLP-coating permits heparin-free ECLS and prevents
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Figure 6.1 Schematic of extracorporeal circuit components to which tethered liquid perfluorocarbon (TLP)
was applied. The components of the TLP bilayer are depicted. Specific segments of the extracorporeal
circuit and catheter that were evaluated in this study are labelled.

118

thrombus formation compared to commercially produced heparin-coated circuits. Further, we
hypothesized that TLP coating is safe and does not impede gas exchange efficiency. Using the
industry standard 6 hour timeline for evaluation of biomaterials, we tested this hypothesis in swine
during 6 hours of extracorporeal circulation without heparin, comparing TLP to immobilized
heparin coating. We assessed vital signs, coagulation status, gas exchange efficiency, histology
and thrombus deposition on circuit materials.
6.3 Materials and methods.
This study was carried out in compliance with the Animal Welfare Act, implementing
Animal Welfare Regulations, and the principles of the Guide for the Care and Use of Laboratory
Animals, National Research Council. The Bridge PTS Animal Care and Use Committee approved
all research conducted.

The Bridge PTS facility is accredited by the Association for the

Assessment and Accreditation of Laboratory Animal Care, International (AAALAC, Intl.).
6.3.1 ECLS equipment. An ECLS Circuit with permitted blood flow between 0.2 – 2.8
L/min was utilized in this study with Avalon Elite® 19 Fr bi-caval dual-lumen catheters (Maquet
Getinge Group; Rastatt, Germany). A total of 3 TLP-coated and 3 uncoated devices were available
for this feasibility study. In the TLP group, standard circuits (tubing, pump and membrane) and
catheters as provided by manufacturer were coated tip-to-tip with TLP (FreeFlow Medical
Devices, LLC; Lancatser, PA) (see Appendix D). ECLS Circuits with BIOLINE® immobilizedheparin coating from the manufacturer were used in the control (CTRL) group with standard
catheters.
6.3.2 Animal preparation. Non-pregnant female Yorkshire swine (51 ± 8 kg) were
endotracheally intubated and anesthetized using inhaled isoflurane (0.5 – 5% volume in oxygen).
Animals were spontaneously breathing (FiO2 = 100%) with tidal volume and minute ventilation
measured hourly. Intravenous lines were placed for monitoring of vital signs and fluid
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administration (see Appendix D). Continuous EKG, arterial blood pressure, oxyhemoglobin
saturation (SpO2), respiratory rate (RR) and end-tidal CO2 (etCO2) were monitored using the
Dräger Infinity® M540 Monitor (Drägerwek AG; Lübeck, Germany).
6.3.3 Initiation of ECLS. A 2000 U heparin bolus was administered to prevent thrombotic
complications during cannulation. The 19 Fr dual-lumen catheter was percutaneously inserted into
the right jugular vein for veno-venous (VV) ECLS. Blood flow through the circuit was 1 L/min,
and the sweep gas (100% O2) was 5 L/min. Following cannulation, no heparin was administered.
6.3.4 Measurements. All vital signs and monitoring tests were recorded following
stabilization of the animal after instrumentation for baseline (BL), immediately post-initiation of
ECLS (post-ECLS), and hourly for six hours. Coagulation measurements were taken at BL, postECLS, and at 3 and 6 hours post-ECLS.
Vital Signs included heart rate, mean arterial blood pressure (MAP), SpO2, RR, tidal
volume, minute ventilation and etCO2. ECLS circuit arterial pressure (Part), venous pressure (Pven),
internal pressure (Pint), transmembrane pressure (∆p), and pump revolutions per minute (RPM)
were recorded hourly. Blood gases (pH, partial pressure CO2 (pCO2) and O2 (pO2), oxygen
saturation (SO2) and lactate) were analyzed using the i-STAT1 Analyzer (Abott; Chicago, IL).
Systemic blood samples were collected from the femoral artery, and pre-/post-membrane blood
samples were collected from the circuit immediately before and after the membrane lung (ML) for
determination of gas exchange efficiency (see Appendix D).
Coagulation testing included prothrombin time (PT), activated partial thromboplastin time
(aPTT), activated clotting time (ACT), thromboelastography (TEG), antithrombin III (ATIII), von
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Willebrand factor (vWF), fibrinogen, d-dimer, and plasma free hemoglobin (PFHb) as previously
reported (see Appendix D) (12, 13).
6.3.5 Post-ECLS procedures. Following 6 hours ECLS, animals were deeply anesthetized
and euthanized by exsanguination to prevent post-mortem clotting caused by euthanasia
medications.
6.3.6 Histology. Tissue samples were taken from lungs, heart, liver, kidney, spleen and
aorta for histology (see Appendix D). Images were evaluated by pathologist blinded to study
conditions (14).
6.3.7 Evaluation of explanted ECLS circuits. After 6 hours, the ECLS circuit and
catheter was explanted from the animal, rinsed with saline and fixed with glutaraldehyde for
scanning electron microscopy (SEM) imaging (see Appendix D). The ML was disassembled to
expose the polymethylpentene (PMP) gas exchange fibers. Samples were collected from the inlet
face, center and outlet face of each ML for analysis as previously described (15). Samples from
the dual-lumen catheter were collected from the inlet and outlet connections, the center of the
catheter and tip (Figure 6.1). Tubing samples were collected from the pre-membrane and postmembrane lines.
6.3.8 Thrombus area. Digital images of the ML inlet, center and outlet PMP layers were
used to determine the percent area of thrombus deposition on each layer, scored by 3 blinded
reviewers using ImageJ Software (NIH; Bethesda, MD).
6.3.9 Field emission SEM imaging and EDS mapping. The ML, tubing and catheter
were imaged using field emission SEM (FEI Teneo; Hillsboro, OR). Energy dispersive X-ray
spectrometry (EDS) was used to determine the distribution and stability of the perfluorocarbon
tether on the ML (see Appendix D).
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6.3.10 Statistics. Statistics were performed using SAS 9.4 (Cary, NC). Tests were twosided with alpha = 0.05 for significance. Groups were tested independently using one-way mixed
models with repeated measures and Dunnett adjustment to assess changes from baseline. Betweengroup differences were examined using two-way mixed model with repeated measures and Tukey
adjustment for multiple comparisons.
6.4 Results.
All animals were maintained on ECLS and survived to the end of study without heparin
administration. There were no thrombotic or hemorrhagic events that would require early
withdrawal of ECLS support, and no emergency procedures were required.
6.4.1 Vital signs and blood gases. There were no between group differences in vital signs
or blood gases (Table 6.1). MAP was lower in the TLP group at 5 and 6 hours versus baseline.
Other values were unremarkable except for a decrease in MV and etCO2 and concomitant increase
in pH in both groups vs. baseline (Table 6.1). Despite spontaneous breathing, ECLS enables
reductions in minute ventilation in both CTRL (28-64% decrease) and TLP groups (20-52%
decrease) (Table 6.1). Isoflurane rate (CTRL = 1.3 ± 0.3 %; TLP = 1.8 ± 0.2%) did not differ
between groups.
6.4.2 ECLS gas exchange and circuit pressures. Trans-membrane reduction in pCO2
ranged from 20-51% in CTRL and 25-41% in TLP (Figure 6.2). There was no difference in oxygen
transfer (Figure 2). Pint was elevated in TLP versus CTRL at post-ECLS (Table 6.1).
6.4.3 Coagulation. There were no group differences in coagulation variables while on
ECLS (Table 6.2). ACT and aPTT were numerically elevated in both groups post-ECLS due to
pre-cannulation heparin bolus (Table 6.2). TEG clot strength was significantly higher in the CTRL
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Table 6.1 Vital Signs and Circuit Parameters.
Variable

Group

Heart rate
(beats per
minute)

CTRL

Mean
arterial
pressure
(mm Hg)

CTRL

TLP

TLP
CTRL

Arterial
pH

TLP
CTRL

PaO2 (mm
Hg)

TLP
CTRL

PaCO2
(mm Hg)
Minute
volume
(L)
End tidal
CO2 (mm
Hg)
Internal
membrane
pressure
(mmHg)
Membrane
inlet
pressure
(mmHg)
Membrane
outlet
pressure
(mmHg)

TLP
CTRL

TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP

Baseline

PECLS

1 hr

2 hrs

3 hrs

4 hrs

5 hrs

6 hrs

114±25

107±25

113±25

115±29

123±27

125±18

130±13

127±23

127±21

124±15

124±14

125±15

128±13

131±10

83±6

80±9

82±8

84±6

76±7

76±3

70±4

72±1

72±2

74±3

73±6

64±2

64±4

60±4

59±1*

58±2*

7.28±0.04

7.36±0.02*

7.51±0.07*

7.55±0.08*

7.54±0.06*

7.51±0.07*

7.53±0.07*

7.47±0.09*

7.28±0.08

7.37±0.01*

7.43±0.02*

7.46±0.03*

7.44±0.02*

7.44±0.04*

7.41±0.03*

7.39±0.05*

463±34

450±37

447±27

459±26

479±16

423±40

477±17

473±18

366±144

345±117

339±121

324±116

340±118

350±119

360±126

326±121

84±10

63±8

56±15

44±10

44±8

47±10

45±8

51±11

83±14

64±3

56±4

51±3

53±1

54±3

59±2

61±7

6.1±0.8

2.9±1.5

2.2±1.3

2.8±1.6

3.0±2.0

3.0±1.0

4.0±3.0

4±2.0

6.7±1.0

4.3±1.0

3.4±0.6*

5.4±1.4

3.0±1.0*

5.0±0.0*

4.0±1.0*

4.0±1.0*

64±3

29±18

22±10

21±10

27±19

32±22

38±7

46±6

72±8

42±4*

27±11*

29±10*

24±10*

40±4*

40±4*

44±1

--

137±4†

138±6

138±5

135±4

137±4

133±6

132±6

--

174±9†

141±9

143±8

142±7

142±5

140±6

137±18

--

-68±5

-67±5

-68±7

-66±4

-67±6

-66±4

-63±6

--

-77±12

-81±8

-75±11

-76±10

-76±10

-75±11

-77±14

--

115±3

114±5

114±5

111±4

110±5

108±5

109±5

--

140±11

122±10

116±8

114±7

113±7

112±6

111±5

117±29
134±25

*Indicates within group change versus baseline; †Indicates between group difference
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Figure 6.2 Figure represents gas exchange efficiency of membrane lungs with tethered liquid
perfluorocarbon (TLP) coating versus immobilized-heparin control coating (CTRL). Panel A lines
represents mean ± standard error oxygen transfer (ml/min) measured from blood samples directly before
and after passage through the membrane lung in the extracorporeal circuit. Panel B bars represent means ±
standard error of pCO2 for blood gases drawn from the pre-membrane (PRE) venous ECLS circuit line and
post-membrane (POST) circuit line located immediately before and after blood passage through the
membrane lung. Lines represent mean ± standard error of percent decrease in pCO2 across the membrane.
A two-sided test was performed with p < 0.05 accepted for significance. *Indicates within group change
vs. baseline; †Indicates between group difference.
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Table 6.2 Coagulation Data and Chemistry.
Variable
Prothrombin time (sec)
Activated partial thromboplastin
time (sec)
Activated clotting time (sec)
Hemoglobin (g/dL)
Hematocrit (%)
Fibrinogen (mg/dL)
D-dimer (ug/mL)
Antithrombin III (%)
Von Willebrand Factor Antigen (%)
TEG Reaction Time (min)
TEG Clot Formation Time (min)
TEG Alpha Angle (degrees)
TEG Clot Strength (mm)
TEG Lysis (%)

Group
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP
CTRL
TLP

Baseline
13.8±0.6
12.8±0.2
24±6
22±3
90±4
87±1
10±1
9±1
33±4
31±3
200±27
166±10
0.13±0.01
0.23±0.03
89±22
101±1
136±74
152±31
6.8±0.9
6.5±0.4
1.5±0.3
1.7±0.2
64±9
60±6
78±2†
71±1†
0.8±0.3
1.3±0.6

Post-ECLS
13.4±0.3
13.3±0.1
70±5
91±42
174±29
141±8
9±1
11±1
31±2
30±2
169±14
198±34
0.16±0.01
0.25±0.07
91±1
93±2
168±40
150±27
5.9±0.5
6.1±0.5
0.4±0.2
1.5±0.2
64±5
64±6
71±1*
70±1
1.9±0.5
1.0±0.7

3 hrs
13.4±0.2
13.1±0.2
22±5
20±2
93±4
88±2
9±1
11±1
28±1
26±2
183±17
156±11
0.15±0.00
0.19±0.05
90±2
87±2
167±40
152±19
5.5±0.7
5.6±0.4
1.5±0.2
1.5±0.2
68±2
67±3
74±2*
72±1
1.4±0.2
0.8±0.4

6 hrs
13.6±.01
13.1±0.1
22±5
20±3
89±1
88±1
9±1
11±1
29±1
28±2
168±16
157±8
0.13±0.01
0.20±0.02
86±5
84±4
168±34
136±29
5.2±0.5
5.8±0.5
1.6±0.3
1.6±0.2
63±3
60±2
75±1*
72±1
1.3±0.5
0.6±0.5

*Indicates within group change versus baseline; †Indicates between group difference.
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group versus TLP at baseline and was reduced within the CTRL group at all timepoints post-ECLS
(Table 6.2).
6.4.4 Histology. Both groups showed atelectasis in dependent lung areas. There was no
histopathologic evidence to suggest toxicity in either group. No evidence of thrombi or
microhemorrhage was found.
6.4.5 Thrombus area. The percent area of thrombus deposition on the ML did not differ
statistically between the groups but was numerically higher in CTRLs at the inlet (2x greater),
center, and outlet. In both groups area of thrombus deposition decreased with progression from the
inlet face (CTRL = 4.6 ± 1.0 %, TLP = 2.0 ± 1.1 %) to the center (CTRL = 0.7 ± 0.2 %, TLP = 0.3
± 0.2 %) and the outlet (CTRL = 0.8 ± 0.7 %, TLP = 0.1 ± 0.0 %).
6.4.6 SEM imaging and EDS mapping. SEM imaging showed significant clot deposition
on CTRL membranes, which was reduced or absent in TLP (Figure 6.3). Thrombus deposition
was minimal on catheter and tubing samples in both groups (Appendix D). Fluorine was detected
by EDS on all TLP membrane segments. The weight percent fluorine detected did not differ
between the inlet (20.01 ± 3.26 wt. %), center (22.54 ± 3.74 wt. %) and outlet (27.82 ± 4.1 wt. %).
6.5 Discussion.
We compared TLP-coating to immobilized-heparin during 6 hours heparin-free ECLS in
swine. Use of TLP and ECLS in this study was investigational and is currently not approved by
the FDA. Our primary finding is that TLP permits heparin-free ECLS for 6 hours, and does not
alter key vital signs, coagulation parameters, or gas exchange efficiency of the ML versus the
clinical standard – immobilized-heparin. Histological evidence suggests that the coating is not
toxic with 6 hours exposure. Based on SEM imaging, TLP prevents thrombus formation to a
greater extent than immobilized-heparin. These findings have important clinical implications as
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Figure 6.3 Field emission scanning electron microscopy images from membrane lungs with tethered liquid
perfluorocarbon (TLP) coating versus immobilized-heparin control coating (CTRL). Panel A representative
images from the inlet face of CTRL membrane lungs with thrombus deposition, platelet activation and
adhesion and fibrin network formation; Panel B representative images from inlet face of TLP-coated
membrane lungs with minimal cellular deposition and clean appearance. Panel C (CTRL) and Panel D
(TLP) demonstrate the clean appearance of membrane lungs sections collected at the center (left image)
and outlet (right image) face of the membrane.
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coagulation management and bleeding are significant complications during ECLS, and TLP may
be a biocompatible alternative to prevent clotting without heparin.
Perfluorocarbons have been utilized in many medical applications due to their multifaceted
properties including hydrophobicity, oxygen solubility and biological inertness (16). Liquid
perfluorocarbons have been used as oxygen carriers, blood substitutes (17), diagnostic reagents
(18), and are under investigation for gene and drug delivery (16). This study describes a novel
application for perfluorocarbons as a hemocompatible coating for ECLS.
A suitable hemocompatible coating for ECLS cannot impede gas exchange efficiency of
the ML. We did not observe differences in CO2 removal between groups. Interestingly, reduction
in systemic CO2 led to decreased respiratory drive and intermittent apnea in 2 TLP animals and 2
CTRLs. The PaCO2 and pH shift we observed post-ECLS is similar to values reported by
Batchinsky et al., in mechanically ventilated swine on low-flow ECLS system in whom, despite
50% reduction in ventilator settings, normocarbia and normal pH were observed (19). Similar
findings were reported by Karagiannidis et al. using the ECLS system we utilized in this study
(20), putting our results in context with reported results and suggesting that TLP does not affect
CO2 removal. O2 transfer also did not differ between groups and was reasonable in comparison
with reports for membranes with similar dimensions and flow rates (20, 21). This information is
lacking from most studies investigating hemocompatible materials for ECLS, as the coating is
generally applied only to tubing and catheters.
Pint was elevated in TLP post-ECLS, which was reduced by 1-hour (Table 6.2). This
suggest that excess lubricant is stripped from the membrane surfaces at start of circulation. If
excess lubricant was stripped from the ECLS surfaces, the volume was below that of intravenous
delivery of perfluorocarbons administered clinically (22). For example, intravenous administration
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of perflubron emulsion had no impact on bleeding time, (1) and function (23); and did not impact
circulating immunoglobins, cytokines or complement activation (24). This is consistent with our
findings, as no signs of systemic damage were observed.
We did not observe group differences in any coagulation measures during ECLS,
demonstrating that hemocompatibility of the TLP is comparable to the current clinical standard
(Table 6.2). There were no deviations from baseline in either group except for clot strength (TEG
MA) in CTRLs. Clot strength, which has a linear relationship with platelet count, was reduced in
CTRLs but was preserved in TLP (25). PFHb was lower than levels indicative of hemolysis,
defined as > 50 mg/dL (4). Additionally, PFHb was comparable to reported results in swine on
ECLS with continuous heparinization over 72 hours (19) and sheep on VV-ECMO without heparin
for 5 hours (12). This lends support to the use of initially heparin-free ECLS in trauma patients
with severe bleeding, in whom heparin-free protocols have been utilized until bleeding is resolved
(26-28).
Artificial surfaces cause thrombosis through protein adsorption, platelet, leukocyte and red
blood cell adhesion, thrombin generation and complement activation. This is presented on artificial
surfaces mainly in the form of fibrin networks and platelet aggregates (29). Thrombus deposition
on CTRL membranes, primarily on the inlet face, is consistent with our previously reported SEM
evaluation of heparin-coated MLs after 14 hours circulation in sheep (15), suggesting that
immobilized-heparin does not prevent thrombus formation on the ML. While some activated
platelets were observed on the TLP membrane inlet, the vast interconnected network of fibrin was
not observed. This inhibition of fibrin network formation prevents circuit occlusion and limits
formation of thrombi that can impede gas exchange by increasing the diffusion barrier. Lehle et
al. used SEM to analyze MLs from patients with severe acute respiratory distress syndrome and
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noted pseudomembrane layers of blood deposits of 30-45 µm (wall thickness of PMP fibers was
75 µm), significantly increasing the gas diffusion barrier (30). Deposition of platelets and cellular
debris on catheters occurred preferentially at the connection points (inlet and outlet) and tip
(Appendix D). The varied diameter of the flow path at the connections can induce turbulence and
promote surface contact. TLP catheters had fewer adherent activated platelets compared to CTRLs.
Tubing had minimal deposition and looked like samples collected before use (Appendix D).
A limitation of this pilot study is the small sample size, due to availability of ECLS circuits;
however, we believe the analysis we performed utilizing manufacturer’s complete circuits in
animals with human-like cardiopulmonary physiology is extremely valuable to duplicate the flow
conditions and shear stress that occur during ECLS. This provides a robust evaluation of the
biomaterials in contrast to assessment of isolated circuit components. The use of healthy animals
does not address coagulopathic complications observed in injured patients; however, in this initial
study we removed this variable as underlying coagulopathy is highly individualized. The
circulation time was selected to compare our results to the literature, as most evaluations of
biomaterials for the Food and Drug Administration are conducted for 4-6 hours. We cannot assume
the results observed will be preserved outside the time frame tested, and additional multi-day
studies will be necessary to establish if TLP is a robust solution for heparin-free ECLS.
6.6 Conclusions.
We demonstrated safety, feasibility and efficacy of heparin-free ECLS for 6 hours using
TLP-coating. We found that TLP prevents thrombus deposition more so than standard
immobilized-heparin as observed by SEM. Finally, we did not observe a reduction in gas exchange
performance of the ML caused by the TLP-coating, or any negative systemic effects. Future studies
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are needed to evaluate TLP applied to ECLS circuits at a clinically relevant multi-day timeframe
in models of lung injury that mimic human pathophysiology.
6.7 References.
1.

Bartlett RH, Deatrick KB: Current and future status of extracorporeal life support for
respiratory failure in adults. Curr Opin Crit Care. 2016;22(1):80-5.

2.

Bembea MM, Annich G, Rycus P, et al: Variability in anticoagulation management of
patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit
Care Med. 2013;14(2):e77-84.

3.

Lotz C, Streiber N, Roewer N, et al: Therapeutic interventions and risk factors of bleeding
during extracorporeal membrane oxygenation. ASAIO J. 2017; 63(5):624-630.

4.

Brogan TV, Lequier L, Lorusso R, et al: Extracorporeal Life Support: The ELSO Red Book
5th Edition. Ann Arbor, Michigan, USA: Extracorporeal Life Support Organization, 2017.

5.

Butruk-Raszeja BA, Łojszczyk I, Ciach T, et al: Athrombogenic hydrogel coatings for
medical devices – Examination of biological properties. Colloids Surf B Biointerfaces.
2015;130:192-8.

6.

Zimmerman AK, Norbert W, Hermann A, et al: WH. Effect of biopassive and bioactive
surface‐coatings on the hemocompatibility of membrane oxygenators. Journ Biomed
Mater Res B Appl Biomater. 2007;80B(2):433-9.

7.

Wang Y-B, Shi K-H, Jiang H-L, et al: Significantly reduced adsorption and activation of
blood components in a membrane oxygenator system coated with crosslinkable
zwitterionic copolymer. Acta Biomaterialia. 2016;40:153-61.

8.

Ranucci M, Isgro G, Soro G, et al: Reduced systemic heparin dose with phosphorylcholine
coated closed circuit in coronary operations. Int J Artif Organs. 2004;27(4):311-9.

9.

Major TC, Handa H, Annich GM, et al: Development and hemocompatibility testing of
nitric oxide releasing polymers using a rabbit model of thrombogenicity. Journ Biomed
Mater Res B Appl Biomater. 2014;29(4):479-501.

10.

Major TC, Brant DO, Reynolds MM, et al: The attenuation of platelet and monocyte
activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing
polymer. Biomaterials. 2010;31(10):2736-45.

11.

Leslie DC, Waterhouse A, Berthet JB, et al: A bioinspired omniphobic surface coating on
medical devices prevents thrombosis and biofouling. Nature Biotechnol.
2014;32(11):1134-40.

131

12.

Prat NJ, Meyer AD, Langer T, et al: Low-Dose Heparin Anticoagulation During
Extracorporeal Life Support for Acute Respiratory Distress Syndrome in Conscious Sheep.
Shock. 2015;44(6):560-8.

13.

Noe DA, Weedn V, Bell WR: Direct spectrophotometry of serum hemoglobin: an Allen
correction compared with a three-wavelength polychromatic analysis. Clin Chem.
1984;30(5):627-30.

14.

Sousse LE, Herndon DN, Andersen CR, et al: Pulmonary histopathologic abnormalities
and predictor variables in autopsies of burned pediatric patients. Burns. 2015;41(3):51927.

15.

Beely BM, Campbell JE, Meyer A, et al: Electron Microscopy as a Tool for Assessment
of Anticoagulation Strategies During Extracorporeal Life Support: The Proof Is on the
Membrane. ASAIO J. 2016;62(5):525-32.

16.

Zhang T, Zhang Q, Tian J-H, et al: Perfluorocarbon-based nanomedicine: emerging
strategy for diagnosis and treatment of diseases. MRS Commun. 2018;8(2):303-313.

17.

Riess JG, Krafft MP: Fluorinated materials for in vivo oxygen transport (blood substitutes),
diagnosis and drug delivery. Biomaterials. 1998;19(16):1529-39.

18.

Tirotta I, Dichiarante V, Pigliacelli C, et al: (19)F magnetic resonance imaging (MRI):
from design of materials to clinical applications. Chem Rev. 2015;115(2):1106-29.

19.

Batchinsky AI, Jordan BS, Regn D, et al: Respiratory dialysis: Reduction in dependence
on mechanical ventilation by venovenous extracorporeal CO2 removal. Crit Care Med.
2011;39(6):1382-7.

20.

Karagiannidis C, Kampe KA, Sipmann FS, et al: Veno-venous extracorporeal CO2
removal for the treatment of severe respiratory acidosis: pathophysiological and technical
considerations. Crit Care Med. 2014;18(3):R124.

21.

Lehle K, Philipp A, Hiller K-A, et al: Efficiency of gas transfer in venovenous
extracorporeal membrane oxygenation: analysis of 317 cases with four different ECMO
systems. Intensive Care Med. 2014;40(12):1870-7.

22.

Maevsky E, Ivanitsky G, Bogdanova L, et al: Clinical results of Perftoran application:
present and future. Artif Cells Blood Substit Immobil Biotechnol. 2005;33(1):37-46.

23.

Leese PT, Noveck RJ, Shorr JS, et al: Randomized safety studies of intravenous perflubron
emulsion. I. Effects on coagulation function in healthy volunteers. Anesth Analg.
2000;91(4):804-11.

132

24.

Noveck RJ, Shannon EJ, Leese PT, et al: Randomized safety studies of intravenous
perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg.
2000;91(4):812-22.

25.

Oshita K, Az-ma T, Osawa Y, et al: Quantitative Measurement of Thromboelastography
as a Function of Platelet Count. Anesth Analg. 1999;89(2):296-9.

26.

Muellenbach RM, Kredel M, Kunze E, et al: Prolonged heparin-free extracorporeal
membrane oxygenation in multiple injured acute respiratory distress syndrome patients
with traumatic brain injury. J Trauma Acute Care Surg. 2012;72(5):1444-7.

27.

Wen PH, Chan WH, Chen YC, et al: Non-heparinized ECMO serves a rescue method in a
multitrauma patient combining pulmonary contusion and nonoperative internal bleeding: a
case report and literature review. World J Emerg Surg. 2015;10:15.

28.

Arlt M, Philipp A, Voelkel S, et al: Extracorporeal membrane oxygenation in severe trauma
patients with bleeding shock. Resuscitation. 2010;81(7):804-9.

29.

Jaffer IH, Fredenburgh JC, Hirsh J, et al: Medical device-induced thrombosis: what causes
it and how can we prevent it? J Thromb Haemost. 2015;13 Suppl 1:S72-81.

30.

Lehle K, Philipp A, Gleich O, et al: Efficiency in extracorporeal membrane oxygenationcellular deposits on polymethylpentene membranes increase resistance to blood flow and
reduce gas exchange capacity. ASAIO J. 2008;54(6):612-7.

133

Chapter Seven:
Evaluation of tethered-liquid perfluorocarbon coating for heparin-free extracorporeal
life support: a 72-hour intensive care unit study
7.1 Abstract.
Extracorporeal life support (ECLS) is a class of technologies to support or replace the
function of failing organs, such as the heart, lungs, kidney and liver. This technology has been
utilized in diverse patient populations from neonates with respiratory failure to combat
casualties with traumatic lung injury. The key limitation that prevents extended use of this life saving therapy is the coagulation disturbances that occur when blood contacts the foreign
surfaces of the devices, as well as the bleeding complications that result from the need to
administer anticoagulant drugs to prevent circuit thrombosis. To address this challenge,
biocompatible surface coatings are being developed to mitigate thrombosis and bleeding caused
by shear stress and contact with the circuit materials, reducing or eliminating the need for
anticoagulants.
Tethered-liquid perfluorocarbon (TLP) is a slippery, non-adhesive coating shown to
improve the biocompatibility of medical polymers by preventing adhesion of plasma proteins
and deposition of cellular debris on ECLS components. Here we examine a novel use of TLP
applied to ECLS membranes, tubing, pumps and catheters during 72 hours of extracorporeal
circulation in healthy swine (n=5/group) without use of systemic anticoagulation. We compare
this heparin-free approach to the standard of care – heparin-coated ECLS circuit with
Portions of this chapter have been prepared for submission to Critical Care Medicine Journal. Roberts,
TR, Choi J, Douglass ME, Dean JB, Handa H, Batchinsky AI. Evaluation of tethered-liquid
perfluorocarbon omniphobic coating for 72 hours heparin-free extracorporeal life support.
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continuous heparin infusion – and evaluate coagulation response, instance of coagulopathic
complications, gas exchange efficiency of the membrane lung and systemic effects. We
hypothesized the TLP would prevent thrombotic circuit occlusion while preserving baseline
platelet counts and coagulation values; without impeding the gas exchange performance of the
membrane lung or causing untoward systemic effects. We found that while instance of bleeding
complications was greater in controls (80%) versus TLP (20%), thrombotic circuit occlusions
occurred in both groups (control = 20%, TLP = 40%), suggesting neither approach is sufficient
for prevention of hemostatic complications during ECLS. Thrombus deposition and protein
adhesion were similar on explanted membranes, and TLP did not preserve platelet or blood cell
counts relative to controls. TLP required higher ECLS sweep gas flow rates and blood flow,
suggesting gas exchange performance was impeded. As we evaluated the impact of ECLS on
coagulation in healthy subjects we concluded that neither TLP nor the standard care is a safe or
efficacious solution to prevent coagulopathy induced by extracorporeal circulation and blood biomaterial contact. Further development of a multi-functional coating that regulates
hemostasis through complementary mechanisms as occurs in the endothelium may be the ideal
solution. Such an approach could incorporate TLP with other agents that inhibit thrombin or
cause platelet quiescence, for example.
7.2 Introduction.
Thrombosis, coagulopathy and inflammation are major issues associated with the use of
blood-contacting medical devices. This challenge is apparent during ECLS where exposure of
blood to foreign materials, shear stress from the blood pump, and turbulent flow caused by
circuit and catheter connections causes significant damage to blood cells. When blood contacts
the circuit, protein adsorption and contact pathway activation rapidly occur followed by platelet
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activation, adhesion and thrombus formation (1, 2). Thrombi in the circuit can impede flow and
reduce the performance of the membrane – such as inhibiting gas diffusion across the membrane
lung (3). Simultaneously, progressive platelet consumption, activation of clotting factors and
hemolysis cause risk of consumptive coagulopathy and bleeding (4, 5). Additionally, circulating
blood cells become activated when exposed to developing thrombi and adsorbed proteins, as
well as turbulent flow, causing release of pro-inflammatory factors and complement activation
as the blood is returned to systemic circulation (6, 7).
The risk of thrombotic complications during ECLS necessitates systemic anticoagulation
therapy; however, there are currently no universal guidelines for anticoagulant administration
during ECLS, resulting in highly variable, center-specific protocols (5, 8). The task of maintaining
therapeutic anticoagulation amidst circuit-induced coagulation disturbances, underlying
conditions and frequent transfusions is extremely challenging. The result is frequent bleeding
complications, which can occur at the cannulation site, concomitant wounds, in the airway,
gastrointestinal tract, and can even cause lethal cerebral hemorrhage (9, 10).
An alternative to systemic anticoagulation is to prevent foreign surface-induced thrombosis
and maintain circuit patency using bio-compatible surface coatings. This approach provides
localized anticoagulation at the blood-biomaterial interface. Modern ECLS devices utilize
biocompatible coatings such as immobilized heparin and surface passivation with albumin;
however, these coatings alone are insufficient to prevent coagulation disturbances, and thus
systemic anticoagulation remains standard practice (11, 12). Other investigational surface coatings
include nitric oxide (NO) releasing surfaces that produce a similar NO flux as occurs in the
endothelium to provide localized platelet inhibition (13-15); immobilization of direct thrombin
inhibitors to prevent thrombus formation with more direct pharmacodynamics than heparin (16);
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and endothelialization of the circuit to cover the foreign-surfaces (17). While these approaches
have shown promise in the laboratory setting, they have been primarily tested when applied to
connective tubing segments only, or to segments of deconstructed membranes and catheters.
Additionally, these materials are often evaluated using stationary incubation in blood; or in vivo
under flow using an arterio-venous shunt, which does not account for the effects of the blood pump
or adequately simulate the range of flows for cardiopulmonary (2-7 L / min) or partial respiratory
support (500 mL – 2 L / min). While such studies are integral for evaluation and optimization of
these materials, to fully understand the efficacy, longevity and functionality of these coatings
evaluation using multi-day studies that closely simulate the clinical care scenario is necessary.
A promising biomaterial solution for ECLS is an omniphobic surface coating called TLP
(18). TLP was developed to prevent adhesion of plasma proteins, cells, bacteria or any biological
medium to medical polymer substrates. This coating was inspired by the Nepenthes pitcher plant,
which has a roughened, tooth-like surface that holds in place a thin layer of liquid water. This
super-hydrophilic surface inhibits adhesion of insects, causing them to slide down the pitcher rim
and become trapped by the carnivorous plant (19). This bilayer coating consisting of the following
components: 1) a tethered perfluorocarbon: an immobilized perfluorinated layer that is covalently
bound to an underlying substrate and acts as a tether; and 2) liquid perfluorocarbon: a mobile,
liquid surface layer that is retained on the substrate surface by the immobilized tether layer,
imparting anti-adhesive properties to the substrate. This omniphobic liquid-infused coating repels
both hydrophilic and hydrophobic materials, including clotting components of blood. For example,
Leslie, et al, demonstrated that TLP prevents the attachment of thrombus and pathogenic microbes
to the surface of an array of medical grade materials, including plastics, glasses and metals (18).
Blood sliding angle on TLP- treated acrylic was less than one degree versus 90 degrees on control
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materials; and results were maintained following exposure to fluid sheer strain (1,000 s-1) for 16
hours. When heparinized blood (0.25 U/mL) was exposed to TLP-treated and untreated acrylic
and polysulfone segments for 90 minutes, percent of fibrin-covered area and platelet adhesion were
significantly reduced with the TLP coating. Additionally, to investigate the performance of the
tubing in an in vivo flow setting, TLP coated polyvinyl chloride (PVC) blood perfusion tubing was
assembled into a femoral arteriovenous shunt for 8 hours. In un-heparinized pigs, 100% of the TLP
circuits maintained patency over the 8 hour period compared to only 20% of control circuits. While
these results are promising, this coating has yet to be evaluated when applied to all components of
the ECLS circuit (coated “tip-to-tip” on all surfaces) and in multi-day studies that simulate clinical
care conditions (18).
In this study we evaluated the use of TLP applied tip-to-tip to a low-flow (< 2 L/min
blood flow rate) ECLS device for partial respiratory support (includes membrane, blood pump,
connective tubing and catheter). ECLS is used as an adjunct therapy to mechanical ventilation
during severe respiratory distress, as the artificial membrane lung supplements the work of gas
exchange of the native lung, permitting reduction in ventilator settings and preventing ventilatorinduced lung injury (VILI) (20, 21). Use of ECLS to mitigate VILI during severe respiratory
distress has been used with good success since the H1N1 pandemic (22, 23).
We compared the TLP coated devices used without supplemental anticoagulation to the
standard-of-care -- heparin-coated circuits with continuous heparin infusion -- for 72 hours of
intensive care unit (ICU) care using ELCS in healthy, mechanically ventilated swine. We
assessed coagulation, thrombus deposition, gas-exchange efficiency, efficacy and safety of the
membrane lungs, systemic response and end-organ damage (Figure 7.1). The objective was to
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Figure 7.1 Schematic of study design for evaluation of tethered-liquid perfluorocarbon (TLP) coating
during 72 hours extracorporeal circulation in healthy swine. A) Depiction of TLP bilayer coating
components including immobilized tether layer and mobile liquid surface layer. B) Timeline of key data
collection points is shown. C) Key outcome measures to assess efficacy and biocompatibility of the TLP
surface coating includes coagulation profile, thrombus deposition on circuit components, gas-exchange
performance of the membrane lung (addition of oxygen (O2) and removal of carbon dioxide (CO2)), and
systemic response including vitals and histology.
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evaluate if TLP is safe and efficacious permitting heparin-free ECLS over 72 hours. We
hypothesized that TLP maintains circuit patency and reduces thrombotic and bleeding
complications relative to the standard-of-care; all while not altering gas exchange performance
of the membrane lung or causing untoward systemic effects.
7.3 Methods.
This study was carried out in compliance with the Animal Welfare Act, the implementing
Animal Welfare Regulations, and the principles of the Guide for the Care and Use of Laboratory
Animals, National Research Council. An Institutional Animal Care and Use Committee (Bridge
PTS, San Antonio, Texas) approved all research conducted in this study (Protocol BRIDGE PTS17-08). Bridge PTS is fully accredited by the Association for the Assessment and Accreditation
of Laboratory Animal Care, International (AAALAC, Intl.).
7.3.1 Equipment. A pediatric size ECLS Circuit compatible with the CARDIOHELP
System (Maquet Getinge Group; Rastatt, Germany) with blood flow between 0.2 – 2.8 L/min was
utilized in this study. Circuits consisted of a ROTASSIST 2.8 centrifugal blood pump with
integrated pressure gauge, a membrane lung (0.98 m2 surface area) with integrated pressure sensor,
and ¼” tube connections. Avalon Elite® 19 Fr bi-caval dual-lumen catheters (Maquet Getinge
Group; Rastatt, Germany) were used for veno-venous ECLS. A total of 5 TLP-coated and 5
uncoated devices were available for this study. In the TLP group, ECLS circuits (tubing, pump
and membrane) and catheters as provided by manufacturer were coated tip-to-tip with the tethered
layer of the TLP coating (FreeFlow Medical Devices, LLC; Lancatser, PA, USA) (see section
7.3.2). ECLS Circuits with BIOLINE® coating (immobilized albumin with covalently bound high
molecular weight heparin) from the manufacturer were used in the control (CTRL) group with
standard Avalon Elite® catheters (Maquet Getinge Group; Rastatt, Germany).
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7.3.2 TLP coating. Application of TLP to ECLS circuits and catheters was carried out in
2 phases. First, we sent entire ECLS circuits and components to Free Flow Medical Devices, LLC
(Lancaster, PA, USA) for attachment of the perfluorinated silane tether layer. The tethered circuits
were returned to our lab for conductance of experiments. Application of the liquid perfluorocarbon
lubricant layer was carried out by us immediately before priming of the ECLS circuit and
cannulation. Namely, 150 µL of liquid lubricant, FluoroLube63 (FL63; Sigma-Aldrich; St. Louis,
MO), was sterilized using a 0.2 µM filter and injected into the pre-membrane/venous face of the
membrane lung. Once the membrane was saturated, FL63 was drained from the oxygenator into
the pump and tubing components. The excess FL63 was then withdrawn, with ~30mL lubricant
remaining in the circuit. The Avalon catheters with tethered layer applied were filled with FL63,
then drained of lubricant immediately prior to cannulation.
7.3.2 Instrumentation. Female Yorkshire swine (CTRL = 48.6 ± 4.6 kg; TLP = 45.3 ± 2.6
kg; p > 0.05) were anesthetized with 6 mg/kg Telazol® (tiletamine/zolazepam) delivered
intramuscularly (IM). Atropine sulphate (0.05 mg/kg) was administered IM to prevent airway
secretions. Endotracheal intubation was performed via direct laryngoscopy using a 10 mm
endotracheal tube. A surgical plane of anesthesia was achieved using inhaled isoflurane (0.5 – 5%
volume in oxygen). A 16 Fr Foley catheter was inserted trans-urethraly. Urine output was
measured by the BARD® CRITICORE® Monitoring System (BARD Medical; Covington,
Georgia, USA) to titrate fluid infusion during multi-day ICU care. The right jugular vein, left
carotid artery and the left and right femoral arteries and veins were cannulated with 7-8.5 Fr sheath
introducers (Arrow International Inc.; Reading, PA, USA) placed percutaneously with ultrasound
guidance. Arterial sheaths were cannulated with IV lines for monitoring arterial blood pressure
(ABP) and for collection of systemic blood samples. Venous sheaths were cannulated with IV lines
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for administration of fluids (normal saline) and anesthesia medications using an Alaris™
MedSystem III® Multi-Channel Infusion Pump (Alaris Medical Systems, Inc.; San Diego, CA,
USA). Following venous line placement, animals were transitioned from inhaled anesthesia to total
IV anesthesia (TIVA) for the remainder of the study. TIVA consisted of continuous infusion of
fentanyl (1-4 mcg/kg/hr), ketamine (2-10 mg/kg/hr), midazolam (1-5 mg/kg/hr) and propofol (1025 mcg/kg/min). Additionally, propofol boluses (1-3 mL) were delivered if evidence of
spontaneous breathing, purposeful movement or discomfort were observed. Endotracheal
intubation was converted to surgical tracheostomy using a 10.0 mm tracheostomy tube. Animals
were volume-control ventilated (V500, Dräger Medical; Lübeck, Germany) with room air, initial
tidal volume (VT) of 10 mL/kg and respiratory rate (RR) of 10-14 breaths/min. Positive end
expiratory pressure (PEEP) was 5 cm H2O. Continuous EKG, arterial blood pressure (ABP) and
oxyhemoglobin saturation (SpO2) were monitored using the Dräger Infinity® M540 Monitor
(Drägerwek AG; Lübeck, Germany). Animals were stabilized for 30 min prior to record of vital
signs and collection of baseline samples.
7.3.3 Initiation of ECLS. Prior to cannulation, all ECLS circuits were primed according
to manufacturer’s instructions using 1 L normal saline to which 5000 U of unfractionated heparin
had been added. A 2000 U unfractionated heparin bolus was administered to prevent thrombosis
during cannulation. A 19 Fr dual-lumen catheter was percutaneously inserted into the right jugular
vein for veno-venous (VV) ECLS. The catheter was connected to the ECLS system in an air-free,
wet-to-wet fashion. Blood flow through the circuit was set to 1 L/min, and the sweep gas (100%
O2) flow rate was set to 5 L/min. Following cannulation, heparin infusion was initiated in the
CTRL group (40 U/kg/hr) and titrated to maintain an ACT of 50% above baseline value. No
heparin was administered in the TLP group for the remainder of the study. Following collection
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of data and blood samples immediately after initiation of ECLS (Post-ECLS time point), the
ventilator settings were incrementally adjusted. First, VT was reduced by 2 cc/kg to achieve a peak
airway pressure below 35 cm H2O; then, VT was lowered to a minimum of 4 cc/kg. This
progressive reduction of ventilator settings has been shown to reduce markers of VILI and
pulmonary inflammation relative to the standard lung-protective ventilation protocol of 6 mL/kg
VT in acute respiratory distress (ARDS) patients (24). RR was incrementally reduced to a target of
4 breaths / min; and FiO2 and ECLS settings were titrated to achieve a PaO2 > 60 mmHg and pH
> 7.2.
7.3.4 ECLS. Data were collected for 72 hours of extracorporeal circulation unless the
circuit became occluded inhibiting flow (RPMs maximized at 5000, with ∆p > 200 mmHg and
decline in flow below 0.5 L / min), at which point the study was terminated. All vital signs, pointof-care monitoring tests and blood labs were taken at baseline (BL), immediately post-initiation of
ECLS (Post-ECLS), and at 3, 6, 12, 24 48 and 72 hours post-ECLS (see Figure 7.1). Animals were
continuously monitored by technicians, study staff and a physician throughout the experiment. If
ECLS settings were insufficient to support the clinical condition of the animal (PaCO2 35-45
mmHg; PaO2 < 60 mmHg), sweep gas flow rate and blood flow rate were increased accordingly.
These changes were recorded and time to onset of required adjustments was reported. If required,
vasopressors (epinephrine) were administered for blood pressure support and a loop diuretic
(Furosemide, 0.5 mg) was given to increase urine output (if < 0.5 ml/kg/hour) and/or the risk of
kidney injury was suspected. ECLS circuit parameters including arterial pressure (Part), venous
pressure (Pven), internal membrane pressure (Pint), pressure drop across the membrane (∆p), and
pump revolutions per minute (RPM) were recorded. Any hemorrhagic or thrombotic complications
observed during circulation were recorded.

143

7.3.4.1 Blood labs and coagulation. To assess the impact of extracorporeal circulation on
circulating blood and hemostasis, complete blood count was performed using the ADVIA
2120 hematology analyzer with veterinary software package (Siemens AG, Germany).
Samples were collected in EDTA tubes and analyzed using porcine settings. Coagulation
testing included prothrombin time (PT), activated partial thromboplastin time (aPTT),
antithrombin III (ATIII), von Willebrand factor (vWF), and concentrations of fibrinogen
and d-dimer measured in previously frozen (-80 ºC) platelet poor plasma (PPP) using the
Stago STA Compact Max Analyzer (Stago; Parsippany, NJ, USA) as previously reported
(25, 26). The PPP was prepared by dual centrifugation (3,000 g, 10 min, 4ºC) of citrated
whole blood. Activated Clotting Time (ACT) was measured using the Hemochron
Signature Elite Whole-Blood Microcoagulation System (Accriva Diagnostics; San Diego,
CA). Thromboelastography (TEG) was performed using the TEG 5000 Hemostasis
Analyzer System (Haemonetics Corp., Braintree, MA) according to manufacturer’s
instructions. 3.8% citrated arterial whole blood was analyzed using the citrated kaolin assay
and heparinase cups to neutralize the effects of heparin. The following variables of interest
were recorded: reaction time (R), initial clot formation time (K), clot strength (MA), and
lysis (Ly60). Platelet aggregation was measured by whole-blood impedance aggregometer
(Multiplate® Analyzer, Roche Diagnostics; Basel, Switzerland) using ADP (final
concentration 10.75 uM; ADPtest, Roche Diagnostics; Basel, Switzerland) and collagen
(final concentration 3.2 ug/mL; Helena Laboratories; Beaumont, Texas) as activators; area
under the curve was calculated as previously described (25). Plasma free hemoglobin
(PFHb) was measured in EDTA plasma (dual centrifugation 3,000 g, 10 min, 4 ºC) by
direct spectrophotometry as previously described (27). To assess systemic inflammatory
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response and endothelial damage, EDTA plasma samples were frozen (-80 ºC) for later
analysis of cytokines (IL-1b, IL-6, IL-8, IL-10 and TNF-α) using a MILLIPLEX Porcine
Magnetic Bead Panel (Millipore Sigma; Burlington, MA) and Luminex® 200 Analyzer
(Luminex Corporation; Austin, TX). Serum samples were collected in BD Vacutainer®
serum collection tubes (Becton Dickinson; Franklin Lakes, NJ), incubated for 1.5 hours,
centrifuged (3,000 g, 10 min, 4 ºC) and frozen for later analysis of syndecan-1
concentration using an ELISA kit (SEB966PO, Cloud-Clone Corp.; Katy, TX).
7.3.4.2 Vital signs, respiration and chemistry. Vital Signs and respiratory measures
included heart rate, mean arterial blood pressure (MAP), SpO2, RR, CO2 production
(V̇CO2), minute ventilation (MV), plateau pressure (Pplat) compliance (Cdyn), pulmonary
resistance and etCO2. Urine output (UO), fluid balance, anesthesia rates and rectal core
temperature were also recorded. Blood gases (pH, partial pressure CO2 (pCO2) and O2
(pO2), oxygen saturation (SO2) and lactate) were analyzed using the i-STAT1 Blood
Analyzer (Abott; Chicago, IL). Systemic blood gas samples were collected from the
femoral artery; pre-membrane blood samples were collected from the right femoral venous
line which was positioned to withdraw blood before entry into the ECLS catheter; and postmembrane samples were collected from a port located within the ECLS connective tubing
directly after blood passage out of the membrane lung for determination of gas exchange
efficiency. The membrane CO2 removal was determined by the percent decrease in pCO2
from a pre-membrane to post-membrane blood gas at each time point. The O2 transfer was
calculated from pre- and post-membrane blood gases as previously reported (28).
Oxygenation index was defined as ([FiO2 x mean airway pressure] / PaO2). The PaO2 to
FiO2 ratio (PFR) was also calculated according to the Berlin Definition (no ARDS = PFR
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> 300, mild ARDS = 200 < PFR < 300; moderate ARDS = 100 < PFR < 200, severe ARDS
= PFR < 100) (29). Blood urea nitrogen (BUN), postassium (K+) and creatinine were
measured using an i-STAT CHEM8+ cartridge (Abott; Chicago, IL).
7.3.5 End of study procedures. End of study was initiated after 72 hrs extracorporeal
circulation or upon occlusion of the ECLS circuit. Animals were irreversibly anesthetized and
euthanized by exsanguination. This was done to prevent post-mortem clotting caused by routine
euthanasia medications.
7.3.5.1 Fixation of explanted ECLS circuits. At the end of study, the ECLS circuit and
catheter were immediately removed from the animal, rinsed with 1.5 L phosphate buffered
saline (PBS) at 1 L/min flow, drained and filled with 2.5% glutaraldehyde in 0.1M sodium
cacodylate buffer for fixation. After 48 hours, the membrane was drained of fixative and
disassembled to expose the polymethylpentene (PMP) gas exchange fibers, as we have
previously described (15). A PMP fiber layer was collected from the inlet face, center and
outlet face of each ML. These segments were then further dissected into 4 equal 1 cm2
quadrants. Samples from the Avalon catheter were collected from the inlet and outlet
connective tubing, the center of the catheter, and the catheter tip. Circuit tubing samples
were collected from the pre-membrane and post-membrane lines immediately before and
after the ML. All samples were dehydrated in graded ethanol (35%, 50%, 70%, 100%; 10
min each) and stored in a desiccator until imaging analysis.
7.3.5.2 Thrombus area. Digital images of the membrane lung inlet, center and outlet PMP
fiber layers were captured and used to determine the percent area of thrombus deposition
on each layer, which was scored by 3 blinded reviewers using ImageJ Software (NIH;
Bethesda, MD, USA) as previously reported (30).
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7.3.5.3 Field Emission SEM imaging. The membrane, tubing and catheter segments were
sputter-coated with gold-palladium at 10 nm thickness (Leica Microsystems Inc.; Wetzlar,
Germany) and imaged using field emission SEM (FEI Teneo; Hillsboro, OR, USA). An
accelerating voltage of 10 kV was applied with a spot size of 9.
7.3.5.4 Protein adhesion: Protein adsorption on circuit tubing and catheters was
determined as previously reported (31, 32) Briefly, following rinse with 100 mL PBS, 2
cm segments were collected in duplicated from circuit connective tubing, catheter
inlet/outlet tubing connections, catheter center and catheter tip. Additional tubing samples
that had not been exposed to blood were cut from the circuit before use as controls.
Segments were incubated in 1 wt% aqueous solution of sodium dodecylsulfate (SDS)
buffer with agitation at 37 C for 1 h. Samples were centrifuged at 200 g for 10 min to
sediment red blood cells, and total protein concentration in the supernatant was determined
using the Pierce™ micro bicinchoninic acid (BCA) test kit (ThermoFisher Scientific;
Waltham, MA). Total protein was divided by the blood-contacting surface area of the
sample.
7.3.5.5 Histology. Following euthanasia, tissue samples were taken from lungs, kidney,
liver, jejunum, left ventricle and aorta for histological imaging and assessment. Samples
were fixed in neutral-buffered 10% formalin for 24 hrs, trimmed, embedded in paraffin,
sectioned at 4 µm, and stained with hematoxylin and eosin (H&E). Histological images
were recorded using a 10x objective (Zeiss Axioskop; Oberkochen, Germany) and were
evaluated by a pathologist blinded to study conditions to assess signs of toxicity, end-organ
damage and diffuse alveolar damage in the lungs (33).
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7.3.6 Statistics. Statistics were performed using SAS 9.4 (Cary, NC, USA). All tests were
two-sided with an alpha = 0.05 for significance. The CTRL and TLP groups were tested
independently using one-way mixed models with repeated measures and a Dunnett adjustment to
test significant changes from baseline measurements. Between-group differences were examined
using a two-way mixed model with repeated measures. A Tukey adjustment was used for multiple
comparisons. Survival analysis was performed with log-rank test for significance.
7.4 Results.
We successfully completed the first multi-day evaluation of heparin-free ECLS using
clinically available ECLS circuits with TLP coating. In the CTRL group, all animals survived
to end of study with one circuit that occluded at the 72-hr mark. In the TLP group 4 animals
died before 72 hr: two due to thrombotic circuit occlusions, one due to pneumothorax and one
after rapid development of desaturation/destabilization unresponsive to vasopressors. Only one
animal survived for 72-hrs circulation (for TLP at 24 hrs, n=5; at 48 hrs, n=3; at 72 hrs n=1).
For TLP mean survival time was 57 ± 13 hrs versus 72 ± 0 hrs in CTRL (p = 0.026).
Complete blood count and coagulation values are shown in Table 7.1. Red cell count
and hemoglobin concentration dropped significantly in both groups after start of ECLS. Platelet
count significantly decreased immediately Post-ECLS in TLP and at 12 hrs in CTRL. PT was
elevated in both groups during ECLS. aPTT and ACT were significantly higher in the CTRL
group versus TLP after start of heparin infusion in CTRL. D-dimer concentration did not change
in either group (Figure 7.2). ATIII activity was significantly reduced from 3h to end of study
in CTRL and was reduced from 3-12hrs in TLP (Figure 7.2). vWF activity numerically
decreased in both groups on the first day of circulation but began to increase at 24 hrs ( Figure
7.2). Thromboelastography (Figure 7.3) showed that R was prolonged versus BL in CTRL and
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Table 7.1 Blood Cell Count and Coagulation.
Variable

Baseline

Post-ECLS

CTRL

14.6±1.5

16.1±1.4

15.0±2.1

15.1±1.9

15.0±1.6

14.4±0.9

15.1±0.9

11.1±1.2

(10 /µL)

TLP

13.9±1.2

13.9±1.6

11.5±1.4

12.0±1.5

12.4±1.2

12.0±1.1

10.5±1.8

8.74

RBC

CTRL

5.8±0.1

5.6±0.2

5.1±0.1*

4.7±0.1*

4.5±0.1*

4.3±0.2*

4.2±0.3*

3.7±0.3*

(103/µL)

TLP

6.1±0.1

5.7±0.1*

5.2±0.1*

5.0±0.1*

4.8±0.1*

5.0±0.4*

4.7±0.4*

3.3

Hb (g/dL)

CTRL

9.9±0.3

9.6±0.4

8.6±0.2*

8.1±0.2*

7.6±0.1*

7.4±0.3*

7.2±0.5*

6.3±0.5*

TLP

9.9±0.2

9.3±0.2*

8.5±0.3*

8.3±0.3*

7.9±0.2*

8.3±0.8

7.7±0.4*

5.9

CTRL

274±38

263±35

236±34

218±38

196±30*

152±16*

122±11*

121±7*

(10 /mm )

TLP

308±30

269±27*

238±21*

225±20*

190±24*

148±23*

130±22*

155

PT (s)

CTRL

13.3±0.2

13.7±0.2*

14.0±0.1*

14.3±0.1*

14.5±0.3*

14.5±0.2*

14.4±0.2*

14.2±0.2*

TLP

13.4±0.2

13.7±0.2

13.9±0.2*

14.0±0.2*

13.8±0.2*

14.5±0.5*

14.1±0.3*

13.9

CTRL

21.3±1.6

40.0±3.6

59±30†

56.7±7.2*†

91.6±15.0*†

65.0±15.9*†

75.2±14.8*†

96.2±27.3*†

TLP

19.3±2.3

40.7±6.0*

18.4±1.8†

18.3±1.7†

18.0±1.4†

17.5±1.3†

18.0±1.5†

15.4†

CTRL

91±4

129±6*

130±13*†

170±16*†

171±20*†

137±7*†

137±8*†

137±6*†

TLP

95±1

126±9

95±3†

95±2†

94±3†

96±3†

94±2†

94†

Fib

CTRL

188±17

171±14

166±14

165±11

196±14

277±17*

426±23*

458±35*

(mg/dL)

TLP

182±20

162±13

159±16

153±12

175±18

208±3

389±61*

210

PFHb

CTRL

27±3

10±2*

10±2*

11±3*

12±2*†

12±1*†

11±1*†

24±7

(g/dL)

TLP

25±5

9±2*

16±3*

16±4*

24±3†

27±3†

28±4*†

68*

BUN

CTRL

7.0±1.5

7.2±1.4

8.8±1.5

9.8±1.5

10.8±1.6

13.2±1.4*

11.4±1.9

10.4±1.2

(mg/dL)

TLP

7±1.7

6.8±1.5

7.4±1.3

8.4±1.1

9.6±2.3

13.8±2.0*

12.3±1.0*

12

Creatinine

CTRL

1.4±0.1

1.6±0.2

1.7±0.2

1.7±0.2*

1.7±0.2*

1.8±0.2*

1.4±0.1

1.4±0.1

(mg/dL)

TLP

1.4±0.1

1.4±0.1

1.4±0.1

1.6±0.1

1.6±0.1

1.6±0.1

1.4±0.1

1.4

K+

CTRL

3.7±0.1

3.6±0.1

3.8±0.1

3.9±0.1

3.7±0.1

3.8±0.1

4.0±0.2

4.1±0.1

(mmol/L)

TLP

3.6±0.1

3.5±0.1

3.7±0.1

4.0±0.1*

4.1±0.1*

3.9±0.2

4.1±0.2*

3.9

WBC
6

Plt
3

3

aPTT (s)

ACT (s)

Group

3 hr

6 hr

12 hrs

24 hrs

48 hrs

72 hrs

Mean ± standard deviation. White blood cell (WBC), red blood cell (RBC), hemoglobin (Hb), platelet
(Plt), prothrombin time (PT), activated partial thromboplastin time (aPTT), activated clotting time
(ACT), fibrinogen (Fib), plasma free-hemoglobin (PFHb), blood urea nitrogen (BUN), potassium (K +).
*Indicates significant change from baseline. †Indicates significant difference between groups.
Significance p<0.05.
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Figure 7.2 Mean ± standard deviation of (A) D-dimer concentration, (B) anti-thrombin III (ATIII) activity
and (C) von Willebrand factor (vWF) activity in platelet poor plasma from control animals (CTRL; n=5)
receiving extracorporeal life support (ECLS) with heparin-coated circuits and continuous heparin infusion
versus tethered liquid perfluorocarbon (TLP) animals (n=5) receiving ECLS using TLP-coated circuits and
no systemic anticoagulation for 72 hours circulation. *Indicates significant change from baseline. †Indicates
significant difference between groups. All tests were two-sided with significance p<0.05.
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Figure 7.3 Mean ± standard deviation of thromboelastography measurement of (A) clot reaction
time (R), (B) initial clot formation time (K) (C) clot strength (MA) and (D) fibrinolysis at 60 minutes
(LY60) in whole-blood from control animals (CTRL; n=5) receiving extracorporeal life support
(ECLS) with heparin-coated circuits and continuous heparin infusion versus tethered liquid
perfluorocarbon (TLP) animals (n=5) receiving ECLS using TLP-coated circuits and no systemic
anticoagulation for 72 hours circulation. *Indicates significant change from baseline. †Indicates
significant difference between groups. All tests were two-sided with significance p<0.05.
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was significantly elevated compared to the TLP group. K increased in both groups with time on
ECLS. Both groups exhibited a reduction in MA after start of ECLS which returned to BL levels
by 24 hours and continued to increase. LY60 was initially elevated in the TLP group Post-ECLS
but was significantly reduced in both groups by 24 hrs. Normalized platelet count (Figure 7.4)
was reduced at 24 hrs in TLP and 48 hrs in CTRL. Both groups exhibited an increase in platelet
aggregation stimulated by collagen and ADP with time on ECLS (Figure 7.4).
All circulation-related complications and significant events are reported in Table 7.2.
Both groups experienced hemorrhagic and thrombotic complications. The most common site of
bleeding was peripheral cannulas; and the most common site for thrombi was the membrane.
Interestingly, arterial bubbles were detected by the integrated circuit alarm in 60% of animals
in the TLP group (mean onset 2 ± 3 hrs post-ECLS) which was normally resolved by 6 hrs. This
did not occur in CTRL. Additionally, 80% of TLP animals required an increase in sweep gas
flow rate and 60% required an increase in circuit blood flow to maintain the patient in
normoxic/normocapnic state; whereas no change in sweep gas or blood flow was required in
CTRL.
Post-circulation assessment of ECLS circuits revealed no difference in thrombus
deposition or protein adhesion between groups. The percent area of thrombus deposition on PMP
fiber sheets collected at the inlet, center and outlet of the membrane was not different between
groups, but progressively decreased in both groups from the inlet/venous face to the outlet/arterial
face (Figure 7.5). There was a significant decrease in thrombus area on the post-membrane face
versus the pre-membrane face in the TLP group. SEM imaging indicated that thrombus deposition
on TLP-coated materials with heparin-free circulation was similar to heparin-coated CTRL devices
with continuous heparin infusion (Figure 7.6). Again, the largest thrombotic deposits and areas of
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Figure 7.4 Mean ± standard deviation of (A) Normalized platelet count (calculated by [platelet (Plt) *
(Hemoglobin concentration at specified time point / baseline hemoglobin concentration)], (B) collagen
(COL)-stimulated platelet aggregation, and (C) adenosine diphosphate (ADP)-stimulated platelet
aggregation in whole-blood from control animals (CTRL; n=5) receiving extracorporeal life support
(ECLS) with heparin-coated circuits and continuous heparin infusion versus tethered liquid perfluorocarbon
(TLP) animals (n=5) receiving ECLS using TLP-coated circuits and no systemic anticoagulation for 72
hours circulation. Platelet aggregation was measured via impedance aggregometry and reported as total
area under the curve (AUC) divided by the platelet count. *Indicates significant change from baseline.
†Indicates significant difference between groups. All tests were two-sided with significance p<0.05.
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Table 7.2 Complications and Significant Events.

Hemorrhage: ECLS Cannula
Site
Hemorrhage: Peripheral
Cannula
Hemorrhage: Airway
Circuit Thrombus: Pump
Circuit Thrombus: Membrane
Circuit Thrombus: Occlusion
Circuit Arterial Bubble Detected
Increase Sweep Gas
Increase Blood Flow
Vasopressors
Diuretic/Furosemide

CTRL % (Time ± SD)
20% (19 h)

TLP % (Time ± SD)
N/A

60% (23 ± 4 h)

20% (47 h)

40% (24 ± 20 h)
N/A
40% (69 ± 1 h)
20% (72 h)
N/A
N/A
N/A
20% (32 h)
60% (3 ± 3 h)

N/A
20% (unknown)
40% (47 ± 15 h)
40% (50 ± 18 h)
60% (2 ± 3 h)
80% (39 ± 22 h)
60% (41 ± 21 h)
80% (44 ± 18 h)
60% (13 ± 18 h)

Instance of significant events during extracorporeal circulation including complications, deviations from
initial circuit settings necessitated by animal condition and membrane performance, and administration
of medications unrelated to anesthesia. The percent instance of each event for control (CTRL; n=5) and
tethered-liquid perfluorocarbon (TLP; n=5) groups are shown. The mean time to onset of event (hours
post-ECLS initiation) ± standard deviation is shown.
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dense fibrin coverage were observed on the inlet/venous face and progressively decreased towards
the outlet/arterial face. Thrombus deposition on the Avalon catheter was similar between groups,
with greatest deposition observed at the catheter inlet and outlet connection (Figure 7.7). Of note,
deposition on connective tubing was minimal or absent. There was no difference between groups
in total protein adsorption on the segments collected from the Avalon catheter (Figure 7.5).
Vital signs and respiratory parameters are reported in Table 7.3. PaCO2 was
significantly reduced versus baseline in both groups at Post-ECLS, which persisted in the CTRL
group until 72 hrs, but was not observed in TLP. MV was reduced in both groups following
ventilator setting decrements made after the Post-ECLS time point. RR was reduced versus
baseline in CTRL from 3 hrs to 72 hrs; but was only reduced in TLP from 3-12 hrs. There were
no differences in VCO2 between groups. CTRL animals were primarily supported by room air;
whereas TLP animals had a significant increase in FiO 2 beginning at 12 hrs. Within hours of
start of ECLS, plateau pressures were higher in the TLP group and C dyn was reduced compared
to CTRL. Pulmonary resistance increased in both groups versus baseline at 3 hrs to end of study.
OI was significantly higher in TLP versus CTRL beginning at 12 hrs. PFR was significantly
reduced in TLP beginning at 12 hrs and was significantly reduced in CTRL at 72 hrs. There
were no significant differences between groups in percent reduction in pCO 2 across the
membrane or oxygen transfer (Figure 7.8). There were no between group difference in ECLS
circuit settings or pressures (Table 7.4).
Systemic cytokine levels (Figure 7.9) were unremarkable, except an increase in IL-6 in
TLP beginning at 48 hrs. Additionally, IL-8 was significantly reduced from 12-24 hrs in both
groups. There was no change in systemic syndecan-1 levels in either group (Figure 7.9).
Following necropsy assessment and histological analysis, there were no obvious signs of toxic
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Figure 7.5 (A) Mean ± standard deviation protein adhesion (total protein concentration / blood
contacting surface area) collected from 19 Fr dual-lumen catheters for veno-venous extracorporeal
life support (ECLS) follow 72 hours circulation in vivo in swine (n=5/group). Control animals
(CTRL) used manufacturer’s standard catheters during ECLS with continuous heparin infusion
versus tethered liquid perfluorocarbon (TLP) animals that used standard catheters with TLP-coating
applied during ECLS with no systemic anticoagulation. (B) Mean ± standard deviation of total
thrombus area determined from digital images of polymethyl pentene fiber layers collected from the
membrane lung inlet/venous face (INLET), center layer of the membrane (MID), and outlet/arterial
face of the membrane (OUTLET). The percent of the total membrane area that was covered in
thrombus was scored by 3 blinded reviewers, and the average of the 3 scores was taken for each
sample. *Indicates significant change versus inlet. †Indicates significant difference between groups.
All tests were two-sided with significance p<0.05.
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Figure 7.6 Field emission scanning electron microscopy images from membrane lungs with immobilized-heparin control coating (CTRL; panels
A-F) used with continuous heparin infusion versus membranes with tethered liquid perfluorocarbon (TLP; panels G-L) coating used without
systemic anticoagulation for 72 hours extracorporeal circulation in swine (n=5/group). Top row images (A-B, G-H) from the inlet/venous face
of the membrane lung. Center row images (C-D, I-J) from the center of the membrane lung. Bottom row images (E-F, K-L) from the
outlet/arterial face of the membrane lung. Significant thrombus deposition present on all membrane lungs, with no apparent difference between
groups. Layers of fibrin mesh cover the gas exchange fibers, potentially inhibiting blood flow and gas transfer. Density and extent of thrombus
formation appeared to decrease from the inlet face to the outlet face.
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Figure 7.7 Field emission scanning electron microscopy images collected from segments of 19 Fr dual-lumen catheters for venovenous extracorporeal life support following 72 hours in vivo circulation in swine (n=5/group). Control catheters (CTRL; top
row, panels A-E) were used with continuous heparin infusion and are compared to tethered liquid perfluorocarbon (TLP; bottom row,
panels G-L) coated catheters used without systemic anticoagulation. Samples were collected from the catheter inlet connection (A, F),
outlet connection (B, G), center of the catheter (C,H) and catheter distal tip (D, I). Greatest deposition in both groups was observed on
the inlet and outlet connections. There was no apparent difference between groups in sample appearance.

Table 7.3 Vital Signs and Respiratory Measurements.
Variable

Group

Baseline

Post-ECLS

3 hr

6 hr

12 hrs

24 hrs

CTRL

102±5

103±6

96±5

90±8

77±2*

TLP

113±4

118±6

99±4

94±8

82±4*

MAP (mm

CTRL

73±4

73±4

79±3

83±5

Hg)

TLP

80±4

70±3

82±3

83±3

CTRL

7.49±0.02

7.60±0.02*

7.54±0.03

HR (bpm)

Arterial pH

48 hrs

72 hrs

73±6*

76±5*

78±6*

94±10

105±13

63

83±4

86±3

83±4

82±4

82±3

83±5

78±3

90

7.52±0.01

7.53±0.01

7.52±0.01

7.46±0.02

7.47±0.02

TLP

7.49±0.01

7.51±0.02

7.49±0.02

7.50±0.02

7.49±0.01

7.40±0.07

7.49±0.03

7.53

PaO2 (mm

CTRL

81±2

92±6

78±3

84±5

80±5

82±2

85±6

83±8

Hg)

TLP

87±4

95±5

88±4

92±10

83±2

77±6

76±9

96

PaCO2 (mm

CTRL

41±2

26±1*

29±1*

32±2*

28±1*

28±1*

33±1*

34±2*

Hg)

TLP

42±1

27±3*

33±3

36±2

35±2

37±3

38±4

34

MV (L /

CTRL

7.6±0.8

7.8±0.8

4.0±0.3*

4.2±0.5*

3.9±0.4*

4.2±0.5*

4.1±0.5*

4.4±0.2*

min)

TLP

8.6±0.3

8.6±0.3

4.2±0.3*

4.6±0.3*

4.7±0.3*

5.5±0.7*

5.1±1.0*

4.2

RR

CTRL

16±1

16±1

10±1*

10±1*

10±1*

10±1*

10±1*

10±2*

(breaths /

TLP

19±1

19±1

14±2*

12±1*

12±1*

16±3

19±7

10

CTRL

21±0

21±0

21±0

22±1

22±1

22±1

24±2

30±5

TLP

21±0

21±0

23±2

25±2

27±4*

53±19*

62±22*

25*

Et CO2

CTRL

38±1

23±1*

32±1*

34±2

31±2*

29±1*

34±2

32±2*

(mm Hg)

TLP

41±2

28±2*

33±3

29±4*

31±2

28±5*

33±1

35

Plateau

CTRL

18±1

20±1

16±1*†

17±1*†

18±1†

18±1†

18±1†

22±2

Pressure

TLP

18±1

22±1*

18±1†

20±1*†

24±2*†

27±5*†

24±3*†

20

Compliance

CTRL

36±1

36±2†

37±1

34±1

31±1*†

30±2*†

30±1*†

24±4*

(Cdyn)

TLP

38±2

29±2*†

32±2

27±3*

21±2*†

18±4*†

16±5*†

29

CTRL

6.2±0.1

6.3±0.1

6.9±0.2*

7.2±0.2*

7.5±0.4*

7.8±0.4*

8.3±0.4*

10.2±0.7*

TLP

6.1±0.2

6.7±0.2

7.2±0.3*

7.6±0.3*

9.2±1.0*

11.4±2.4*

10.8±0.9*

8.5

Oxygenatio

CTRL

2.5±0.1

2.3±0.2

2.6±0.1

2.6±0.1†

2.8±0.1*†

2.9±0.2

3.1±0.2*†

5.0±1.1*

n Index

TLP

2.3±0.2

2.2±0.2

2.7±0.5

3.4±0.4*†

4.3±0.7*†

17.5±10.5*

22.0±11.4*†

2.86

CTRL

387±10

438±27

373±16

384±14

369±20

379±10

360±13

301±47*

TLP

413±18

454±22

390±24

376±24

322±35*

255±79*

215±84*

384

min)
FiO2 (%)

(Pplat)

Resistance

PFR

Mean ± sd control (CTRL) versus tethered liquid perfluorocarbon (TLP) (n=5/grop. Heart rate (HR),
mean arterial pressure (MAP), partial pressure oxygen and carbon dioxide in arterial blood (P aO2
and PaCO2), minute ventilation (MV), respiratory rate (RR), fraction inspired oxygen (F iO2), endtidal carbon dioxide (Et CO2), respiratory compliance (C dyn), PFR (PaO2 to FiO2 ratio) *Indicates
significant change from baseline. †Indicates significant difference between groups. Sig nificance
accepted as p<0.05.
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Figure 7.8 Figure represents gas exchange efficiency of membrane lungs with tethered liquid
perfluorocarbon (TLP; n=5) coating versus immobilized-heparin control coating (CTRL; n=5). Time points
are post-initiation of ECLS (PE) and at 3-72 hours after start of circulation. Panels A and B bars represent
means ± standard deviation of partial pressure of carbon dioxide (pCO2) and partial pressure of oxygen
(PO2), respectively, for blood gases drawn from the pre-membrane (PRE) venous ECLS circuit line and
post-membrane (POST) circuit line located immediately before and after blood passage through the
membrane lung. Panel C represents mean ± standard deviation of percent decrease in pCO2 from premembrane to post-membrane blood samples. Panel D represents mean ± standard deviation oxygen transfer
(ml/min) measured from blood samples directly before and after passage through the membrane lung in the
extracorporeal circuit. A two-sided test was performed with p < 0.05 accepted for significance. *Indicates
within group change vs. baseline; †Indicates between group difference.
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Table 7.4 ECLS Circuit Paramters
Variable
Flow
(L / min)
Sweep gas
(L / min)
Pump RPM

P ven
(mmHg)

Group

Post-ECLS

3 hr

6 hr

12 hrs

24 hrs

48 hrs

72 hrs

CTRL

1±0

1±0

1±0

1±0

1±0

1±0

1±0

TLP

1±0

1±0

1±0

1±0

1.1±0.1

1.1±0.1

1.0

CTRL

5±0

5±0

5±0

5±0

5±0

5±0†

5±0

TLP

5±0

5±0

6±1

7±2

10±4

14±4†

10

CTRL

2780±40

2660±20

2630±20

2620±40

2650±40

2700±40

3300±430

TLP

2840±40

2760±40

2750±40

2730±40

2840±150

3000±170

2750

CTRL

-77±6

-67±1

-64±2

-62±2

-63±2

-64±2

-63±1

TLP

-71±2

-67±2

-66±2

-65±2

-73±9

-79±9

-64

CTRL

23±1

21±1

20±1

19±1

21±1

23±1

142±85

TLP

31±1

28±1

26±2

27±1

38±7

34±2

27

∆p

Mean ± standard deviation in control animals (CTRL; n=5) receiving extracorporeal life support
(ECLS) with heparin-coated circuits and continuous heparin infusion and tethered liquid
perfluorocarbon (TLP; n=5) group receiving ECLS using TLP-coated circuits and no systemic
anticoagulation for 72 hours. RPM = pump revolutions per minute, Pven = membrane inlet
pressure/negative pressure, ∆p = membrane pressure gradient/pressure drop. *Indicates significant
change from baseline. †Indicates significant difference between groups. Significance p<0.05.
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Figure 7.9 Mean ± standard deviation of systemic cytokine levels expressed as the relative quotient (RQ) from blood samples
collected throughout 72 hours of extracorporeal life support (ECLS). Control animals (CTRL; n=5) received ECLS with heparin coated circuits and continuous heparin infusion versus tethered liquid perfluorocarbon (TLP) animals (n=5) that received ECLS
using TLP-coated circuits and no systemic anticoagulation. (A) Interleukin-1β (IL-1b), (B) interleukin-6 (IL-6), (C) interleukin8 (IL-8), (D) interleukin-10, (E) tumor necrosis factor α, and (F) endothelial damage marker sydnecan-1 were measured at
baseline (BL), post-initiation of ECLS (PE) and at 3, 6, 12, 24, 36, 48, 60 and 72 hours post-ECLS. *Indicates significant change
from baseline. †Indicates significant difference between groups. All tests were two-sided with significance p<0.05.

damage or distinctive pathologies in the lungs, kidney, liver or jejunum for either group.
Findings were mostly unremarkable, with the exception that all animals had signs of lower lung
consolidation likely due to positional atelectasis and mechanical ventilation (see Supp. Fig 1).
Two animals in each group had signs of more severe lung damage including fibrosis, edema,
accumulation of protein aggregates and type II epithelial cell damage. Additionally, one animal
in each group had hepatic congestion and inflammation. Two TLP animals and one CTRL
animal had signs of kidney damage (see Appendix E)
7.5 Discussion
This is the first multi-day study reporting heparin-free ELCS using TLP-coated circuits. In
comparison to the standard-of-care, heparin-coated circuits and continuous heparin infusion, TLP
did not offer an advantage leading to worse oxygenation and higher mortality. To our knowledge
this is also the first evaluation of an investigational (not clinically available) hemocompatible
coating applied to complete, standard ECLS circuits coated tip-to-tip (including membrane, blood
pump, tubing and catheter) evaluated on a multi-day time frame in vivo in an ICU setting. The
study closely represents the clinical care scenario which is a third unique feature of our work. We
hypothesized the TLP is safe, efficacious and preserves native blood parameters during 72 hours
of ECLS without supplemental anticoagulation. Our primary finding is the TLP coating alone is
insufficient to prevent circuit thrombosis for 72 hours of ECLS. Additionally, we found that
membrane performance was altered in the TLP group requiring higher sweep gas flow than
controls (Table 7.4). Finally, we found that heparin-coated ECLS with continuous heparin infusion
also does not prevent circuit thrombosis for 72 hours, and we document the impact of this therapy
on healthy animals including platelet count and aggregation, thromboelastography, coagulation
and hemolysis.
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Blood parameters were similar in both groups with time on ECLS, and we did not notice
significant preservation of native cell counts in the TLP group (Table 7.1). Red blood cell count
and hemoglobin were significantly decreased in both groups by 3 hrs after start of ECLS. Shear
stress from the blood pump causes hemolysis and necessitates blood transfusion in most ECLS
patients (34). Interestingly, PFHb, which is used to measure hemolysis, did not increase with time
on ECLS in CTRL. In TLP, PFHb was significantly higher versus CTRL beginning at 12 hours
Post-ECLS; however, the average concentration was still below levels indicative of clinical
hemolysis (PFHb > 50g/dL) (35), except for the one TLP animal that survived to end of study
(PFHb = 68 g/dL at 72 hours). The blood pump revolutions per minute (RPMs), although not
statistically significant, were consistently ~100-200 revolutions higher in the TLP group than
CTRL, which could cause greater hemolysis. This seemingly minimal difference in RPMs needs
to be seen as an indication of early and sustained increase in resistance within the TLP circuits,
likely due to thrombus formation; and is concurrent with the trend toward elevated ∆p observed in
TLP. We previously evaluated TLP-coated ECLS circuits compared to heparin-coated circuits for
6 hrs of heparin-free circulation. We noted an elevated transmembrane pressure immediately postECLS; however these levels declined and were the same at controls by 1-hour after start of
circulation (Chapter 6). There were no differences in RPMs or other circuit parameters for the 6
hour duration of the study.
Platelet count (both concentration shown in Table 7.1 and normalized count corrected for
hemodilution in Figure 7.4) was reduced with time on ECLS in both groups, and no between
groups differences were observed. Platelet count is widely utilized as a measure of
biocompatibility of blood contacting surfaces (36, 37) and has repeatedly been shown to decrease
with time on veno-venous ECLS with heparin infusion (4). Our results show no benefit of TLP on

164

preservation of platelet count relative to CTRL over 72 hours. TLP has been shown to reduce
plasma protein adsorption and platelet adhesion but does not address the effects of shear stress and
contact pathway activation on platelet activation and aggregation, which could contribute to
platelet consumption.
Fibrinogen concentration, which is normally reduced with protein adsorption and thrombus
formation during ECLS, was significantly elevated in both groups between 24-72 hrs, potentially
as an acute inflammatory response (38, 39). aPTT and ACT were significantly higher in the CTRL
group versus TLP following start of heparin infusion; in TLP the aPTT and ACT transiently
increased following the cannulation heparin bolus but returned to baseline levels shortly after and
were stable throughout. Despite similar blood cell counts throughout the study, bleeding
complications were more frequent in CTRL (occurred in 4 of 5 animals) and began much earlier
between 19-26 hrs after start of ECLS; whereas, in TLP only 1 animal had secondary bleeding
which began at 47 hrs (Table 7.2). This could suggest that the bleeding observed was primarily
due to anticoagulant administration in the CTRL group. This finding is in line with reports by
Andrews and the current Extra Corporeal Life Support Organization (ELSO) summary, stating
that cannulation site bleeding is the most frequently reported hemorrhagic complication during
adult respiratory therapy (5, 10).
D-dimer levels (Figure 7.2), which have been used as an indicator of clot formation in the
membrane, were not significantly different from baseline in either group despite formation of
occlusive thrombi in 3 animals; additionally, D-dimer levels in animals where circuits became
occluded did not show an obvious increase prior to occlusion. Of note, all circuit occlusions were
preceded by a rapid increase in in ∆p (Table 7.4). A transient decrease in ATIII levels was
observed in both groups compared to baseline at 3-6 hours after start of ECLS; however, after this
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point ATIII continued to decrease in CTRL animals but returned to baseline levels in TLP (Figure
7.2). Decrease in ATIII levels is often observed with time on ECLS when heparin anticoagulation
is used and can require administration of supplemental ATIII (40). The anticoagulant effects of
heparin occur through potentiation of ATIII activity, increasing activity nearly 1000-fold; and
without adequate ATIII levels, the anticoagulant effects of heparin will decrease. The decrease in
ATIII observed in CTRL was accompanied by an increased rate of heparin infusion (100,000 U /
L) from Post-ECLS (7.8 ± 2.0 mL/hr) to 72 hours (33.6 ± 1.2 mL/hr). We saw a transient decrease
in vWF (Figure 7.2) in both groups during the first 24 hours on ECLS, which can occur due to
shear stress-induced uncoiling and cleavage of high molecular weight multimers of vWF (41) or
vWF-mediated platelet adhesion in high shear environments; however baseline levels were
recovered by 24 hours and there were no between-group differences.
Thromboelastography was used to evaluated coagulation in whole blood from start of clot
formation to clot retraction and fibrinolysis (Figure 7.3). We observed a prolonged R time in
CTRL despite the use of heparinase cups to neutralize the effects of heparin infusion. The observed
increase in K may be due to hemodilution and consumption of clotting factors; and was concurrent
with reduction in platelet count and increase in PT in both groups. Interestingly, clot strength (MA)
which is related to platelet count and function (42), initially decreased with platelet count, but
returned to baseline levels by 24 hours and continued to increase despite progressive platelet loss.
This may be due to hyperactivity and aggregation of platelets, as we observed a significant increase
in both ADP and collagen induced platelet aggregation at 24-48 hrs in both groups (Figure 7.4).
This increase in aggregation is consistent with the findings of Prat, et al, that reported an increase
in collagen and ADP stimulated platelet aggregation in healthy anesthetized sheep on veno-venous
ECLS for five hours, regardless of whether the animals received standard heparin infusion during
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ECLS or no continuous heparin (25). The increase in aggregation was contradictory to the findings
of a recent clinical systematic review of platelet function during extracorporeal membrane
oxygenation (ECMO) (43). In the reviewed studies, time on ECMO reduced or did not impact
ADP-stimulated platelet aggregation. We think this discrepancy is explained by the fact that, as
the authors point out, the reviewed studies do not account for the effect of platelet count on
measurement of aggregation, so the reduced aggregation may be due to a significant reduction in
platelet count with time on ECMO (43).
We assessed thrombus deposition on all circuit materials at the end of study to investigate
the location and extend of thrombus formation. We observed substantial thrombus deposition on
the membranes in both groups (Figures 7.5 and 7.6); and the membrane was the most common
site of thrombus deposition, which is consistent with clinical findings (34). Additionally, we noted
in both groups that thrombus deposition was most prominent on the inlet/venous face and gradually
reduced toward the outlet. Dense fibrin layers with incorporated white and red blood cells and
platelets were observed around the PMP fibers and likely impeded gas exchange (3). The density
and area of coverage of these deposits were notably less on the outlet face of the membrane.
Interestingly, in our previous study comparing TLP to heparin coating during 6 hours heparin-free
ECLS, we saw notable thrombus formation and fibrin sheets on the control, heparin-coated
materials that were significantly reduced or absent on TLP membranes (see Chapter Six). In this
way, TLP coating may be suitable for short-term applications, but did not reduce thrombus
formation over the 72 hour time-frame performed in this study.
Thrombus formation on the catheter was visibly less significant compared to the
membrane. The catheter outlet and inlet were the sites where most thrombi and cellular deposition
were present on the catheters (Figure 7), likely because the blood path diameter rapidly changes
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at these connection points, inducing turbulent flow. This is similar to what we observed in our 6
hour evaluation of TLP-coated ECLS circuits and catheters (Chapter 6). Clot formation was
minimal on the tubing samples for both groups, which is important to note as most in vitro studies
only examine tubing, thereby neglecting other regions where thrombus formation can occur. We
assessed protein adhesion as this method has previously been utilized to demonstrate the
omniphobic properties of TLP (18). We utilized higher flow rates and a longer duration of blood
exposure compared to other reports and did not observe a difference in protein deposition between
TLP coated catheter and tubing segments versus CTRL (Figure 7.5). These findings, along with
the instance of thrombotic circuit occlusion in both TLP and CTRL groups, not only suggest that
TLP coating alone without supplemental anticoagulation is insufficient for prevention of thrombus
formation for multi-day ECLS; but also suggests that the clinical standard of tethered heparin and
continuous heparin infusion is inadequate.
We assessed vital signs and respiratory parameters to evaluate the safety of TLP coating
and potential impact on membrane performance. While there were no differences in key vital signs
between groups, specific critical differences in respiratory parameters were observed (Table 7.3).
ECLS initially enabled ~50% reduction in mechanical ventilator settings in both groups, as has
been reported for partial respiratory support using veno-venous extracorporeal CO2 removal in
healthy swine (20). This 50% reduction is now a standard for modern ECLS technology. In the
CTRL group, ECLS enabled reduction in ventilator settings that persisted for the duration of the
72 hours, reflected in the decrease in RR and MV and sustained reduction in PaCO2. In TLP PaCO2
was only reduced immediately following start of ECLS prior to reduction in ventilator settings.
Additionally, in TLP an increase in RR to baseline levels was necessary by 24 hrs; and an increase
in FiO2 was required to maintain normoxia beginning at 12 hrs post-ECLS. TLP also had a
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significantly higher oxygenation index compared to controls beginning at 6 hours. Cumulatively
these findings imply that the gas exchange efficiency and respiratory support of the TLP-coated
membranes was inferior to the CTRL membranes. The TLP group also had significantly higher
plateau pressures and reduced compliance versus CTRL within the first 12 hours of ECLS, which
could suggest pulmonary inflammation, edema and development of consolidation. In CTRL the
PFR was consistent throughout the study and stayed above 300, signifying absence of ARDS. In
contrast, in TLP animals PFR gradually decreased with time on ECLS and was even indicative of
mild acute respiratory distress syndrome (ARDS) by the Berlin definition (mild ARDS = 200 <
PaO2 to FiO2 ratio < 300) from 24-48 hrs (29). Interestingly, despite increased FiO2 requirements
in TLP, there was no difference between groups in O2 transfer across the membrane lung (Figure
7.8 D); and the rate of O2 transfer was comparable to what has been reported for membranes of
similar dimensions and blood flow rates (44, 45). While there was no statistical difference in
percent reduction in pCO2 across the membrane, numerically the pCO2 gradient (% decrease
between pre- and post-membrane blood samples) was always lower in the TLP group compared
to CTRL (Figure 7.8, A and C). The sweep gas flow rate had to be increased from 5 L/min up to
10-20L/min in 80% of the TLP animals to achieve this pCO2 gradient. Taken together this suggests
that gas transfer was not as efficient using the TLP membranes as it was in CTRL. Whether this
decrease in performance is due to deposition of blood components and thrombi on the membrane
that increase the diffusion barrier for gas exchange as others have reported (3); or due to damage
to the native polymers during the coating process altering the gas permeability of the membrane
itself, remains unclear – although the fact that we observed similar thrombus formation on CTRL
membranes without the same alterations in membrane function may suggest the latter. This are
critical findings that were not observed in our 6 hour evaluation of TLP heparin-free ECLS, due
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to the short duration of the study; highlighting the importance of the multi-day testing format that
we have performed here.
We evaluated systemic cytokine expression, endothelial damage marker sydnecan-1 and
histology to assess potential untoward systemic effects, inflammation and end-organ damage
(Figure 7.9). ECMO has been shown to elicit complex inflammatory sequelae reminiscent of the
cytokine storm described for systemic inflammatory response syndrome (SIRS). Foreign-surface
contact and shear stress activate the coagulation and complement systems, promoting release of
proinflammatory cytokines, leukocyte activation and migration, endothelial cell activation and
infiltration of neutrophils causing end-organ damage (7). In CTRL, we did not see any change in
cytokine expression compared to baseline, but in TLP we saw a numerical increase in interleukin1β (IL-1b) and statistical increase in interleukin-6 (IL-6) beginning at 48 hrs. IL-1b is influential
in endothelial cell activation and expression of cellular adhesion molecules that allow for
neutrophil migration and infiltration, leading to end-organ damage (46). IL-6 has been previously
reported to be elevated during ECLS, predictive of poor clinical outcomes (47), and associated
with parenchymal damage in an animal model of veno-venous ECLS (46). While we observed a
difference between groups in systemic inflammatory markers, our histological evaluation of endorgan damage did not reveal any stark differences between groups. We consistently observed
lower-lung consolidation, but more severe damage such as fibrosis, edema, hemorrhage and
necrosis that have been observed in clinical trials and animal studies was less frequently observed
and was not specific to CTRL or TLP (46, 48). No specific evidence of toxic damage resulting
from the TLP coating was observed, and we saw no change in syndecan-1 expression in either
group. This important data suggests that more clinical histopathological data is needed following
ECLS to elucidate the status of the inflammatory response during blood-polymer interactions.
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While TLP has been previously shown to prevent thrombus formation without heparin in
an extracorporeal shunt for 8 hours under low flow and in a 6 hour ECLS model, the material did
not prevent occlusion when applied to complete ECLS circuits during 72 hours of testing in our
study. It is possible that the shear stress induced by the blood pump can displace the lubricant layer
from the surface, degrading the omniphobic properties of the surface. This is substantiated by the
significant thrombotic deposition and occlusive thrombotic complications we observed. Another
issue with this approach is that it only targets one component of ECLS-induced coagulopathy,
which is adhesion of protein and cellular components. The coating does not address the contact
pathway of coagulation activation, hemolysis, or shear-induced cellular activation that can drive
systemic coagulation and inflammatory responses. The vascular endothelium incorporates
numerous pro- and anti-thrombotic regulators to maintain blood fluidity and prevent inflammation.
For these reasons utilization of several complementary approaches may be the best to avoid
heparinization during ECLS. Along these lines, we believe a multi-factorial coating approach that
incorporates not only an omniphobic surface like TLP, but also bioactive hemostatic regulators
like nitric oxide (14, 15, 36, 49), which prevents platelet activation and aggregation, and direct
thrombin inhibitors (16), which inhibit thrombin without a co-factor and can inhibit clot-bound
thrombin, may be the ideal solution to prevent thrombotic and hemorrhagic complications during
ECLS (50). Our laboratory has just begun studies involving this type of approach. Additionally,
just as the endothelium is heterogenous with different regulatory mechanisms present in different
locations based on tissue-specific demands, blood flow rate and lumen diameter; it is possible that
the ideal coating for one component of the circuit may not be ideal for another; and a heterogenous,
component-specific coating approach may be required for different ECLS applications (51, 52).
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Many novel coatings are currently under development and will require a robust, pre-clinical
assessment as we have performed here (53).
A limitation of this study is the relatively small sample size that was due to the number of
circuits available for testing. The expense of the ECLS circuits ($12,000 per unit) makes them
difficult to commit to these pre-clinical studies, making our sample size and experiment very
unique for the translational research and clinical care community. The analysis we have performed
here utilizing complete circuits and close replication of the clinical care scenario is extremely
valuable and essential to fully evaluate the efficacy and longevity of a biomaterial for ECLS. We
also did not have an adequate number of circuits to evaluate the use of immobilized-heparin
coating without supplemental heparin; or to assess the performance of TLP with heparin infusion
– to better decipher the effects of blood-biomaterial interactions versus systemic anticoagulation.
Additionally, the circuits we evaluated were designed for low-flow (< 2 L / min) extracorporeal
CO2 removal; the results we report may not be applicable for other forms of ECLS that utilize
different blood flow rates. While there are subtle species differences in coagulation between pigs
and humans, pigs were selected based on similar cardiopulmonary physiology to humans and are
the standard for evaluation of new technology and coagulation during ECLS (54). We used healthy
animals in this study to first understand the blood-biomaterial interaction without the additional
variability of subject-to-subject coagulopathic response to injury; however, the results we observed
may not be substantiated in injured subjects.
7.6 Conclusions.
In summary, we believe that the work we have performed here outlines a robust testing
system for evaluation of hemocompatible materials for ECLS. The work we have conducted
provides an evaluation of blood-biomaterials interactions utilizing all components of the ECLS
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circuit, rather than isolated circuit components, at the flow rate which the device we evaluated is
clinically utilized. We used an animal model and ICU setting that closely approximate clinical
conditions; and we evaluated the materials on a multi-day time frame, rather than the standard 68 hr testing term commonly reported in the literature. We assessed not only the anti-thrombogenic
potential of the coatings, but also assessed impact on device performance and systemic
complications, which are vital considerations. We found that TLP currently does not enable
heparin-free ECLS and may alter performance of the membrane. We also provide an informative
assessment of ECLS-induced coagulopathy utilizing standard heparin-coated circuits and
continuous heparin infusion in healthy subjects without underlying coagulopathy. The
comprehensive platform we have developed for evaluation of biomaterials for ECLS incorporates
techniques from biomaterials engineers (18, 49), prominent clinical scientists (14, 25, 26, 36, 49),
and our extensive experience with round-the-clock multi-day animal ICU models of combatrelevant injury supported by ECLS (20, 55-58); putting us in a unique position to incorporate these
transdisciplinary methodologies for a robust pre-clinical, translational assessment of biomaterials
for ECLS. Going forward, we plan to test other novel biomaterials for ECLS utilizing this same
format in order to identify a robust solution for heparin-free ECLS that is suitable for clinical
application.
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Chapter Eight:
Conclusions and final considerations
8.1 Summary of major findings.
In this dissertation, we have outlined a systematic approach to evaluate biomaterials for
extracorporeal life support (ECLS); and have demonstrated this approach through assessment of
two novel hemocompatible surfaces: 1) a nitric oxide (NO)-generating metal organic framework
(CuBTTri) and 2) a non-adhesive, liquid-infused surface called tethered-liquid perfluorocarbon
(TLP). We evaluated these materials using three sequential testing phases. First, we evaluated the
materials ex vivo in whole-blood preparations using standard hemocompatibility assays that
demonstrate the efficacy of the materials according to their specific mechanisms of action. In this
phase, we showed the CuBTTri reduces the time and rate of clot initiation, reduces clot strength
and inhibits platelet aggregation both with and without addition of an NO-donor species ex vivo
(Chapter Four). We also showed that TLP reduces rate of clot formation, clot strength and
adherent clot weight ex vivo (Chapter Five).
In phase two, we evaluated TLP applied to all surfaces of a standard ECLS circuit in a
pilot feasibility study and live swine model for 6 hours circulation time (Chapter Six). This phase
puts our results in context with the literature where this 6 hour study duration is standard. We
compared the TLP coating to standard heparin-coated circuits in healthy animals that did not
receive supplemental anticoagulation. We evaluated not only thrombus formation and coagulation
status of the animal, but also assessed the impact of the coating on ECLS membrane performance
and systemic effects. We found that TLP reduces thrombus formation on ECLS membranes and
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does not impede membrane gas exchange relative to controls; and exhibited no signs of toxic or
systemic damage during the 6 hour testing timeline.
In our final stage of testing, we evaluated TLP-coated ECLS circuits on a multi-day (72
hour) time frame (Chapter Seven), as these technologies are used to provide therapy for days to
weeks or even months at a time. We equated all aspects of this large animal study in an intensive
care unit (ICU) setting to human standards of care, including equipment, anesthesia medications
and provider interventions such as fluids, vasoactive drugs, diuretics, etc. We evaluated thrombus
formation, coagulation status, membrane performance, systemic effects and histopathological
evidence. We found that at the 72 hour timescale TLP does not reduce thrombus formation
compared to the standard of care - use of heparin-coated circuits with continuous heparin infusion
- and does not prevent circuit occlusion on a multi-day time frame. Additionally, we noted
decreased gas exchange performance of the TLP-coated membranes, potentially from damage to
the native polymers during the coating application process, that required higher sweep gas flow
and greater mechanical ventilation support of animals in the TLP group. We also provide
unprecedented data regarding the use of heparin-coated ECLS circuits with supplemental heparin
administration in healthy subjects without underlying coagulopathic complications on a multi-day
time-frame, reporting on frequency and time to onset of bleeding complications, alterations in
native blood parameters and post-mortem histological assessment.
8.2 Contributions to the field.
The comprehensive testing approach we have developed in this study was built on the
methodologies of world-class physician scientists and biomaterials engineers (1-3). We have
adapted their techniques and combined them with our clinical expertise and unique round-the-
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clock animal ICU care capabilities (4-7) to produce a truly translational evaluation system to
rigorously assess biomaterials for ECLS prior to clinical use.
The novelty of our systematic approach is in the key principles that we emphasize
throughout the testing process. We propose that the testing model 1) must incorporate all
components of the device for which the coating was developed (for ECLS includes the membrane,
catheter, blood pump and tubing), 2) must be functional under the flow conditions for which the
device is utilized, 3) must perform for the intended duration of use of the device, 4) must not alter
the performance of the device or cause untoward effects and 4) must be evaluated in vivo in an
animal model that closely approximates the clinical scenario.
The first phase of evaluation, ex vivo assessment in whole-blood, is not unique to us and
is the type of assessment performed by most biomaterial research laboratories. These methods do
not closely replicate the clinical care scenario; however, we include this phase to emphasize that
these tests are vital for understanding the basic mechanisms underlying blood-biomaterial
interactions. Additionally, this phase is critical to fully characterize and optimize the coating before
progression to more costly in vivo testing.
In the second phase of testing, we used techniques from established biomaterials studies
such as assessment of thrombus formation, platelet count and function, and plasma coagulation
times to provide a comprehensive assessment of blood-biomaterial interactions (1, 8). Where our
study differed is that we utilized a large animal model with human-like cardiopulmonary
physiology, a standard ECLS circuit with the coating applied to all components and a blood flow
rate that would be used clinically. In standard in vivo biomaterial studies such as arterio-venous
shunt models and the well-characterized rabbit thrombogenicity model, the coating is only applied
to tubing segments and blood flow is driven by the animal’s circulation, at a significantly lower
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flow rate than what is generated by the blood pump. Our model allowed us to account for the flow
conditions and shear stress that occur in the clinical scenario, and also to assess the impact of the
coating on the device performance as we incorporated the functional unit (the membrane) of the
circuit.
The third phase of testing is where we truly distinguished our work from what has been
reported previously. In the literature, studies that utilize ICU/human-like standards of care in large
animal models of ECLS are generally focused on cardiopulmonary function, mechanical
ventilation, device performance and clinical outcomes – without an intensive assessment of
coagulation and biomaterials interactions (4, 9, 10). On the contrary, studies that included detailed
assessment of coagulation and biomaterials performance utilize animal models that are farremoved from the clinical scenario. Here we have combined the strengths of both approaches to
generate what is, to our knowledge, the most clinically-relevant model for assessment of
biomaterials for ECLS, and specifically for extracorporeal partial respiratory support.
Additionally, our ability to perform round-the-clock animal ICU studies allowed us to extend our
assessment beyond the standard 6 hour time-frame to 72 hours. The 72 hour timeframe is a critical
new paradigm in combat casualty care and mass casualty situations, and so our timeline is also
particularly unique and relevant to applications in military and civilian care. We have shown
through our evaluation of TLP that the study duration is crucial; as our promising 6 hour results
were not substantiated at 72 hours.
8.3 Future directions.
We plan to utilize the biomaterials evaluation template we have developed in this study to
assess other novel biomaterials for ECLS. Specifically, we plan to evaluate a multi-functional
coating that has non-adhesive properties like TLP, but also inhibits platelet activation and
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aggregation via NO-release similar to CuBTTri. This approach could prevent thrombus formation
by targeting not only the protein adsorption that initiations thrombus formation on the biomaterial
surface; but also combat the flow and shear-induced hyperactivation and consumption of platelets
that propagates both bleeding and thrombotic complications (11). Multi-functional coatings that
modulate blood interactions through multiple mechanisms such as occurs in the endothelium will
likely be essential for development of a robust biomaterial solution to enable heparin-free ECLS.
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Supplement Figure 4.1 Powder X-ray diffraction results confirming synthesis of H3[(Cu4Cl)3-(BTTri)8]
(H3BTTri = 1,3,5-tris(1H-1,2,3-triazol-5-yl)benzene) (CuBTTri). All measurements were performed at 435θ with a step count of 1.0.
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Appendix D:
Chapter 6 Supplement
Supplemental Methods
ECLS circuit information: The ECLS circuits utilized consisted of a ROTASSIST 2.8
centrifugal blood pump with integrated pressure gauge, a membrane lung (ML) (0.98 m2 surface
area) with integrated pressure sensor, and ¼” tube connections. The ML is designed for use with
the CARDIOHELP System (Maquet Getinge Group; Rastatt, Germany)
Initiation of anesthesia and instrumentation. Following overnight fast with water
available, anesthesia was induced with 6 mg/kg Telazol® (tiletamine/zolazepam) delivered
intramuscularly (IM) via 21-25 gauge needle. Atropine sulphate (0.05 mg/kg) was administered
IM to dry bronchiole secretions. Endotracheal intubation was performed via direct laryngoscopy
using a 10 mm endotracheal tube. A 16 Fr Foley catheter was inserted trans-urethraly. Urine output
was measured by the BARD® CRITICORE® Monitoring System (BARD Medical; Covington,
Georgia, USA). Tidal volume and minute volume measured using a Haloscale® Standard
respirometer (nSpire™ Health, Inc.; Longmont, CO, USA). The right jugular vein, and the left and
right femoral arteries and veins were cannulated with 7-8.5 Fr sheath introducers (Arrow
International Inc.; Reading, PA, USA) placed percutaneously with ultrasound guidance. Venous
sheaths were cannulated with IV lines for administration of fluids (normal saline) using an Alaris™
MedSystem III® Multi-Channel Infusion Pump (Alaris Medical Systems, Inc.; San Diego, CA,
USA). Arterial sheaths were cannulated with IV lines for monitoring arterial blood pressure and
for collection of systemic blood samples.
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Initiation of ECLS. ECLS circuits were primed according to manufacturer’s instructions
using 1 L normal saline with 5000 U of unfractionated heparin. The 19 Fr dual-lumen catheter was
percutaneously inserted into the right jugular vein for veno-venous (VV) ECLS. The catheter was
connected to the ECLS system in an air-free, wet-to-wet fashion. Blood flow through the circuit
was 1 L/min, and the sweep gas (100% O2) was 5 L/min. Following cannulation, no heparin was
administered.
Assessment of gas exchange efficiency. CO2 removal by the membrane was determined
by the percent decrease in pCO2 from a pre-membrane to post-membrane blood gas at each time
point. O2 transfer was calculated from pre- and post-membrane blood gases as previously reported
(S1). Blood chemistry (potassium, urea nitrogen, creatinine, hematocrit and hemoglobin) was
analyzed from arterial blood samples using the i-STAT CHEM8+ cartridge (Abott; Chicago, IL,
USA).
Coagulation testing. Prothrombin time (PT), activated partial thromboplastin time
(aPTT), antithrombin III (ATIII), von Willebrand factor (vWF) and concentrations of fibrinogen
and d-dimer were measured in previously frozen (-80 ºC) platelet poor plasma (PPP). PPP was
prepared by dual centrifugation (3,000 g, 10 min, 4ºC) of citrated whole blood. Samples were
analyzed using the Stago STA Compact Max Analyzer (Stago; Parsippany, NJ, USA). Activated
Clotting Time (ACT) was measured using the Hemochron Signature Elite Whole-Blood
Microcoagulation System (Accriva Diagnostics; San Diego, CA). Thromboelastography (TEG)
was performed using the TEG 5000 Hemostasis Analyzer System (Haemonetics Corp., Braintree,
MA) according to manufacturer’s instructions. 3.8% citrated arterial whole blood was analyzed
using the citrated kaolin assay. Heparinase cups were used at all time points to neutralize heparin
in the specimen following the bolus administered during cannulation. The following variables of
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interest were recorded: reaction time (R), initial clot formation time (K), amplification rate (αangle), clot strength (MA), and lysis (Ly30). Plasma free hemoglobin was measured by direct
spectrophotometry as previously described (S2).
ICU care. Animals were continuously monitored by technicians, study staff and a
physician throughout the experiment. Isofluorane anesthesia was titrated and monitored such that
the animal was anesthetized for the duration of the study while spontaneously breathing. Fluid
administration was adjusted hourly to achieve a minimum 0.5 ml/kg/hr urine output. All vital signs
and sensor data were recorded by manual transcription hourly. Urine output, fluid balance,
anesthesia rates and rectal core temperature were also recorded.
Application of TLP coating to ECLS circuits. Application of TLP coating to ECLS
circuits was carried out in 2 phases. In the first phase, application of the perfluorocarbon tether
layer was done by Free Flow Medical Devices, LLC (Lancaster, PA, USA). Briefly, circuits were
exposed to low-pressure radio frequency oxygen plasma at 100 W. A liquid silane solution was
circulated by peristaltic pump through the circuit for 24h. Circuits were then rinsed and dried. The
tether layer was applied to the dual-lumen ECLS cannulas in the same fashion. All circuits and
cannulas were then shipped to San Antonio, TX, for testing. The second phase of coating,
application of the liquid perfluorocarbon lubricant layer, was carried out on the morning of the
study before cannulation. A volume of 150 µL of the liquid lubricant, FluoroLube63 (FL63), was
injected directly into the pre-membrane/venous face of the membrane lung with clamps placed on
the inlet and outlet tubing to ensure that the entire membrane was saturated with the liquid. Empty
syringes were connected to ports on the post-membrane/arterial face to prevent pressure build-up
within the oxygenator. Once the membrane was saturated with liquid, the FL63 was flushed back
and forth between syringes placed on the pre- and post-membrane faces of the oxygenator to ensure
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thorough coating. The clamps were then removed to allow the FL63 to drain from the oxygenator
into the pump and tubing components. The tubing and pump were positioned to ensure that all
surfaces were exposed to the liquid. The excess FL63 was then withdrawn from the circuit.
Approximately 30 mL of lubricant remained within the circuit. The Avalon catheters with tethered
perfluorocarbon layer applied were filled with FL63, then drained of lubricant immediately prior
to cannulation in the TLP group.
Histology. Tissue samples for histology were fixed in neutral-buffered 10% formalin for
24 hrs, trimmed, embedded in paraffin, sectioned at 4 µm, and stained with hematoxylin and eosin
(H&E). Histological images were recorded using a 10x objective under (Zeiss Axioskop;
Oberkochen, Germany).
Preparation of extracorporeal circuits for analysis. Following 6 hours of extracorporeal
circulation, circuit tubing was clamped adjacent to the inlet and outlet of the catheter, then cut and
disconnected from the animal. Circuits were then rinsed with 1.5 L of PBS (1 L / min flow), drained
of saline and filled with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer for fixation. After
a minimum of 48 hours of fixation, MLs were drained of fixative and disassembled from the outer
plastic housing to expose the stack of polymethylpentene (PMP) gas exchange fibers as we have
previously described (S3). The top PMP fiber layer from the inlet face, the layer from the center
of the fiber stack, and the bottom PMP layer from the outlet face of the membrane oxygenator
were collected and imaged. The inlet, center and outlet layers were then further dissected into 4
equal square quadrants. The samples were dehydrated in graded ethanol (35%, 50%, 70%, 100%;
10 min each) and stored in a desiccator until scanning electron microscopy (SEM) analysis.
The Avalon catheter was carefully removed from the subject at the end of study and flushed
with 100 mL saline. Circuit tubing samples were collected from the pre-membrane and post199

membrane lines both before use (cut from the circuit after priming with saline and before
connecting to the patient) and after the explanted circuit was flushed with PBS at the end of the
study. Tubing and catheter samples were fixed as described for ML samples.
Circuit tubing samples were collected from the pre-membrane and post-membrane lines
both before use (cut from the circuit after priming with saline and before connecting to the patient)
and after the explanted circuit was flushed with PBS at the end of the study. Tubing and catheter
samples were fixed as described for ML samples.
Field emission SEM imaging and EDS mapping. The ML, tubing and catheter segments
were sputter-coated with gold-palladium (Leica Microsystems Inc.; Wetzlar, Germany) and
imaged using field emission SEM (FEI Teneo; Hillsboro, OR, USA). An accelerating voltage of
5kV was applied with a spot size of 9. The weight percent fluorine on membrane segments was
measured by SEM using a JEOLISM-IT100 InTouchScope (JEOL USA, Inc.; Peabody, MA,
USA) equipped with energy dispersive X-ray spectrometer (EDS). Four points of interest were
selected on each sample for elemental analysis, and the average of the 4 outputs was taken for each
sample. The weight percent fluorine was used to assess even distribution of the TLP coating
throughout the membrane and to identify potential stripping of the coating.
Additional statistics. For all data sets, a Shapiro-Wilk test was conducted to test the
distribution of data for normality. If skewed, data was then transformed, or the nonparametric
version of the test was used. For percent area thrombus deposition scores, an interclass correlation
for inter-rater reliability was performed using a one-way analysis of variance. The Shrout-Fleiss
reliability method was used to generate a kappa statistic the inlet, center and outlet scores to
measure agreement between reviewers.

200

Supplemental references.
S1.

Lehle K, Philipp A, Hiller K-A, Zeman F, Buchwald D, Schmid C, et al. Efficiency of gas
transfer in venovenous extracorporeal membrane oxygenation: analysis of 317 cases with
four different ECMO systems. Intensive Care Medicine. 2014;40(12):1870-7.

S2.

Noe DA, Weedn V, Bell WR. Direct spectrophotometry of serum hemoglobin: an Allen
correction compared with a three-wavelength polychromatic analysis. Clin Chem.
1984;30(5):627-30.

S3.

Beely BM, Campbell JE, Meyer A, Langer T, Negaard K, Chung KK, et al. Electron
Microscopy as a Tool for Assessment of Anticoagulation Strategies During Extracorporeal
Life Support: The Proof Is on the Membrane. ASAIO J. 2016;62(5):525-32.

Supplemental figures.

201

202

Supp Figure 6.1 Field Emission scanning electron microscopy images collected from 19 Fr dual-lumen catheters for veno-venous
extracorporeal life support following 6 hours in vivo circulation. Control (CTRL, top row) catheters were compared to catheters with tetheredliquid perfluorocarbon (TLP) anti-thrombogenic coating (bottom row). Segments from the inlet and outlet tubing connecting the cannula to
the ECLS circuit, the center of the cannula inner lumen, and the tip of the catheter were imaged. Greater deposition of cellular debris and
platelets was observed on the CTRL materials versus TLP-coated materials.
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Supp Fig 6.2 Scanning electron microscopy images collected from extracorporeal life support circuit connective tubing. Control (CTRL, top
row) tubing was compared to tubing with tethered-liquid perfluorocarbon (TLP) anti-thrombogenic coating (bottom row). Tubing segments
from the pre-membrane venous line directly before the membrane lung (Panel A) and tubing segments from the post-membrane arterial circuit
line (Panel B) were collected before exposure to blood (columns A1, B1) and after 6 hours in vivo extracorporeal circulation (columns A2,
B2). Minimal deposition of debris was observed on any sample in either CTRL or TLP group. Tubing samples collected after 6 hours
circulation were comparable to those collected before use.
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Supp Figure 7.1 Representative images from control animals (CTRL) receiving ECLS with heparincoated circuits and continuous heparin infusion and tethered liquid perfluorcarbon (TLP) animals
receiving TLP-coated ECLS without systemic anticoagulation for 72 hours circulation. CTRL images (top
row, panels A-D) were comparable to TLP images (bottom row, panels F-I) in this subset of animals
where tissue from the lung (A, F), kidney (B, G), liver (C, H) and jejunum (D, I) were unremarkable with
no signs of toxic injury, organ damage or thrombosis/hemorrhage.
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Supplemental Figure 7.2 Representative images from control animals (CTRL) receiving ECLS with
heparin-coated circuits and continuous heparin infusion and tethered liquid perfluorcarbon (TLP) animals
receiving TLP-coated ECLS without systemic anticoagulation for 72 hours circulation. CTRL images (top
row, panels A-C) and TLP images (bottom row, panels D-F) from a subset of animals in both groups
demonstrated abnormal histopathological findings. Lung (A, D) tissue from two CTRL and two TLP
animals showed fibrosis, edema, accumulation of protein aggregates and cell damage. Kidney (B,E) from
one CTRL and two TLP animals showed significant inflammation and cellular damage; and liver (C, F)
from one CTRL and one TLP animal showed congestion and inflammation.
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